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Abstract 
Statins are the first line therapy for treatment and prevention of cardiovascular disease. The 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins, reduce 
plasma cholesterol levels by inhibiting the rate-limiting step in cholesterol biosynthesis. 
While statins are well tolerated, up to 15% of patients develop myopathy, manifesting as 
muscle aches and pain and in rare cases, potentially life-threatening statin-induced 
rhabdomyolysis. Given that approximately 3 to 4 million Canadians are treated with statins, 
an estimated 500,000 patients experience associated skeletal muscle side effects that may 
prevent the continued treatment of hypercholesterolemia. Despite the prevalence of this side 
effect, little is known regarding the molecular determinants of statin myopathy. Increased 
systemic statin exposure is linked to risk of developing myopathy, but the role of skeletal 
muscle exposure and its relevance to muscle toxicity remains to be determined. 
Drug transporter proteins are important determinants of drug absorption, tissue exposure and 
drug elimination. Statins are substrates of multiple drug transporters and require hepatic 
uptake to exert their cholesterol lowering effect. However, little is known about the role drug 
transporters have in the skeletal muscle distribution of statins and their toxicity. We aimed to 
identify drug transporters in skeletal muscle involved in controlling muscle exposure. We 
found that the uptake transporter OATP2B1 and three novel statin efflux transporters, MRP1, 
MRP4 and MRP5, are expressed in skeletal muscle. We demonstrate that OATP2B1 
sensitizes muscle to toxicity and MRP1 attenuates toxicity of atorvastatin and rosuvastatin in 
an in vitro skeletal muscle model. 
 iv 
 
We studied the regulation and function of two transcriptional variants of OATP2B1, 
demonstrating that these variants had similar function but differential regulation, resulting in 
ubiquitous expression for OATP2B1 full length form and primarily hepatic expression for the 
truncated variant. We employed a novel Oatp2b1 knockout mouse model to examine the in 
vivo role of Oatp2b1 in rosuvastatin disposition. We found that Oatp2b1 does not have a 
significant effect on rosuvastatin pharmacokinetics but the hepatic exposure was increased in 
Oatp2b1 knockout mice. 
Taken together, these studies further our understanding of the in vitro and in vivo 
involvement of drug transporters in the context of statin myopathy. 
Keywords 
Organic anion transporting polypeptides, multidrug resistant associated proteins, drug 
transporter, drug transporter regulation, statins, statin transport, statin pharmacokinetics, 
statin myopathy, rhabdomyolysis 
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1 INTRODUCTION 
  
2 
1.1 Overview of Statin Pharmacology 
1.1.1 Therapeutic Indications 
Cardiovascular disease (CVD), which can result in myocardial infarction or stroke, is a 
leading cause of death in Canada and the world, accounting for about 30% of all deaths. 
The economic impact of cardiovascular disease has been estimated at a cost of $22 billion 
annually, in direct or indirect health care expenses (Genest et al., 2009). Multiple 
epidemiological studies have confirmed that age, smoking status, diabetes, hypertension, 
and hypercholesterolemia are major risk factors for the development of CVD.  Elevation 
of low density lipoprotein cholesterol (LDL-C) was first shown in the 1960s by the 
Framingham Heart Study to be a major risk factor for CVD (Kannel et al., 1961). Since 
then, compelling evidence from multiple randomized clinical trials (RCTs) has revealed 
that LDL-C reduction is effective for the treatment of cardiovascular disease. One such 
class of drugs used to lower LDL-C are the statins, or 3-hydroxy-3-methylglutaryl-
coemzyme A (HMG-CoA) reductase inhibitors. Meta analysis of 14 large RCTs has 
demonstrated that a statin-mediated reduction of 1 mmol/L in LDL-C correlates with 20-
25% reduction in risk for major cardiovascular events and a 12% reduction in all cause 
mortality (Baigent et al., 2005). This has led to wide spread use of statins as first-line 
therapy for primary and secondary prevention of coronary, cerebral and peripheral artery 
disease.   
1.1.2 Mechanisms of Action 
Approximately 70% of cholesterol is produced endogenously in the liver through the 
cholesterol biosynthetic pathway (Ikonen, 2008).  The statin class of drugs acts to reduce 
the endogenous production of cholesterol in the liver by inhibiting hydroxyl-
methylglutaryl-CoA (HMG-CoA) reductase and synthesis of mevalonate. This is the rate 
limiting step in the 30 step cholesterol biosynthetic pathway (Endo, 2010). The reduction 
in hepatic cholesterol synthesis results in the upregulation of the LDL-receptor on surface 
of hepatocytes and ultimately leads to a reduction in circulating LDL-C (Hafner et al., 
2011). A simplified diagram showing statin inhibition of the cholesterol biosynthetic 
pathway is presented in Figure 1.1. 
  
3 
 
 
 
 
Figure 1.1 Simplified diagram of the cholesterol biosynthetic pathway.  
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1.1.3 Development 
In the early 1970s, Dr Akira Endo discovered the first statin named mevastatin or 
compactin. Mevastatin was isolated from the fungus Penicillium citrinum while screening 
microbial strains for the ability to block lipid synthesis (Endo, 1992). Despite being 
shown to be effective at lowering LDL-C, mevastatin was never marketed over concerns 
of carcinogenicity in dogs (Endo, 1992). In 1979, another statin, termed lovastatin, was 
successfully isolated from 2 sources; Aspergillus terrus by Merck Research Laboratories 
and Monascus ruber by Dr Akira Endo (Endo, 2010). Lovastatin was shown to be safe 
and effective in early clinical trials and was approved by the U.S. Food and Drug 
Administration (FDA) in 1987, becoming the first marketed statin. Since then seven other 
statins have followed suit for the treatment of hypercholesterolemia including 
simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin and 
pitavastatin (Fig. 1.2). While all statins share the same pharmacophore, similar to the 
open acid ring structure of HMG-CoA, they differ widely in their chemical attributes, 
dosage forms, and potency. Statins can be administered in the open β-hydroxyacid form 
(active) or the closed lactone form (inactive) because interconversion between forms 
occurs in vivo (Shitara and Sugiyama, 2006). The pharmacological properties of statins 
are summarized in Table 1.1. 
  
5 
 
Figure 1.2 Chemical structures of HMG-CoA reductase inhibitors.  
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Table 1.1 Pharmacological Properties of Statins. 
Statin FDA Approval Form Dose IC50 (nM) 
LogD  
(pH 7.0) 
Atorvastatin 1996 acid 10 - 80 mg 0.82 1.53 
Cerivastatin 1997 (Withdrawn 
in 2001) 
acid 0.2 - 0.8 mg 2.50 2.32 
Fluvastatin 1993 acid 20 - 80 mg 4.80 1.75 
Lovastatin 1987 lactone 10 - 80 mg 4.70 3.91 (acid 
1.51) 
Pitavastatin 2009 acid 1 - 4 mg 1.70 1.5 
Pravastatin 1991 acid 10 - 40 mg 5.00 -0.47 
Rosuvastatin 2003 acid 5 - 40 mg 0.30 -0.25 to -0.50 
(pH 7.4) 
Simvastatin 1991 lactone 5 - 80 mg 5.20 4.4 (acid 
1.88) 
IC50 = half maximal inhibitory concentration of HMG-CoA reductase activity in 
cultured rat hepatocytes; LogD = distribution coefficient 
References: (Aoki et al., 1997; Shitara and Sugiyama, 2006; Yee and Wright, 2011) 
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1.2 Statin Pharmacokinetics 
Statins are administered orally on a daily basis, but the differences in biopharmaceutical 
and biochemical properties results in different pharmacokinetic profiles. For several 
statins, extensive first pass effects limits their oral bioavailability. Metabolism by the 
cytochrome (CYP) P450 enzymes also plays an important role in the pharmacokinetics of 
some statins. Lovastatin and simvastatin are both lipophilic statins administered in their 
lactone forms making them easily absorbed from the intestine. However, lovastatin and 
simvastatin are substrates of P-glycoprotein (P-gp) and CYP3A4, which are expressed in 
the liver and intestine. Both P-gp and CYP3A4 play an important part in the first pass 
effects of these two statins leading to their low bioavailabilities (<5%) (Shitara and 
Sugiyama, 2006). Atorvastatin is dosed in the β-hydroxyacid form and it is also 
metabolized by CYP3A4. However, it is relatively more hydrophilic than lovastatin and 
simvastatin and requires transporters for its hepatic uptake (Lau et al., 2006; Shitara and 
Sugiyama, 2006). Fluvastatin is unique from the other statins, since it is primarily 
metabolized by CYP2C9. As a result, inhibition of CYP3A metabolism does not affect 
pharmacokinetics of fluvastatin. Cerivastatin also has distinct metabolism via a dual 
metabolic pathway involving CYP3A4 and CYP2C8 metabolism (Shitara et al., 2004). 
Pravastatin and rosuvastatin are hydrophilic and do not undergo any major metabolism 
involving CYPs. They are primarily eliminated from the body by transport mediated 
processes in the liver (Shitara and Sugiyama, 2006). The newer statins, like atorvastatin 
and rosuvastatin, have much longer biological half lives (>14.5h) compared to the other 
statins (<3h). Most statins are highly protein bound in plasma and are primarily 
eliminated in the bile except in the case of pravastatin. The pharmacokinetic properties of 
some statins are summarized in Table 1.2. 
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Table 1.2 Pharmacokinetic Properties of Statins. 
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Pharmacokinetics 
      
Tmax (h) 1.0-2.0 0.5-1.0 2.0-4.0 1.0-1.5 3.0-5.0 1.3-3.0 
Cmax (ng/mL) 27-66 448 10-20 45-55 37 10-34 
Bioavailability (%) 12-14 19-29 <5 18 20 <5 
Plasma Protein 
Binding (%) 
>98 >98 >95 45-54 88 95 
Metabolism 
      
CYP 3A4 2C9 3A4 - 
Minimal: 
2C9, 
2C19 
(minor) 
3A4 
UGT 
1A1, 
1A3      
Number of known 
active metabolites 
2 0 3 0 1  3 
T1/2 (h) 14.5 3.0 2.0 2.0 20.0 1.4-3.0 
Excretion 
      
Renal (%) ≤2 <6 ≥10 20 10 13 
Biliary (%) 70 90 83 
53 (non-
renal) 
90 58 
Values based on a 40 mg oral dose for each statin 
References: (Bellosta and Corsini, 2012; Shitara and Sugiyama, 2006) 
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1.2.1 Drug Transporters Involved in Statin Pharmacokinetics 
1.2.1.1 Overview of Drug Transporters 
Transporters are membrane spanning proteins that act as gate keepers for all cells 
controlling the uptake and efflux of endogenous substrates such as amino acids, sugars, 
ions, and hormones. Compounds that are large or polar cannot pass through biological 
membranes by simple diffusion and rely on transporter proteins to facilitate membrane 
crossing. Transporters are not only limited to recognizing endogenous compounds, but 
some also have the potential to transport xenobiotics like drugs, dietary and 
environmental compounds. Drug transporters are particularly important in drug 
disposition because of their expression in organs such as the intestine, liver and kidney 
(Giacomini et al., 2010; Ho and Kim, 2005). 
Drug transporters can be broadly classified into two classes, uptake and efflux 
transporters. Uptake transporters belong to the solute carrier superfamily (SLC) and they 
are responsible for the movement of substrates into cells. SLC transporters utilize 
facilitated diffusion, ion coupling, or ion exchange to transport substrates down or against 
their concentration gradients (DeGorter et al., 2012b). In contrast, efflux transporters 
belong to the ATP-binding cassette (ABC) superfamily and are responsible for the 
extrusion of compounds from cells into the extracellular environment. ABC transporters 
have an intracellular nucleotide binding domain that catalyzes the hydrolysis of ATP to 
generate energy to power the transport of substrates across membranes (Schinkel and 
Jonker, 2003). 
The pharmacokinetics of statins are highly dependent upon membrane transporters from 
the ATP-binding cassette and solute carrier families. Importantly, statin response requires 
hepatic uptake to their intracellular target, to exert their clinical effects. Specifically, 
statins rely on drug transporting systems for their hepatic uptake including: organic anion 
transporting polypeptides (OATP) 1B1, OATP1B3, OATP2B1 and sodium-taurocholate 
co-transporting polypeptide (NTCP). Biliary excretion of statins involves drug transport 
systems on the hepatocyte canalicular membrane including P-glycoprotein (P-gp, MDR-
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1, ABCB1), breast cancer resistance protein (BCRP, ABCG2) and multidrug resistance-
associated protein 2 (MRP2, ABCC2).   
All of the marketed statins are well absorbed in the intestine but the absorption 
mechanism is thought to vary from one statin to another. Lovastatin and simvastatin are 
lipophilic and are considered to be absorbed by passive diffusion. Both are also substrates 
of P-gp in the intestine, which may account partially for their low bioavailability 
(Sakaeda et al., 2002). The pharmacokinetics of simvastatin and lovastatin may be 
affected by inhibition of P-gp leading to increased bioavailability and area under the 
curve (AUC) (Holtzman et al., 2006; Shitara and Sugiyama, 2006). Hydrophilic statins 
like pravastatin are predicted to be absorbed by a transporter mediated mechanism versus 
passive diffusion (Tamai et al., 1995). The OATPs are thought to be responsible for the 
transport-mediated absorption of pravastatin (Shirasaka et al., 2010). OATP2B1 is 
expressed in the intestine and is capable of transporting rosuvastatin, pravastatin, 
pitavastatin, and atorvastatin (Grube et al., 2006; Hirano et al., 2006; Ho et al., 2006; 
Kobayashi et al., 2003; Nozawa et al., 2004). Transport-mediated by OATP2B1 is also 
reported to be pH dependent and may contribute to the intestinal absorption of statins 
(Kobayashi et al., 2003; Nozawa et al., 2004). The intestinal transporter OATP1A2 could 
also be involved in the absorption of the substrates including pitavastatin, atorvastatin 
and rosuvastatin (Ho et al., 2006; Knauer et al., 2010; Shirasaka et al., 2011).  
In general the renal elimination of most statins, except for pravastatin, is low. The renal 
elimination of pravastatin accounts for about 47% of total elimination. Renal clearance of 
pravastatin is also much greater than glomerular filtration rate suggesting a role for 
transporters in pravastatin secretion (Hatanaka, 2000). Studies in rats and humans suggest 
a role of organic anion transporter 3 (OAT3) in the renal excretion of pravastatin 
(Hasegawa et al., 2002; Takeda et al., 2004). However, polymorphisms in OAT3 have 
not been associated with changes in pravastatin elimination or pharmacokinetics 
(Nishizato et al., 2003). 
Some of the drug transporters involved in the pharmacokinetics of statins are discussed 
below and summarized in Table 1.3.  
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1.2.2 Statin Uptake Transporters 
1.2.2.1 Organic Anion Transporting Polypeptides 
Organic anion transporting polypeptides (OATPs), gene family SLCO, represent a 
superfamily of important drug transporters that mediate the sodium independent transport 
of a diverse range of substrates (Hagenbuch and Gui, 2008). The OATPs are integral 
membrane proteins that are predicted to consist of 12 transmembrane domains and have a 
characteristic OATP superfamily amino acid sequence (Hagenbuch and Meier, 2003). 
The amino and carboxy tails of OATP proteins are located intracellularly. N-
glycosylation of OATP proteins occurs on conserved amino acid regions in extracellular 
loops two and five (Hagenbuch and Gui, 2008). The human OATP superfamily consists 
of 11 members including; OATP1A2, OATP1B1, OATP1B3, OATP1C1, OATP2A1, 
OATP2B1, OATP3A1, OATP4A1, OATP4C1, OATP5A1, and OATP6A1. The 
mechanism of transport appears to be an anion exchange consisting of counter transport 
of endogenous intracellular substances like bicarbonate and glutathione (Hagenbuch and 
Gui, 2008). Statins have been identified as substrates of OATP1A2, OATP1B1, 
OATP1B3 and OATP2B1. These transporters are thought to facilitate the intestinal 
absorption, and hepatic uptake of statins. 
OATP1A2 and OATP2B1 are expressed in a wide variety of tissues, while others have 
tissue specific expression like OATP1B1 and OATP1B3. OATP1B1 and OATP1B3 are 
expressed on the basolateral membrane of hepatocytes and are involved in the hepatic 
uptake of statins (Hirano et al., 2004; Ho et al., 2006; Kitamura et al., 2008). OATP1B1 
is highly polymorphic (Niemi et al., 2011; Tirona et al., 2001) and reduced function 
variants have been studied for their involvement in the pharmacokinetics of statins. One 
of the most well characterized variants is the 521T>C (rs4149056) single nucleotide 
polymorphism (SNP) denoted *5. This variant results in reduced cell surface trafficking 
and reduced transport function (Tirona et al., 2001). Multiple pharmacokinetic studies 
have shown that the OATP1B1*5 variant increases the area under the curve (AUC) for 
many statins. 
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OATP2B1 is found much more widely expressed than OATP1B1 and OATP1B3 
transporters in tissues that include liver, kidney, brain, intestine, colon, heart, lung, 
placenta, ovary, testis and skeletal muscle (Knauer et al., 2010; Kullak-Ublick et al., 
2001; Tamai et al., 2000). Mutation analysis of extracellular loop five revealed that 
mutation of cysteine residues or deletion of the loop results in protein mistrafficking to 
the cell surface (Hanggi et al., 2006). Mutation of cysteine residues in extracellular loop 
five has revealed distinct higher molecular weight species of OAPT2B1. Crosslinking 
experiments with wild type OATP2B1 have revealed that homo-dimerization is possible 
and responsible for the higher molecular weight bands (Hanggi et al., 2006). Rapid 
regulation of OATP activity has been shown to occur by protein phosphorylation of 
OATP1B1 and OATP2B1 by PKA and PKC, respectively (Kock et al., 2010; Sun et al., 
2008). Increased phosphorylation of OATP2B1, by PKC, results in transporter 
internalization via a clathrin-dependent pathway (Kock et al., 2010). Phosphorylation of 
OATPs is predicted to influence physiological and pharmacokinetic transport functions 
but the in vivo relevance remains to be determined.  
Functionally, OATP2B1 has a much narrower substrate specificity compared to members 
of the OATP1B family (Hagenbuch and Gui, 2008). However, human OATP2B1 has 
been shown to possess substrate-specific pH-dependent transport properties (Kobayashi 
et al., 2003; Nozawa et al., 2004). This pH-dependent transport mechanism and 
expression on the apical membrane of enterocytes of the intestine suggests a potential 
role in the intestinal absorption of substrates. Based on structural modeling of OATP1B3 
and OATP2B1, OATPs are thought to transport solutes across membranes by a rocker-
switch type of mechanism through a positively charged central pore (Meier-Abt et al., 
2005). 
Pharmacogenetic variations have also been observed in OATP2B1 (SLCO2B1); however, 
only a few have had their functional impact on OATP2B1 mediated transport 
characterized (Konig, 2011). The SLCO2B1 935G>A polymorphism has been associated 
with reduced plasma levels of the leukotriene receptor antagonist montelukast (Mougey 
et al., 2009). However, recently it has been demonstrated that montelukast is not a 
substrate of OATP2B1 (Chu et al., 2012). The most common variant in SLCO2B1 gene is 
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the 1475C>T polymorphism with an allele frequency of 30.9% in a Japanese population. 
The 1475C>T polymorphism shows reduced maximal transport activity (Vmax) for 
estrone sulfate compared to wild type protein in vitro (Nozawa et al., 2002). One 
pharmacokinetic study in humans has shown that carriers of the SLCO2B1 1475C>T 
have a significant reduction in the fexofenadine area under the plasma concentration-time 
curve (AUC) compared to wild type subjects (Imanaga et al., 2011). 
 
1.2.2.2 Organic Anion Transporters 
Organic anion transporters (OATs) represent a superfamily of important drug transporters 
that mediate the sodium independent transport of a diverse range of substrates (VanWert 
et al., 2010). OATs have been shown to play important roles in mediating the renal 
reabsorption and secretion of drugs, xenobiotics and endogenous compounds. OAT3 is 
one member of this family, predominantly expressed in the renal proximal tubule cells, 
that likely functions as an organic anion/α-ketoglutarate exchanger (Burckhardt and 
Burckhardt, 2011). OAT3 facilitates the uptake of a wide range of endogenous anions 
and xenobiotics from the blood into tubular cells (Erdman et al., 2006). OAT3 facilitates 
the renal uptake of pravastatin and rosuvastatin while other statins have been shown to be 
inhibitors of OAT3 (Burckhardt and Burckhardt, 2011; Takeda et al., 2004; Windass et 
al., 2007). 
 
1.2.2.3 Sodium Taurocholate Co-transporting Polypeptide 
Sodium taurocholate co-transporting polypeptide (NTCP) is the primary uptake system 
for bile acids from the portal blood into the liver. NTCP has seven putative 
transmembrane domains with the carboxy tail in the cytoplasm (Klaassen and Aleksunes, 
2010). In addition to transporting bile acids, NTCP has also been shown to facilitate the 
sodium dependent hepatic uptake of various statins (Choi et al., 2011; Ho et al., 2006). 
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1.2.3 Statin Efflux Transporters 
1.2.3.1 Breast Cancer Resistance Protein 
Breast cancer resistance protein (BCRP) has wide spread tissue expression. The BCRP 
protein has six transmembrane domains and is considered a half transporter that must 
homo-oligomerize in order to function. BCRP is expressed on the apical membrane of 
enterocytes and the canalicular membrane of hepatocytes and functions to limit oral 
bioavailability and facilitate biliary excretion, respectively (Meyer zu Schwabedissen and 
Kroemer, 2011). Atorvastatin, pravastatin, pitavastatin and rosuvastatin have all been 
shown to be substrates of BCRP (Hirano et al., 2005; Keskitalo et al., 2009b; Kitamura et 
al., 2008). 
1.2.3.2 Multidrug Resistance Associated Proteins 
Multidrug resistance associated proteins (MRPs) are a family of ATP dependent efflux 
pumps with a broad substrate specificity for both endogenous compounds and 
xenobiotics (Leslie et al., 2005). MRP2 is one member of this family that is capable of 
statin transport. MRP2 is expressed on the bile canalicular membrane and is involved in 
the elimination of xenobiotic and bilirubin glucuronide conjugates and statins (Kitamura 
et al., 2008; Kivisto et al., 2005). Other members of the MRP family have been shown to 
transport statins. In Chapter Three we discuss MRP1, MRP4 and MRP5 as novel statin 
transporters expressed in skeletal muscle.  
1.2.3.3 P-glycoprotein 
P-glycoprotein (MDR1, P-gp, ABCB1) is an ABC transporter that has important roles in 
protecting tissues from toxic xenobiotics. P-gp is expressed in the apical membrane of 
enterocytes, hepatocytes, and proximal tubule cells of the kidney as well as endothelial 
cells of the blood brain barrier (Cascorbi, 2011). P-gp is capable of transporting some 
statins (Dong et al., 2008; Shirasaka et al., 2011) and data suggests that P-gp affects statin 
pharmacokinetics by modulating statin absorption and elimination (Rodrigues, 2010). 
  
15 
Table 1.3 Statin Transporters. 
Transporter 
Transport 
Mode 
Tissue 
Localization A
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P-gp Efflux Intestine, Liver, Kidney, Brain Y N Y Y Y Y Y 
MRP1 Efflux Lung, Brain, Heart, Muscle Y ? ? ? ? Y ? 
MRP2 Efflux Intestine, Liver, Kidney, Brain Y ? ? ? Y Y ? 
MRP4 Efflux 
Muscle, 
Kidney, 
Intestine 
Y ? ? ? Y Y ? 
MRP5 Efflux Muscle, Heart, Lung, Intestine ? ? ? ? Y Y ? 
BRCP Efflux Intestine, Liver, Brain Y Y ? Y Y Y ? 
BSEP Efflux Liver ? Y ? ? Y ? ? 
OATP1A2 Uptake Intestine ? ? Y ? Y Y ? 
OATP1B1 Uptake Liver Y Y Y Y Y Y Y 
OATP1B3 Uptake Liver Y Y ? Y Y Y Y 
OATP2B1 Uptake 
Intestine, Liver, 
Kidney, Brain, 
Muscle 
Y Y ? Y Y Y ? 
OAT3 Uptake Kidney, Brain ? Y Y ? Y Y Y 
NTCP Uptake Liver Y Y ? Y Y Y Y 
Y = yes substrate, N = not substrate, ? = Unknown 
References: (Bellosta and Corsini, 2012; Knauer et al., 2010; Shitara and Sugiyama, 
2006) 
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1.2.4 Ethnic Differences in Pharmacokinetics 
It is well known that ethnicity may affect drug disposition and response. In the case of 
statins, many believe that Asians need lower statin doses because of a lower body mass 
index (BMI). In fact, most statins have lower recommended doses approved in Japan then 
those in North America (Saito et al., 2005). The Canadian Cardiovascular Society 
guidelines recommend that lower doses of statins be used in all Asian patients for the 
management and treatment of dyslipidemia (McPherson et al., 2006). The package insert 
for rosuvastatin recommends a starting dose of 5 mg per day in Asian subjects. This 
recommendation is based on pharmacokinetic studies revealing that rosuvastatin plasma 
exposure is about two-fold higher in Asian compared to Caucasian subjects (Tzeng et al., 
2008; Wang, 2011). Lee and colleagues demonstrated a striking difference in rosuvastatin 
plasma exposure between Chinese, Malay, Asian-Indians and white subjects living in 
Singapore. They showed that Asians had 1.6 to 2.3-fold greater rosuvastatin exposure in 
comparison to white subjects living in the same environment (Lee et al., 2005). There is 
good evidence that rosuvastatin exposure is higher in Asian subjects, but similar evidence 
for other statins is lacking. To date, no ethnic differences have been reported in 
cerivastatin or atorvastatin exposure (Gandelman et al., 2012; Muck et al., 1998). 
Although, Asians need lower doses of rosuvastatin compared to Caucasians, this does not 
appear to be a class effect. Importantly, there does not appear to be differences in the 
efficacy or safety in Asian populations (Wang, 2011). 
 
1.3 Statin-Associated Myopathy 
Statins are generally very effective and well tolerated with a good safety profile 
(McKenney et al., 2006; Pasternak, 2002; Ward et al., 2007). Although statins are well 
tolerated, their use is associated with a number of side effects. The most common adverse 
effect associated with statin therapy is skeletal muscle toxicity. All statins have the ability 
to cause muscle toxicity but the incidence rate varies widely between statins (Thompson 
et al., 2003).  In fact, this side effect resulted in the withdrawal of cerivastatin (Baycol) 
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from the market in 2001 due to an unexpectedly high incidence of life-threatening muscle 
toxicity (rhabdomyolysis) compared with other marketed statins.  
Statin induced myopathy encompasses a broad spectrum of muscle disorders ranging 
from myalgia to potentially life-threatening rhabdomyolysis (Bosch et al., 2009; Harper 
and Jacobson, 2007; Thompson et al., 2006). Rhabdomyolysis is characterized by skeletal 
muscle breakdown with leakage of muscle contents leading to acute renal failure, 
hypocalcaemia and hyperkalaemia, which may result fatal cardiac arrhythmias (Lane and 
Phillips, 2003; Warren et al., 2002). Collectively, statin-induced myopathies have been 
defined into 3 clinical categories on the basis of clinical presentation and plasma creatine 
(CK) levels – myalgia, myositis, and rhabdomyolysis (Table 1.4).  
The prevalence of myalgia according to meta analysis of statin RCTs is between 1.5-5% 
(Bays, 2006; Law and Rudnicka, 2006). The rate of statin myalgia, myopathy and 
rhabdomyolysis in patients treated with statins or placebo was estimated by a meta- 
analysis of 21 clinical trials providing 180,000 person years of follow-up. They defined 
myalgia, as minor muscle pain, myopathy, as muscle symptoms with an elevation in CK 
levels above 10 times the upper limit of normal (ULN), and rhabdomyolysis, as CK 
levels above 10,000 IU/L or above 10 times the ULN with an elevation in serum 
creatinine or requirement for hydration therapy. The estimated rate for myalgia, 
myopathy and rhabdomyolysis was 190, 5, and 1.6 patients per 100,000 person years 
respectively (Law and Rudnicka, 2006). In contrast other meta-analysis studies report 
that the incidence of myalgia, rhabdomyolysis, elevations in CK or statin withdrawal 
were not significantly different between those receiving statins or placebo (Kashani et al., 
2006). Voluntary reporting of rhabdomyolysis in statin treated patients to the FDA 
Adverse Events Reporting System (AERS) reports the rate of rhabdomyolysis is 0.70 per 
100,000 person years (Harper and Jacobson, 2007). In 2001, the FDA AERS rates for 
fatal rhabdomyolysis were: 0.19, 0.12, 0.043, 0.037 and 3.2 reported case per 1 million 
prescriptions for lovastatin, simvastatin, atorvastatin, pravastatin, and cerivastatin 
respectively (Staffa et al., 2002). Since there are several definitions for types of statin 
myopathy (Table 1.4), it has been difficult to compare the incidence of myopathy in 
RCTs. Importantly, the data from RCTs do not represent the real world clinical practice. 
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The frequency of statin myopathy is reported more frequently in clinical practices, since 
RCTs are not explicitly designed to assess myopathy and the patient population studied 
does not reflect the same population. Indeed, observational evidence estimates that 
skeletal muscle myopathies occur in 10-15% of patients (Bruckert et al., 2005; Buettner 
et al., 2008; Jacobson, 2008; Thompson et al., 2003). All statins have been implicated in 
causing muscle side effects, albeit at differencing frequencies. The in vitro rank order for 
statin cytotoxicity has been reported to be cerivastatin > simvastatin acid > fluvastatin > 
atorvastatin > lovastatin acid > pitavastatin ≫ rosuvastatin, pravastatin (Kobayashi et al., 
2008). Analysis of the FDA AERS database from 1990-2002 for statin associated 
rhabdomyolysis reports a similar pattern to the in vitro cytotoxicity. Cerivastatin was the 
most commonly implicated statin in 57% of cases followed by simvastatin (18%), 
atorvastatin (12%), pravastatin (7%), lovastatin (4%) and fluvastatin (2%) (Thompson et 
al., 2003). The frequency of muscle symptoms associated with statins was estimated in 
the observational PRIMO study in patients receiving high dose statins. Muscle related 
symptoms were reported by 10.5% of patients. The reports of muscle symptoms were 
most common in patients receiving simvastatin (18.2%), followed by atorvastatin 
(14.9%), pravastatin (10.9%) and fluvastatin (5.1%) (Bruckert et al., 2005). 
While serum biochemistry is a useful diagnostic tool for myopathy, it should be noted 
that there have been case reports of statin-induced muscle myopathies without elevated 
plasma CK (Phillips et al., 2002). Myopathy associated with statin usage can begin as 
early as one week into therapy but onset also can be delayed for several years. On 
average, myopathy is reported to occur 6 months after starting therapy (Hansen et al., 
2005). The duration of myopathy lasts an average of 2.3 months after discontinuation of 
statin and over 50% of patients experiencing myopathy cannot tolerate another statin 
(Bruckert et al., 2005; Hansen et al., 2005; Thompson et al., 2006). Muscle complaints 
from statins are dose dependent, of diffuse origin (Ballantyne et al., 2003; Bays, 2006) 
and often result in the structural damage to muscle fibres which can persist even after 
discontinuation of therapy (Draeger et al., 2006; Mohaupt et al., 2009).   
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Table 1.4 Definitions of Statin-Related Myopathy 
  ACC/AHA/HHLBI NLA FDA 
Myopathy General term referring to 
any disease of muscles 
Complaints of 
myalgia (muscle pain 
or soreness), 
weakness, and/or 
cramps plus elevation 
in serum CK 
CK ≥ 10 x ULN 
Myalgia Muscle aches or 
weakness without CK 
elevation 
NA NA 
Myositis Muscle symptoms with 
CK elevation 
NA NA 
Rhabdomyolysis Muscle symptoms with 
significant CK elevation 
(>10 x ULN) with 
myoglobinuria 
CK > 10,000 IU/L or 
CK > 10 x ULN plus 
an elevation in serum 
creatinine or medical 
intervention with 
intravenous hydration 
CK > 50 x ULN 
and evidence of 
organ damage, 
such as renal 
compromise 
ACC/AHA/HHLBI = American College of Cardiology/American Heart 
Association/National Heart, Lung and Blood Institute, NLA = National Lipid 
Association, FDA = Food and Drug Administration 
CK = creatine kinase, ULN = Upper Limit of Normal 
References: (Ballantyne et al., 2003; Joy and Hegele, 2009) 
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1.3.1 Etiology of Statin-Associated Myopathy 
The pathophysiology of statin-induced myopathy is not completely understood. Multiple 
pathophysiological mechanisms have been proposed to attempt to explain the relationship 
between statins and myotoxicity including isoprenoid depletion, depletion of ubiquinone 
or coenzyme Q-10 (CoQ10) synthesis, decreased or altered sarcolemma membrane 
cholesterol, or disturbed calcium homeostasis. 
 
1.3.2 Depletion of Membrane Cholesterol 
Initially, it was hypothesized that decreased membrane cholesterol levels lead to myocyte 
membrane destabilization and degeneration (Baker, 2005). This mechanism has been 
challenged by the results of clinical studies involving the novel squalene synthase 
inhibitors, which block cholesterol synthesis downstream of HMG-CoA reductase. 
Squalene synthase catalyzes the first committed step in the biosynthesis of cholesterol 
(Fig. 1.1). Inhibitors of squalene synthase selectively inhibit cholesterol synthesis and not 
the other non-sterol end products, and clinical studies of these drugs did not reveal 
indications of muscle toxicity (Do et al., 2009; Flint et al., 1997; Nishimoto et al., 2003; 
Seiki and Frishman, 2009). 
 
1.3.3 Isoprenoid Depletion 
The leading mechanism proposed for statin-induced myopathy involves the cellular 
depletion of secondary metabolic intermediates of mevalonate in the development of 
myotoxicity (Baker, 2005). HMG-CoA reductase inhibition by statins decreases 
mevalonate and cholesterol synthesis. However, cholesterol is not the only end product of 
this pathway and in addition to decreased cholesterol there are subsequent reductions in 
the levels of downstream metabolic products including isoprenoids, dolichol and 
ubiquinone (CoQ10) (Baker, 2005; Hanai et al., 2007; Itagaki et al., 2009; Sakamoto et 
al., 2007). Geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP) are 
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two very important isoprenoid secondary metabolic intermediates of the cholesterol 
synthesis pathway. GGPP and FPP are involved in the post-translational modification of 
an estimated 300 cellular proteins through isoprenylation. Isoprenylation involves the 
covalent addition of geranylgeranyl or farnesyl groups to cysteine residues at or near the 
C-terminus of proteins such as members of the small G protein superfamily (McTaggart, 
2006). Isoprenylation allows proteins to anchor to cell membranes and in some cases is 
required for activation of some proteins including small GTPases such as Rho and Rab 
(Konstantinopoulos et al., 2007). Recently, induction of the muscle atrophy-linked 
protein atrogin-1 has been shown to mediate statin myotoxicity through a mechanism 
involving decreased isoprenylation (Cao et al., 2009; Hanai et al., 2007). A reduction in 
prenylation of small GTPases appears to stimulate the mitochondrial apoptotic cell death 
pathway by increasing levels of cytosolic calcium (Liantonio et al., 2007), calpain 
activation, Bax translocation to the mitochondria (Sacher et al., 2005), cytochrome C 
release (Kaufmann et al., 2006) and induction of pro-apoptotic caspases (Dirks and Jones, 
2006; Johnson et al., 2004) (Fig 1.3). The importance of isoprenylation in statin induced 
myotoxicity is highlighted by the findings that supplementation of GGPP leads to 
attenuation of statin toxicity in cultured skeletal myotubes or isolated myofibers (Cao et 
al., 2009; Itagaki et al., 2009; Johnson et al., 2004; Sakamoto et al., 2007), while 
inactivation of Rab and RhoA has been shown to induce toxicity through inhibition of 
endoplasmic reticulum to golgi vesicular trafficking (Itagaki et al., 2009; Sakamoto et al., 
2007; Sakamoto et al., 2011).  
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Figure 1.3 A proposed mechanism of statin induced skeletal muscle damage. 
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1.3.4 Mitochondrial Dysfunction and Depletion of Coenzyme Q10 
CoQ10 is synthesized from mevalonate and is an essential cofactor for oxidative 
respiration in the mitochondria. Depletion of CoQ10 might contribute to statin myopathy 
because it affects oxidative phosphorylation, protects from statin-induced oxidative stress 
and regenerates antioxidant vitamins C and E (Marcoff and Thompson, 2007). Extensive 
evidence demonstrates that statins lower plasma CoQ10 levels in a drug and dose 
dependent manner (Folkers et al., 1990; Kawashiri et al., 2008; Mabuchi et al., 2007; 
Schaars and Stalenhoef, 2008). However, the reduction in plasma CoQ10 levels can be 
attributed to the lowering of LDL cholesterol, since it is the primary carrier of plasma 
CoQ10 (Laaksonen et al., 1994; Tomasetti et al., 1999). If CoQ10 concentrations are 
normalized for decreased LDL or total cholesterol there is no significant change in 
CoQ10 concentration (Marcoff and Thompson, 2007). Interestingly, the serum 
concentrations of CoQ10 do not consistently reflect muscle concentrations (Paiva et al., 
2005; Schaars and Stalenhoef, 2008) and evidence suggests that low dose statin treatment 
does not affect the intramuscular CoQ10 levels (Marcoff and Thompson, 2007). 
However, one study suggests that even if CoQ10 is decreased in muscle, most patients 
have no histochemical or biochemical evidence of mitochondrial myopathy or 
morphologic evidence of apoptosis (Lamperti et al., 2005). Supplementation of CoQ10 
during statin therapy can increase the circulating CoQ10 concentrations (Palomaki et al., 
1998; Schaars and Stalenhoef, 2008) and provide protection from statin-induced 
oxidative stress. Compelling clinical evidence is lacking regarding the efficacy of CoQ10 
treatment for statin myopathy (Caso et al., 2007; Marcoff and Thompson, 2007; Young et 
al., 2007); there is no evidence that supplementation has any effect on muscle CoQ10 
levels (Schaars and Stalenhoef, 2008).  
If reduced CoQ10 levels mediate statin-induced myopathy, there should be evidence of 
impaired mitochondrial function. However, only a few studies have shown indirect 
evidence of mitochondrial dysfunction in humans. Decreased CoQ10 was associated with 
mitochondrial dysfunction when measuring an increase in the blood lactate to pyruvate 
ratio (De Pinieux et al., 1996). This ratio is used as a marker of mitochondrial impairment 
because it shows a shift toward anaerobic metabolism (De Pinieux et al., 1996). Muscle 
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biopsies from patients with statin induced myopathy have also suggested a link between 
mitochondrial dysfunction and clinical symptoms despite normal CK levels (Levy and 
Kohlhaas, 2006; Phillips et al., 2002). One study reported that muscle pain and weakness 
was more prevalent in patients with mitochondrial respiratory chain defects (Vladutiu et 
al., 2006). 
 
1.3.5 Impairment of Calcium Homeostasis 
The regulation of calcium release and uptake is critical for the normal function of muscle 
cells. The initial increase in intracellular calcium, mediated by an action potential, results 
in the opening of ryanodine receptors on the sarcoplasmic reticulum leading to muscle 
contraction. In vitro studies show that statins impair calcium homeostasis and lead to 
membrane depolarization (Liantonio et al., 2007; Sirvent et al., 2005). Muscle biopsies 
from patients with statin-induced myopathy have shown alterations in expression of 
genes regulating calcium homeostasis, impairment of calcium signalling and structural 
changes to the T-tubular system and sarcoplasmic reticulum (Draeger et al., 2010; 
Mohaupt et al., 2009; Sirvent et al., 2012). However, it is still unclear if these statin-
induced muscle dysregulations contribute to or are a consequence of myotoxicity. 
 
1.3.6 Patient Related Risk Factors 
Many clinical factors have been shown to increase the risk of statin-induced myopathy 
including age, female gender, Asian descent, low body mass index, strenuous exercise, 
excess alcohol consumption, diet (grapefruit and other fruit juices), drugs of abuse 
(cocaine), untreated hypothyroidism, impaired hepatic or renal function and perioperative 
periods (Abd and Jacobson, 2011; Ballantyne et al., 2003; Joy and Hegele, 2009; 
Pasternak, 2002; Rosenson, 2004). Family history of statin induced myopathy and 
previous history of statin myopathy are also significant risk factors (Bruckert et al., 
2005). Inherited muscle diseases like McArdle’s disease and carnitine palmitoyl 2 (CPT-
2) deficiencies have also been associated with the development of myopathy (Vladutiu et 
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al., 2006). Recently deficiency in vitamin D has been associated with statin induced 
myopathy and supplementation can result in the resolution of myalgia (Ahmed et al., 
2009; Gupta and Thompson, 2011).  
An epidemiology study recently developed a model to predict statin adverse reactions 
based on risk factors readily available and recorded in patient health records. The Qstatin 
risk score was developed from data encompassing 2.2 million patients in the UK and it 
has proven useful for predicting the 5 year statin risk of developing acute renal failure, 
cataracts, and myopathy (Collins and Altman, 2012). The Qstatin score is currently the 
only quantitative measure to assess myopathy risk using the following factors: statin 
usage, age, sex, BMI, self assigned ethnicity, treated hypertension, corticosteroid usage, 
diagnosis of type 1 or 2 diabetes, diagnosis of chronic liver disease, and diagnosis of 
hypothyroidism. The 5 year risk of developing myopathy, CK ≥ 4 x ULN or 
rhabdomyolysis, is predicted to be between 0.05% and 0.25%, depending on age and 
gender. Factors that increase the risk of statin induced myopathy are summarized in Table 
1.5. 
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Table 1.5 Risk Factors for Statin-Induced Myopathy 
 ● Increased age 
   ● Female gender 
  ● Low body mass index 
  ● Asian descent 
   ● Renal or hepatic impairment 
 ● Hypothyroidism 
  ● Perioperative periods 
  ● Metabolic muscle disease 
 ● Family history of statin induced myopathy 
● Previous history of statin induced myopathy 
● Vitamin D deficiency 
  ● Strenuous exercise 
  ● Excess alcohol consumption 
 ● Diet - grapefruit juice 
  ● Drugs of abuse 
  ● Co-medications 
  
 
○ Other myotoxic drugs 
 
 
○ Metabolic inhibition of CYP or UGT 
● Statin Characteristics 
  
 
○ High statin dose 
  
 
○ Lipophilicity? 
    ○ Potential for metabolic drug interactions 
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1.3.7 Drug Interactions 
It is well documented that myotoxicity is statin dose-dependent, and myopathy risk 
increases when statins are co-administered with drugs that either interact to increase 
plasma statin levels or themselves have propensity for muscle damage (Ballantyne et al., 
2003; Huerta-Alardin et al., 2005; Jones and Davidson, 2005; Neuvonen et al., 2006).  
Co-administered drugs that cause increases in statin blood levels are a significant risk 
factor for development of myotoxicity. Many of the statins are significantly metabolized 
in the intestinal enterocytes and hepatocytes by the cytochrome (CYP) P450 superfamily 
and UDP-glucuronosyltransferases (UGT) resulting in low bioavailability (Table 1.2). 
Therefore, inhibition of these enzymes by co-administered medications can be associated 
with increased plasma statin levels (Ballantyne et al., 2003; Bottorff, 2006; Jones and 
Davidson, 2005). Grapefruit juice, macrolide antibiotics and azole antifungals are well 
known drug inhibitors of hepatic statin metabolism via CYP P450 enzymes, particularly 
CYP3A4, and their interaction can lead to a many-fold increase in plasma statin levels 
and risk of myopathy (Lilja et al., 1998; Lilja et al., 1999; Neuvonen et al., 1998; 
Neuvonen et al., 2006). The importance of CYP3A4 in statin metabolism is demonstrated 
by published reports associating more than 50% of statin induced rhabdomyolysis cases 
with a CYP3A4 inhibitor and possible drug interaction (Bottorff, 2006; Dreier and 
Endres, 2004; Omar et al., 2001; Sorokin et al., 2006). It has been estimated that 7% of 
individuals taking statins are co-prescribed drugs that would cause metabolic interactions 
(Ratz Bravo et al., 2005). One important drug interaction occurs with the often co-
prescribed fibrate drug, gemfibrozil, which interacts through inhibition of statin 
glucuronidation (Prueksaritanont et al., 2002) and CYP2C8 mediated statin oxidation 
(Wang et al., 2002). Combination treatment of gemfibrozil with a statin appears to 
increase myopathy risk up to 50-fold compared to statin monotherapy. In fact for 
cerivastatin, the absolute rhabdomyolysis incidence with fibrate co-administration is an 
astounding 10% or a 1400-fold increase over statin monotherapy (Graham et al., 2004).  
However, gemfibrozil has been shown to only modestly increase the plasma levels of 
other statins (2 to 3-fold) (Jacobson and Zimmerman, 2006). Therefore, alterations in 
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systemic exposure by gemfibrozil mediated inhibition of statin metabolism do not 
entirely account for the enhanced risk of myopathy. 
Atorvastatin is metabolized by CYP3A4 into two primary active metabolites o-
hydroxyatorvastatin and p-hydroxyatorvastatin. Recently it was reported that patients 
with atorvastatin related myopathy had an altered metabolic profile with significantly 
higher plasma levels of atorvastatin lactone, o-hydroxyatorvastatin and p-
hydroxyatorvastatin with no change in the atorvastatin plasma levels (Hermann et al., 
2006). This demonstrates distinct metabolic profiles, in the absence of CYP3A4 
inhibitors, for patients with atorvastatin induced myopathy and healthy controls. 
Concurrent treatment of atorvastatin and CYP3A4 inhibitors, leads to increased levels of 
atorvastatin lactone, and is associated with an increased risk of developing muscular side 
effects (Kantola et al., 1998; Omar and Wilson, 2002).  
Drug interactions with statins can also involve drug transport proteins. Cyclosporine is an 
immunosuppressant drug and a potent inhibitor of several drug transporters including; 
OATP1B1, OATP1B3, OATP2B1, NTCP, MRP2, and P-gp (Chen et al., 1999; Hirano et 
al., 2006; Ho et al., 2006; Kajosaari et al., 2005; Rao and Scarborough, 1994; Shitara et 
al., 2003). The AUC of statins is increased with cyclosporine use by 2 to 25-fold without 
effecting the terminal half life (Neuvonen et al., 2006). This interaction could be a result 
of increased statin bioavailability or decreased systemic clearance through inhibition of 
hepatic uptake or billary efflux transporters (Neuvonen et al., 2006). Drug interactions 
have also been reported for protease inhibitors and statins. Simvastatin and lovastatin are 
contraindicated in the presence of protease inhibitors due to inhibition of CYP3A4/5. 
Statins undergoing minimal hepatic metabolism, like rosuvastatin and pravastatin, are 
also subject interactions involving the activity or expression of uptake or efflux 
transporters including; OATP1B1, P-gp, BCRP and, MRP2 (Bachmeier et al., 2005; Dixit 
et al., 2007; Kim et al., 1998). Many studies involving rosuvastatin, pravastatin and 
atorvastatin have reported increases in the AUC when taken concurrently with protease 
inhibitors (Busti et al., 2008; Kiser et al., 2008; Pham et al., 2009; Samineni et al., 2012). 
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1.3.8 Cerivastatin – What Can Be Learned? 
Cerivastatin was withdrawn from the market in 2001 because of a pronounced increase in 
the risk of rhabdomyolysis and myopathy (Staffa et al., 2002). Approximately 100 deaths 
have been linked to cerivastatin use and rhabdomyolysis (Furberg and Pitt, 2001; 
Thompson et al., 2003). Approximately half of the rhabdomyolysis cases reported to the 
FDA were linked to a drug interaction with gemfibrozil (Psaty et al., 2004). Gemfibrozil 
has been shown to inhibit the major elimination pathways for cerivastatin including; drug 
metabolizing enzymes CYP2C8, UGT1A1, UGT1A3 and the hepatic uptake transporter 
OATP1B1 (Backman et al., 2002; Muck et al., 1998; Shitara et al., 2004). In one 
pharmacokinetic study, gemfibrozil was shown to greatly increase the AUC of 
cerivastatin by 559% in healthy volunteers (Backman et al., 2002).  
Although the risk of muscle side effects with statins was known before, the cerivastatin 
experience unfortunately gave us the opportunity to study the link between statins and 
myopathy in many more cases. The cerivastatin experience was the first to demonstrate a 
clear statin dose-response relation with myopathy and a threshold effect above which 
myotoxicity increases significantly. Cerivastatin gave us insights into the mechanism of 
statin induced muscle toxicity and expanded our knowledge of risk factors. The 
pronounced effect of gemfibrozil on genes involved with cerivastatin suggests that 
genetic variants might play a major role in statin myopathy in patients who did not use 
gemfibrozil (Jacobson, 2006; Marciante et al., 2011).  
The tragic rate of rhabdomyolysis with cerivastatin was at least 10 fold higher than other 
statins (Farmer, 2001). This highlighted problems in the post-marketing surveillance of 
pharmacologic agents with the potential for adverse effects. The cerivastatin experience 
significantly increased the initial awareness of safety issues for all of the statins. The 
FDA became much more stringent with new drug applications (NDA) for statins. 
Rosuvastatin, approved in 2003, initially had data on 3,903 patients in its NDA. The FDA 
requested more safety data from AstraZeneca, and as a result, additional studies were 
completed, to include 12,569 patients in the revised rosuvastatin NDA (Jacobson, 2006). 
From a risk benefit standpoint, if high dose statins are only marginally more efficacious 
at lowering LDL-C, but have even just a mild increase in muscle adverse events, then a 
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lower maximal dose is more appropriate dose to market (Bays, 2006; Rosenson and Bays, 
2003). In the case of rosuvastatin the FDA did not approve the 80 mg dose because the 
lipid-lowering benefits were outweighed by the increased risks for renal toxicity and 
myotoxicity (Jacobson, 2006). 
 
1.3.9 Therapeutic Approaches in the Management of Statin 
Intolerance 
It is inevitable that some patients will discontinue statin therapy because of adverse 
effects. To be certain of a diagnosis of statin intolerance, it is recommended that patients 
undergo rechallenge with the same or lower dose of the statin after the resolution of their 
symptoms. In general, patients will not be able to tolerate high dose statin treatment but 
they may tolerate lower doses or alternate dosing regimes. The goal in patients with 
confirmed statin intolerance is to maintain sustained LDL-C lowering and prevention of 
CVD. Switching to a different statin should be considered because over 40% of patients 
will tolerate another statin without incident (Hansen et al., 2005). Rosuvastatin and 
fluvastatin have been considered preferred choices because they appear to be associated 
with lower risks of myopathy (Glueck et al., 2006; Stein et al., 2008). One study showed 
that 57% of patients intolerant to the usual dose of simvastatin were able to tolerate low 
dose simvastatin of 0.825 to 8.75 mg daily (Degreef et al., 2010). Studies evaluating 
alternate dosing regimes of rosuvastatin have also been assessed in patients with previous 
statin intolerance. Alternating-day dosing of rosuvastatin was tolerated in 72.5% of 
patients at a mean does of 5.6 mg, and LDL-C was reduced by 34.5% (Backes et al., 
2008). Once weekly dosing of rosuvastatin was also studied in 10 patients with statin 
intolerance. This dosing regime was tolerated by 8 patients and with an average LDL-C 
reduction of 29% (Backes et al., 2007). Atorvastatin has also been successful in reducing 
LDL-C when used in alternate dosing regimes (Ferrer-Garcia et al., 2006; Juszczyk et al., 
2005; Matalka et al., 2002). Other alternatives for the treatment of hypercholesterolemia 
not involving statins include: ezetimibe, niacin, fibrates, and bile acid sequestrants; 
however, the use of these agents as monotherapy only results in mild reductions of LDL-
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C. Combination therapy of these agents with low dose statins or alternate statin dosing 
may allow statin intolerant individuals to achieve target LDL-C levels. 
Other strategies have been investigated as symptomatic therapies, targeting muscle 
symptoms in patients. As discussed above, CoQ10 is an important cofactor in the 
mitochondrial electron transport chain and depletion has been considered a cause of statin 
myopathy. There are currently conflicting results for the use of CoQ10 in treatment of 
statin intolerance and pain (Caso et al., 2007; Young et al., 2007). A systemic review 
concluded that there was insufficient evidence to support the use of CoQ10 in treatment 
of pain or myopathy (Marcoff and Thompson, 2007). Vitamin D has also been suggested 
for treatment of statin induced myalgia. One report shows that supplementation of 50,000 
U per week of vitamin D can reduce myalgia by 92%; however, vitamin D levels in 
patients with and without myalgia were reported to be the same (Ahmed et al., 2009; 
Backes et al., 2011). More evidence, such as a placebo controlled trial, is need to decide 
if vitamin D is of benefit for relief of statin myalgia (Gupta and Thompson, 2011). 
No strategy is currently available to solely target the relief of muscle symptoms while 
taking statins. Management of this adverse effect generally requires a combination of a 
statin dose reduction, switching statins, alternate dosing regime, changing to an alternate 
lipid lowering agent, or combination therapy. 
 
1.4 Statin Pharmacogenomics 
There is wide variation among individuals and their response to statin efficacy and 
toxicity. This is partially due to differences in genes involved in statin pharmacokinetics. 
Ethnic and interindividual differences in plasma statin levels and area under the curve 
(AUC) has been reported before (Lee et al., 2005; Wang, 2011). The differences in statin 
pharmacokinetics has been linked to variation in the CYP P450 superfamily and the 
OATP superfamily of drug uptake transporters. 
 
  
32 
1.4.1 Pharmacogenomics of Statin Pharmacokinetics 
The CYP superfamily is involved in the metabolism of many statins; therefore, genetic 
variation in these enzymes can be associated with changes in statin pharmacokinetics. 
CYP3A is the most prominent pathway for statin metabolism. To date, no polymorphisms 
in CYP3A4 have been reported to change statin pharmacokinetics (Shitara and Sugiyama, 
2006). However, reports of significant variation within intestinal and hepatic expression 
of CYP3A4 may have profound effects on statin pharmacokinetics (Wandel et al., 2000). 
One polymorphism in CYP3A4 intron 6 (rs35599367, C>T) causes a significant 
reduction in the expression of CYP3A4. Carriers of the T allele have been shown to 
require lower doses of atorvastatin, simvastatin, or lovastatin for optimal lipid control 
compared to non-T carriers (Elens et al., 2011; Wang et al., 2011). Individuals expressing 
CYP3A5 have a reduced lipid lowering response to lovastatin, simvastatin and 
atorvastatin (Kivisto et al., 2004). Healthy individuals expressing CYP3A5 have a 
significantly reduced AUC and increased oral clearance over non-expressors (Kim et al., 
2007). Interestingly, polymorphisms within CYP2D6, CYP2C9 and CYP2C8 have also 
been associated with pharmacokinetic changes in simvastatin, fluvastatin and 
cerivastatin, respectively (Ishikawa et al., 2004; Kirchheiner et al., 2003; Mulder et al., 
2001; Vermes and Vermes, 2004). 
Pharmacokinetic changes are also seen with variation in drug transporter genes. As 
mentioned above OATP1B1 is highly polymorphic (Niemi et al., 2011; Tirona et al., 
2001) and the reduced function SLCO1B1*5 521T>C variant has been well studied for 
involvement in statin pharmacokinetics. The OATP1B1*5 variant has been shown in 
multiple pharmacokinetic studies to increase the AUC for many statins including: 
atorvastatin (Lee et al., 2010; Pasanen et al., 2007), pravastatin (Ho et al., 2007; Igel et 
al., 2006; Maeda et al., 2006; Mwinyi et al., 2004; Niemi et al., 2006; Niemi et al., 2004; 
Nishizato et al., 2003), pitavastatin (Chung et al., 2005; Deng et al., 2008; Ieiri et al., 
2007), rosuvastatin (Choi et al., 2008; Lee et al., 2005; Pasanen et al., 2007), and 
simvastatin (Pasanen et al., 2006). 
The nonsynonymous ABCG2 (BCRP) 421C>A SNP results in lower expression levels 
and function of the ABCG2 efflux transporter protein in hepatocytes, enterocytes and 
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other tissues (Cusatis and Sparreboom, 2008). Various pharmacokinetic studies have 
shown that individuals carrying the 421C>A variant have increased plasma 
concentrations of atorvastatin, fluvastatin, simvastatin lactone and rosuvastatin (Keskitalo 
et al., 2009a; Keskitalo et al., 2009b; Zhang et al., 2006). Although no effect has been 
seen on the pharmacokinetics of pitavastatin, pravastatin or simvastatin acid (Ho et al., 
2007; Ieiri et al., 2007; Keskitalo et al., 2009a). The ABCG2 421C>A has not been 
reported to effect the elimination T½ of rosuvastatin or atorvastatin suggesting that the 
increase in plasma statin concentration is due to enhanced absorption and increased 
bioavailability rather than decreased hepatic elimination (Keskitalo et al., 2009b; Zhang 
et al., 2006). The ABCG2 421 SNP has a much higher prevalence in Asian subjects 
compared to Caucasians (35% vs 9-15%) (Hu et al., 2011). The different frequencies of 
ABCG2 polymorphisms in different ethnic groups, such as Asians, may contribute to the 
interethnic variability in the pharmacokinetics and pharmacodynamics of statins. 
However, the ABCG2 SNPs cannot completely explain ethnic differences in statin 
pharmacokinetics between Asians and Caucasians (Wang, 2011). 
 
1.4.2 Pharmacogenomics of Statin Efficacy 
It is well documented that drug transporters are involved in the pharmacokinetics of 
statins. In theory changes to the pharmacokinetics of a drug will influence the 
pharmacodynamics and efficacy of the drug. To date only a few studies have looked at 
the genetic variation with regards to the LDL-C reduction associated with statins using 
both genome wide association studies (GWAS) and candidate gene approaches. The 
Genetics Effects On STATins (GEOSTAT-1) was a prospective genetic study in 601 
patients taking simvastatin 40 mg or rosuvastatin 10 mg. Using a candidate gene 
approach they found an enhanced reduction in LDL-C in patients taking rosuvastatin with 
a ABCG2 (BCRP) variant with reduced function (421C>A, rs2231142) (Bailey et al., 
2010). The Justification for the Use of statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin (JUPITER) study looked at the use of rosuvastatin for the 
primary prevention of CVD in patients without hyperlipidemia (Ridker et al., 2008). In a 
subsequent analysis using a GWAS approach, Chasman and colleagues identified that 
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ABCG2 421C>A genotype was associated with increased efficacy for LDL-C reduction 
with rosuvastatin. In a candidate gene analysis, they also demonstrated that variations in 
OATP1B1 (SLCO1B1) (rs4149056 and rs4363657) were associated with decreased 
efficacy in reducing LDL-C (Chasman et al., 2012). The SEARCH trial also found a 
small but significant association between SLCO1B1 SNP rs419056 and lower LDL-C 
reductions, in patients from the Heart Protection Study (HPS) (Link et al., 2008). One 
small study reported that variation in ABCB1 (P-gp) is associated with increased 
simvastatin efficacy. They found that homozygous carriers of ABCB1 polymorphisms, 
1236C>T and 2677G>A or T, had an enhanced reduction in total cholesterol and LDL-C 
compared to non-carrier individuals (Fiegenbaum et al., 2005). 
 
1.4.3 Pharmacogenomics of Statin Toxicity 
Genetic variation in drug transporters is also associated with pharmacokinetic changes 
and toxicity of statins. As discussed above, genetic variation in the hepatic uptake 
transporter, OATP1B1, and biliary efflux transporter, BCRP, are associated with 
variability in statin pharmacokinetics and plasma levels. Polymorphisms in these genes 
lead to increased systemic exposure and possible statin myopathy. 
Hepatic uptake of all statins is facilitated to some extent by OATP1B1 on the sinusoidal 
membrane. The OATP1B1*5 associated with increased plasma levels of a number of 
statins (Pasanen et al., 2007). In 2008, the SEARCH study preformed the first GWAS for 
statin-induced myopathy including over 300,000 polymorphisms in 85 patients with 
simvastatin myopathy and 90 matched drug exposed controls. They found one 
polymorphism in SLCO1B1 (*5, rs4149056) to be the most robust predictor of the risk 
for simvastatin-induced myopathy, revealing an odds ratio of 4.5 per copy of the variant 
allele (Link et al., 2008). They also estimated that SLCO1B1*5 variant increased 5 year 
cumulative risk for myopathy in subjects with one or two alleles by 3% and 18% 
respectively. The link between the SLCO1B1*5 and simvastatin-induced myopathy has 
been confirmed and expanded to include atorvastatin but not pravastatin induced 
myopathy (Voora et al., 2009). Another study has also replicated the link between 
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SLCO1B1*5 and simvastatin induced myopathy but not atorvastatin induced myopathy 
(Brunham et al., 2012). The Genetics of Diabetes Audit and Research (Go-DARTS) 
study replicated the impact of the SLCO1B1*5 polymorphism on statin intolerance in a 
real world population. They suggest that at least one-third of individuals with the 
SLCO1B1*5 variant are likely to suffer from side effects on high dose statins (Donnelly 
et al., 2011). 
Simvastatin induced myopathy has also been associated with variation in the efflux 
transporter ABCB1 (P-gp). Significant differences in allele frequencies were observed for 
ABCB1 (P-gp) polymorphisms, 1236C>T, 2677G>A or T, and 3534C>T, in patients with 
myalgia associated with simvastatin treatment (Fiegenbaum et al., 2005). Interestingly, in 
110 patients with statin induced myopathy, only 10% had a rare heterozygous mutation in 
a gene normally related to myopathy syndromes including McArdle disease, CPT-II 
deficiency, and myoadenylate deaminase deficiency (Vladutiu et al., 2006). This suggests 
that the genetic basis for statin myopathy may include a complex mixture of rare and 
common DNA polymorphisms (Mancini et al., 2011). 
 
1.4.4 Current Guidelines for Statin Pharmacogenetics 
All statins are substrates of OATP1B1 but the effect of the SLCO1B1*5 polymorphism 
differs depending on the statin. The SLCO1B1*5 has the largest effect on simvastatin 
exposure; the AUC of simvastatin acid increases by 221% in individuals homozygous for 
the *5, 521CC, genotype (Pasanen et al., 2006). The AUCs of atorvastatin, pravastatin, 
and rosuvastatin are increased by 144%, 57-130% and 62-119%, respectively in 
homozygous *5, 521CC, individuals (Wilke et al., 2012). Given that statin induced 
myopathy appears to be a plasma concentration dependent adverse effect, it would be 
advisable to avoid high statin doses in patients with this genetic polymorphism. 
Recommendations have been made to reduce the maxim dose of simvastatin, pitavastatin 
and atorvastatin by half for each copy of the *5 allele an individual carries (1 copy ½ 
maximal dose, 2 copies ¼ maximal dose). While rosuvastatin and pravastatin doses 
should also be reduced by half in carriers of the *5 allele (Niemi, 2010). The FDA 
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updated the simvastatin product label in 2011, recommending against the use of 80 mg 
simvastatin in any patient unless it has been previously tolerated for at least 12 months 
(Wilke et al., 2012). More recently the Clinical Pharmacogenomics Implementation 
Consortium recommended gene-based dosing for simvastatin based on their SLCO1B1*5, 
521T>C, genotype. They recommend the use of decision support tools to direct 
physicians away from using 80 mg simvastatin doses and warn providers that doses of 40 
mg of simvastatin daily also has a modest increased risk of myopathy (Wilke et al., 
2012). The Clinical Pharmacogenomics Implementation Consortium also point out that 
the wild type genotype SLCO1B1 521TT does not imply the absence of other potentially 
deleterious variants in SLCO1B1 or elsewhere (Wilke et al., 2012). Based on the *5 allele 
frequency and the rate of adverse reactions on high dose simvastatin, only 30 subjects 
would have to be genotyped to avoid one adverse drug reaction (ADR) (Wilke et al., 
2012). Since, genotyping for one SNP can be achieved very rapidly and at a low cost, 
SLCO1B1 genotyping is recommended to increase the safety of high dose statin therapy 
(Niemi, 2010; Wilke et al., 2012). 
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Table 1.6 Transporter Polymorphisms Involved in Statin Pharmacokinetics and Response 
 
Statin 
Transporter 
poly-
morphism Population 
Effect on 
PK 
Effect on 
Response Ref 
Atorvastatin SLCO1B1*5 
521T>C 
Healthy 
Participants 
(n=32) 
144% 
increase 
in AUC 
 
(Pasanen et 
al., 2007) 
  Healthy 
Participants 
(n=290) 
123% 
increase 
in AUC 
 
(Lee et al., 
2010) 
  Patients 
(n=509) 
 increased 
muscle 
toxicity, 
OR 2.7 
(Voora et al., 
2009) 
  Patients 
(n=25, 85 
controls) 
 no 
association 
with 
muscle 
toxicity 
(Brunham et 
al., 2012) 
 ABCG2 
421C>A 
Healthy 
Participants 
(n=32) 
72% 
increase 
in AUC 
 
(Keskitalo et 
al., 2009b) 
Cerivastatin SLCO1B1*5 
521T>C 
Patients 
(n=185, 732 
control) 
 increased 
muscle 
toxicity, 
OR 1.89 
(Marciante et 
al., 2011) 
Fluvastatin SLCO1B1*5 
521T>C 
Healthy 
Participants 
(n=32) 
no effect 
on AUC 
 
(Niemi et al., 
2006) 
 ABCG2 
421C>A 
Healthy 
Participants 
(n=32) 
97% 
increase 
in AUC 
 
(Keskitalo et 
al., 2009a) 
Pitavastatin SLCO1B1*15 
388A>G + 
521T>C 
Healthy 
Participants 
(n=11) 
162% 
increase 
in AUC 
 
(Deng et al., 
2008) 
  Healthy 
Participants 
(n=24) 
76% 
increase 
in AUC 
 
(Chung et al., 
2005) 
  Healthy 
Participants 
(n=38) 
209% 
increase 
in AUC 
 
(Ieiri et al., 
2007) 
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 ABCG2 
421C>A 
Healthy 
Participants 
(n=38) 
no effect  
(Ieiri et al., 
2007) 
Pravastatin SLCO1B1*5 
521T>C 
Healthy 
Participants 
(n=41) 
106% 
increase 
in AUC 
 
(Niemi et al., 
2004) 
  Healthy 
Participants 
(n=32) 
232% 
increase 
in AUC 
 
(Niemi et al., 
2006) 
  Healthy 
Participants 
(n=107) 
149% 
increase 
in AUC 
 
(Ho et al., 
2007) 
  Pediatric 
Patients 
(n=32) 
62% 
decreased 
AUC 
lower LDL 
cholesterol 
reduction 
(Hedman et 
al., 2006) 
  Patients 
(n=45) 
 lower total 
cholesterol 
reduction 
(Zhang et al., 
2007) 
  Patients 
(n=66) 
 lower total 
cholesterol 
reduction 
(Tachibana-
Iimori et al., 
2004) 
  Healthy 
Participants 
(n=30) 
42% 
increase 
in AUC 
 
(Mwinyi et al., 
2004) 
 SLCO1B1*15 
388A>G + 
521T>C 
Healthy 
Participants 
(n=38) 
98% 
increase 
in AUC 
 
(Deng et al., 
2008) 
  Healthy 
Participants 
(n=41) 
93% 
increase 
in AUC 
 
(Niemi et al., 
2004) 
  Healthy 
Participants 
(n=107) 
92% 
increase 
in AUC 
 
(Ho et al., 
2007) 
  Healthy 
Participants 
(n=16) 
110% 
increase 
in AUC 
 
(Igel et al., 
2006) 
 ABCG2 
421C>A 
Healthy 
Participants 
(n=32) 
no effect  
(Keskitalo et 
al., 2009a) 
  Healthy 
Participants 
(n=107) 
no effect  
(Ho et al., 
2007) 
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Rosuvastatin SLCO1B1*5 
521T>C 
Healthy 
Participants 
(n=142) 
117% 
increase 
in AUC 
 (Lee et al., 
2005) 
  Healthy 
Participants 
(n=32) 
65% 
increase 
in AUC 
 (Pasanen et 
al., 2007) 
  Healthy 
Participants 
(n=30) 
72% 
increase 
in AUC 
 (Choi et al., 
2008) 
 ABCG2 
421C>A 
Healthy 
Participants 
(n=32) 
144% 
increase 
in AUC 
 (Keskitalo et 
al., 2009b) 
  Healthy 
Participants 
(n=32) 
76%% 
increase 
in AUC 
 (Zhang et al., 
2006) 
  Patients 
(n=6989) 
 enhanced 
LDL 
cholesterol 
reduction 
(Chasman et 
al., 2012) 
 
	  
Myocardial 
Infarction 
Patients 
(n=601) 
	  
enhanced 
LDL 
cholesterol 
reduction 
(Bailey et al., 
2010) 
Simvastatin 
acid 
SLCO1B1*5 
521T>C 
Healthy 
Participants 
(n=32) 
221%  
increase 
in AUC 
 (Pasanen et 
al., 2006) 
Simvastatin  SLCO1B1*5 
521T>C 
Patients 
(n=25, 84 
control) 
 increased 
muscle 
toxicity 
(Brunham et 
al., 2012) 
  Patients 
(n=509) 
 increased 
muscle 
toxicity 
(Voora et al., 
2009) 
  Diabetic 
Patients 
(N=4196) 
 increased 
statin 
intolerance 
(Donnelly et 
al., 2011) 
  Patients 
(n=85, 90 
control) 
 increased 
muscle 
toxicity 
(Link et al., 
2008) 
 ABCG2 
421C>A 
Healthy 
Participants 
(n=32) 
111% 
increase 
in AUC 
 
(Keskitalo et 
al., 2009a) 
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 ABCB1 
1236C>T 
Patients 
(n=116) 
 lower 
LDL-C 
reduction, 
increased 
muscle 
toxicity 
(Fiegenbaum 
et al., 2005) 
 ABCB1 
2677G>A or 
T 
Patients 
(n=116) 
 lower 
LDL-C 
reduction, 
increased 
muscle 
toxicity 
(Fiegenbaum 
et al., 2005) 
  ABCB1 
3534C>T 
Patients 
(n=116) 
  increased 
muscle 
toxicity 
 (Fiegenbaum 
et al., 2005) 
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1.5 Drug Transporters and Statin Exposure and 
Myopathy 
Clearly, the evidence suggests that increased statin plasma exposure causes an increased 
risk of muscle adverse effects and myopathy. Therefore, drug interactions or genetic 
polymorphisms that lead to increased statin exposure cause higher risk of developing 
myopathy. Most classical drug interactions involve inhibition of metabolism but drug 
transporters can also be involved. Most of the statins are administered in their active 
ionized β-hydroxyacid, which are less membrane permeable at physiological pH 
(Neuvonen et al., 2006). Statins also have a wide variability in LogD values for the active 
hydroxyacid form ranging from hydrophilic (pravastatin) to hydrophobic (atorvastatin) 
(Table 1.1). It is often suggested that hydrophobic statins have an increased risk of 
muscle injury compared with hydrophilic statins because of the greater permeability to 
cross myocyte membranes (Hamelin and Turgeon, 1998; Masters et al., 1995; Reijneveld 
et al., 1996). However, there is no reported change in the relative incidence of 
myotoxicity associated with statin lipophilicity (Thompson et al., 2003) suggesting that 
passive diffusion into muscle fibres does not completely determine the risk for toxicity. 
Furthermore, studies on the tissue distribution of statins show preferential accumulation 
in the liver and exclusion from skeletal muscle, suggesting involvement of drug 
transporters controlling systemic and tissue exposure (Duggan et al., 1989; Madsen et al., 
2008). Most of the attention has been given to transporters the in small intestine, kidney 
and liver and their involvement in statin absorption and elimination (Tirona, 2005). In 
contrast, very little study has been done on statin transporters within skeletal muscle and 
their influence on myotoxic side effects of statins. 
The strongest evidence for the involvement of drug transporters in statin myopathy 
relates to the hepatic uptake transporter OATP1B1. The study pharmacogenetics of 
OATP1B1 and statins has emphasized a role for OATP1B1 in controlling statin hepatic 
uptake and systemic exposure and the corresponding increase in muscle side effects. 
Drug interactions with OATP1B1 drug transport activity also presents another 
mechanism for transporter involvement in statin myopathy. Inhibition of OATP1B1 
mediated statin uptake into the liver by gemfibrozil has been shown to increase the 
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plasma exposure of pravastatin (Kyrklund et al., 2003), cerivastatin (Shitara et al., 2004), 
and rosuvastatin (Schneck et al., 2004). Importantly, OATP1B1 is not expressed in 
skeletal muscle and cannot explain changes in muscle exposure that are thought to occur 
in myopathy.  
OATP2B1 is another member of this uptake transporter family capable of transporting 
rosuvastatin and atorvastatin (Grube et al., 2006; Ho et al., 2006). OATP2B1 is widely 
expressed in the heart, kidney, intestine, liver, and placenta in comparison to the hepatic 
statin transporter OATP1B1 (Klaassen and Aleksunes, 2010) and expected to be 
responsible for controlling statin entry in to extrahepatic tissues. Studies in rats have 
suggested that drug transporters in muscle such as Oatp2b1 and Mrp1 may contribute to 
the skeletal muscle toxicity (Dorajoo et al., 2008; Sakamoto et al., 2008). Taken together 
evidence suggests that drug transporters have important roles in governing statin systemic 
exposure and that they may be involved in controlling muscle exposure and risk for 
myopathy.  
 
1.6 Animal Models of Statin Myopathy and Drug 
Transport 
The administration of statins induces myopathy in various preclinical animal models such 
as: guinea pigs, mice, rats, rabbits, dogs, pigs and monkeys (Bergman et al., 2003; 
Fukami et al., 1993; Madsen et al., 2008; Meador and Huey, 2011; Nakahara et al., 1998; 
Reijneveld et al., 1996; Sidaway et al., 2009; von Keutz and Schluter, 1998; Westwood et 
al., 2005; Westwood et al., 2008). However, the doses of statins required to induce 
myopathy in these species is very high when compared to therapeutic doses used in 
patients. Statin induced myopathy with elevations in serum CK has been demonstrated in 
the rat after repeated dosing for 10-14 days with lovastatin, pravastatin, simvastatin, 
cerivastatin, and rosuvastatin (Sidaway et al., 2009; Smith et al., 1991). The guinea pig 
has been suggested as a better model to study the safety margins of statins because of 
similarities in lipid metabolism compared with the human versus rat (Madsen et al., 
2008). 
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The advent of drug transporter knockout mouse models has made studying the in vivo 
role of drug transporters in statin disposition possible. Many studies have examined statin 
pharmacokinetics in knockout models of Oatp1b2, the murine ortholog of human 
OATP1B1 and OATP1B3. Increased systemic exposure and decreased hepatic uptake 
have been reported for lovastatin, pravastatin, atorvastatin, and rosuvastatin (Chen et al., 
2008; Degorter et al., 2012a; Zaher et al., 2008). However, there is a lack of data looking 
at muscle levels of statins in knockout mice. One study has looked at the toxicity 
associated with chronic pravastatin exposure in Oatp1a/1b knockout mice (Iusuf et al., 
2012). Despite highly increased plasma concentrations Oatp1a/1b knockout mice, only 
one in five mice showed muscle lesions along the vertebral column. Oatp1a/1b knockout 
mice had significant increased CK after 15 days, but not 30 or 60 days, of treatment 
suggesting only transient muscle lesions in Oatp1a/1b knockout mice (Iusuf et al., 2012). 
Since, pravastatin has a lower risk of causing myopathy compared with other statins, 
more studies are needed to examine myopathy of other statins in transporter knockout 
mice. 
Studies in rats and guinea pigs have cast doubt on the importance of drug uptake 
transporters. Muscle to plasma ratios of statins are much less than unity, and suggest that 
muscle is protected from statin accumulation (Madsen et al., 2008; Sidaway et al., 2009). 
Efflux transporters may be involved in maintaining low statin muscle concentrations and 
protecting muscle from toxicity. Co-administration of probenecid, a nonspecific Mrp 
inhibitor, and rosuvastatin in rats resulted in increased skeletal muscle toxicity (Dorajoo 
et al., 2008).  
 
1.7 Summary 
Statins are highly effective at lowering LDL-C and the treatment of cardiovascular 
disease. However, the risk of skeletal muscle toxicities may lead to the discontinuation of 
therapy and poor outcomes from CVD. It is well documented that statin skeletal muscle 
toxicities are dependent upon drug exposure. Statins are heavily dependent upon drug 
transporters for controlling their hepatic uptake and efficacy for reducing LDL-C. Drug 
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interaction and pharmacogenetic studies have demonstrated that drug transporters have a 
major role in controlling the statin system exposure and risk of statin myopathy. 
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2 HYPOTHESES AND SPECIFIC AIMS 
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2.1 Focus of the Thesis 
Given that at least 3-4 million Canadians are treated with statins, an estimated 500,000 
patients experience the associated skeletal muscle side effects. These muscle side effects 
often prevent the continued treatment of hypercholesterolemia and prevention of CVD, 
making statin-induced muscle myopathies a significant health concern to Canadians. 
It is well documented that statin myotoxicity is dose dependent and that increases in 
statin blood levels are a significant risk factor for the development of myotoxicity. As 
discussed above, the determinants of systemic statin exposure, such as the amount of 
drug absorbed and the duration and magnitude of exposure, play significant roles in the 
development of myopathy. However, statins cause toxicity directly in isolated myofibres 
in vitro, indicating that myopathy in vivo results from a direct effect on muscle and not an 
indirect action of statins on other tissues (Sakamoto et al., 2008). It is reasonable to 
assume that skeletal muscle fibre concentration of statins is equally as important as the 
plasma concentration, since many individuals are exposed to high statin blood levels but 
do not develop myopathy (Jacobson, 2006). The overall exposure of skeletal muscle to 
statins is partially determined by the systemic exposure and pharmacokinetic processes 
controlling absorption and elimination, occurring in the small intestine, liver and kidney. 
However, the process of statin distribution into skeletal muscle and how this relates to the 
muscle damaging effects has not been well studied. My overall hypothesis is that the 
statin level in the skeletal muscle itself is a key determinant of myotoxicity. This 
thesis focuses on drug transporting proteins in the skeletal muscle that govern the entry 
and exit of statins into muscle, regulating their exposure and toxic side effects. 
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2.2 Specific Aim 1  
To determine the spectrum, localization and function of statin transporters 
expressed in human skeletal muscle. 
Although the exact mechanism of myotoxicity is unknown, statins must gain entry into 
myocytes to exert the adverse effect of myotoxicity. Statins are large amphipathic 
compounds that have difficulty crossing biological membranes. Drug transporter proteins 
are extremely important in statin pharmacokinetics and are involved in their absorption, 
hepatic distribution and elimination. Drug transporters are involved in controlling tissue 
distribution of many different compounds in the body. Biological barriers like the 
placenta and blood brain barrier use drug transporters to selectively control entry of 
compounds into tissues. Skeletal muscle has been shown to express transporters involved 
in the uptake of amino acids, ions and glucose but little is known about expression of 
known drug transporters. In Chapter Three, we sought to identify the expression of statin 
transporters in skeletal muscle and determine their impact on statin exposure and toxicity 
in vitro. 
We hypothesized that the functional expression of statin uptake and efflux 
transporters modulate the toxic response to skeletal muscle statin exposure. To test 
this hypothesis, we screened skeletal muscle cDNA for the expression of known drug 
transporters. We tested the ability of the skeletal muscle drug transporters to transport 
atorvastatin and rosuvastatin. Adenoviral modulation of drug transporters in primary 
human skeletal muscle cells was used to determine changes in toxicity. We describe in 
Chapter Three that the uptake transporter OATP2B1 and three novel statin efflux 
transporters, MRP1, MRP4 and MRP5, are found in skeletal muscle. We demonstrate that 
OATP2B1 sensitizes muscle to toxicity and MRP1 attenuates toxicity of atorvastatin and 
rosuvastatin in an in vitro skeletal muscle model. 
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2.3 Specific Aim 2 
To examine the regulation and function of OATP2B1 transcription start site 
variants. 
OATP2B1 is ubiquitously expressed in various tissues in the body like, small intestine, 
liver, brain, kidney and skeletal muscle.  Many statins are also known to be substrates of 
OATP2B1 and due to the expression pattern we believe that OATP2B1 is involved in the 
bioavailability and extrahepatic distribution of statins including skeletal muscle exposure. 
Recently, it has been shown that differential promoter usage in tissues results in 
expression of five OATP2B1 transcriptional start site variants which utilize distinct first 
exons but share common subsequent exons (Pomari et al., 2009). These variants are 
expected to encode either a full length or shortened protein lacking 22 amino acids from 
the N-terminus. To date, there is an absence of information regarding the relative 
expression of the OATP2B1 transporter variants in key tissues responsible for drug 
absorption, elimination and skeletal muscle distribution. Moreover, the transport 
competency of the short OATP2B1 protein variant has not previously been demonstrated.  
In Chapter Four, we sought to examine the function and regulation of OATP2B1 
transcription start site variants. 
We hypothesized that OATP2B1 full length and short variant proteins would have 
differential tissue expression or transport function. To test this hypothesis we used 
absolute quantitative polymerase chain reaction to find that the full length variant is the 
major form expressed in duodenum but the short variant predominates in liver. The full 
length OATP2B1 protein variant is predominantly expressed in skeletal muscle.  
Function of the OATP2B1 variants were assessed using a transient heterologous cell 
expression system, we found that the transport activities of the short OATP2B1 variant 
towards substrates estrone sulfate and rosuvastatin are similar to the well-characterized 
full length variant. Transcriptional activity screening of the liver enriched OATP2B1 
variant promoter identified hepatocyte nuclear factor 4 alpha (HNF4α) as a novel 
transacting factor.  With a combination of in silico screening, promoter mutation in cell-
based reporter assays and chromatin immunoprecipitation studies, we identified a 
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functional HNF4α binding site close to the transcription start site. We conclude that the 
major OATP2B1 protein form in liver is transport competent and its hepatic expression is 
regulated by HNF4α. 
 
2.4 Specific Aim 3 
To investigate the contribution of Oatp2b1 to the pharmacokinetics and tissue 
distribution of rosuvastatin in Oatp2b1 knockout mice. 
Drug transporter knockout (KO) mouse models are useful in providing insight into the in 
vivo contribution that transporters have on drug distribution. Members of the Oatp1a and 
Oatp1b families have been successfully knocked out in a few different mouse models 
(Chen et al., 2008; van de Steeg et al., 2010; Zaher et al., 2008). These models have 
shown the importance of Oatp1a and 1b transporters in the pharmacokinetics and 
pharmacodynamics of some substrates. Oatp2b1 is the murine ortholog of the human 
OATP2B1 transporter and the effect of Oatp2b1 deletion on the substrate 
pharmacokinetics has not been previously described. In Chapter Five, we describe for the 
first time an Oatp2b1 KO mouse. This novel Oatp2b1 KO mouse provided the 
opportunity to investigate the role of Oatp2b1 in statin pharmacokinetics and distribution 
into skeletal muscle. 
We hypothesize that Oatp2b1 is involved in the absorption, hepatic uptake and 
skeletal muscle distribution of rosuvastatin. To test this hypothesis we characterized 
the pharmacokinetics of rosuvastatin in Oatp2b1 KO mice after oral and intravenous 
administration. As described in Chapter Five, we demonstrate that Oatp2b1 does not 
affect the systemic exposure of rosuvastatin after oral and intravenous dosing. The 
extrahepatic distribution of rosuvastatin in Oatp2b1 KO mice is similar to wild type 
animals. However, we found that Oatp2b1 KO had an increased rosuvastatin liver to 
plasma ratio compared to wild-type mice. Importantly, we did not observe a significant 
difference in the skeletal muscle distribution of rosuvastatin.  
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3 HUMAN SKELETAL MUSCLE DRUG 
TRANSPORTERS DETERMINE LOCAL EXPOSURE 
AND TOXICITY OF STATINS1 
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transporters determine local exposure and toxicity of statins. Circ Res 106(2): 297-306. 
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3.1 Introduction 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, statins, are 
highly effective drugs for the treatment of hypercholesterolemia, a major risk factor of 
cardiovascular disease. Statins inhibit the synthesis of mevalonate, the rate-limiting step 
in cholesterol biosynthesis (Endo, 1992; Jacobson, 2008). While statins are generally well 
tolerated (Pasternak, 2002), skeletal muscle side-effects are a common complaint among 
those treated. One such side-effect, myalgia, which is defined as muscle aches or 
weakness in the absence of blood creatine kinase (CK) elevation, occurs in 5-15% of 
statin-treated patients (Bruckert et al., 2005; Buettner et al., 2008; Draeger et al., 2006; 
Evans and Rees, 2002; Jacobson, 2008; Thompson et al., 2003). In rare cases, potentially 
life-threatening statin-induced rhabdomyolysis may occur; a condition characterized by 
acute muscle damage resulting in pronounced elevation in CK levels and renal failure 
(Thompson et al., 2006). 
The pathophysiology of statin-induced myopathy is not completely understood. The 
leading mechanism suggests a role for cellular depletion of secondary metabolic 
intermediates of mevalonate in the development of statin-induced myotoxicity (Baker, 
2005). In addition to decreased cholesterol synthesis, HMG-CoA reductase inhibition by 
statins causes a commensurate reduction in the levels of downstream metabolic products 
including isoprenoids, dolichol and ubiquinone (coenzymeQ10, CoQ10) (Baker, 2005; 
Hanai et al., 2007; Itagaki et al., 2009; Sakamoto et al., 2007). Among these are the 
isoprenoid secondary metabolic intermediates geranylgeranylpyrophosphate (GGPP) and 
farnesylpyrophosphate that are involved in protein isoprenylation and activation of small 
GTPases such as Rho and Rab. An important role for diminished isoprenylation in the 
mechanism of statin myotoxicity is mediated by induction of the muscle atrophy-linked 
protein atrogin-1 (Hanai et al., 2007). This is highlighted by the findings that 
supplementation of GGPP to cultured skeletal myotubes or isolated myofibers treated 
with statins leads to attenuation of toxicity (Cao et al., 2009; Itagaki et al., 2009; Johnson 
et al., 2004; Sakamoto et al., 2007), while inactivation of a Rab and RhoA induces 
toxicity (Itagaki et al., 2009; Sakamoto et al., 2007). Decreased geranylgeranylation of 
small GTPases by statins appears to stimulate the mitochondrial apoptotic cell death 
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pathway in skeletal myotubes (Itagaki et al., 2009; Johnson et al., 2004). In addition to 
isoprenoids, CoQ10 levels in plasma (De Pinieux et al., 1996) and skeletal muscle 
(Lamperti et al., 2005) are decreased with statin treatment. Although depletion of CoQ10 
is thought to affect oxidative phosphorylation and protection from statin-induced 
oxidative stress, compelling clinical evidence is lacking regarding the efficacy of CoQ10 
treatment of statin myopathy (Marcoff and Thompson, 2007). There is recent evidence to 
indicate that fatty acid oxidation is perturbed in cultured myotubes of statin intolerant 
(myalgic) patients (Phillips et al., 2009), a finding that differs from patients with 
rhabdomyolysis (Phillips and Haas, 2008). Such data suggest that the mechanisms of 
statin toxicity are different between those affected with myalgia and rhabdomyolysis. 
It is well documented that myotoxicity is statin dose-dependent, and myopathy risk 
increases when statins are co-administered with drugs that either interact to increase 
plasma statin levels or themselves have propensity for muscle damage (Ballantyne et al., 
2003; Huerta-Alardin et al., 2005; Jones and Davidson, 2005; Neuvonen et al., 2006). 
Indeed, macrolide antibiotics and azole antifungals are well known drug inhibitors of 
hepatic statin metabolism via cytochrome P450 enzymes (CYP), dramatically increasing 
plasma statin levels (Ballantyne et al., 2003; Neuvonen et al., 1998; Neuvonen et al., 
2006). Moreover, inhibition of statin liver uptake (transport) mediated by multiple 
members of the organic anion transporting polypeptide (OATP) family by drugs such as 
gemfibrozil, cyclosporine A and rifampin can elevate drug levels (Kyrklund et al., 2003; 
Neuvonen et al., 2006; Noe et al., 2007; Schneck et al., 2004; Shitara et al., 2004). 
Furthermore, we have previously reported that a common genetic polymorphism 
resulting in a single nucleotide difference in the SLCO1B1 gene encoding hepatic 
OATP1B1 (521C>T, V174A; rs4149056) (Tirona et al., 2001) is associated with 
increased plasma levels of a number of statins (Pasanen et al., 2007). In a genome-wide 
association study, the rs4149056 polymorphism in SLCO1B1 was found to be the most 
robust predictor of the risk for simvastatin-induced myopathy (Link et al., 2008). In 
addition, efflux transporters in liver that mediate secretion of statins into bile could play a 
role in risk for statin myopathy. For example, genetic variation in the statin biliary efflux 
transporters, multidrug resistance-associated protein 2 (MRP2) and breast cancer 
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resistance protein (BCRP), are associated with variability in pravastatin and rosuvastatin 
plasma levels, respectively (Hirano et al., 2005; Ieiri et al., 2007; Kitamura et al., 2008). 
Despite that the currently marketed statins have varying physicochemical characteristics, 
membrane transporters that act to facilitate drug uptake or efflux in tissues appear to have 
significant influence on the pharmacokinetics of most statins. This is evidenced by 
marked changes in plasma drug levels following transporter inhibition or through their 
attendant genetic polymorphisms (Neuvonen et al., 2008; Shitara and Sugiyama, 2006). 
Considerable attention has been given to drug transporters in the small intestine, kidney 
and liver, which affect systemic exposure to statins. However, there is a paucity of 
studies that have examined statin transporters within skeletal muscle and their influence 
on myotoxic side effects of statins, despite that this has been considered conceptually 
(Thompson et al., 2003). Given that plasma drug levels do not entirely predict risk for 
statin myopathy (Jacobson, 2006), we hypothesize that factors which control local 
skeletal muscle statin concentrations, such as muscle transporters, may be more relevant. 
Specifically, we propose that the interplay between statin uptake versus efflux 
transporters modulates the response to skeletal muscle statin exposure. 
In this study, we identify drug transporters in human skeletal muscle that affect the 
distribution of two prototypical lipophilic and hydrophilic statins, atorvastatin and 
rosuvastatin. We demonstrate that the uptake transporter, OATP2B1, and the efflux 
transporters, MRP1, MRP4 and MRP5 are expressed in skeletal muscle and are capable 
of transporting atorvastatin and rosuvastatin.  Importantly, we show that by affecting drug 
transporter activity in a model of human skeletal muscle, statin toxicity can be 
modulated. 
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3.2 Methods 
3.2.1 Reagents 
[3H] atorvastatin (5 Ci/mmol, 99% radiochemical purity) and [3H] rosuvastatin (5 
mCi/mmol, 99% radiochemical purity) was purchased from American Radiolabeled 
Chemicals (St. Louis, MO). [3H] rosuvastatin (79 Ci/mmol, 97.1% radiochemical purity) 
and unlabeled rosuvastatin were also kindly provided by Dr. Yi Wang (AstraZeneca, 
Wilmington, DE). Unlabeled atorvastatin, cerivastatin and gemfibrozil-glucuronide were 
obtained from Toronto Research Chemicals (North York, ON). All other chemicals and 
reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. 
 
3.2.2 Plasmids 
Expression plasmids for OATP1A2, OATP1B1, OATP1B3, OATP2B1, rOatp1b2, BCRP 
and P-gp are described elsewhere (Kim et al., 2001; Tirona et al., 2003; Urquhart et al., 
2008). MRP2 and MRP4 cDNA was provided by Dr. R.H. Ho (Vanderbilt University) 
and Dr. J.D. Schuetz (St. Jude Children’s Research Hospital), respectively. MRP1 cDNA 
was obtained by PCR, using Expand Long Template PCR System (Roche Applied 
Science, Indianapolis, IN), from a cDNA library of human skeletal muscle cDNA using 
oligonucleotide primers 5'-ACCGCCATGGCGCTCCGGGGCTTCTGCAGC-3' and 5'-
GTCTATACGGTCGTCTGGGGCTCACACCAA -3'. Similarly, OAT3 was amplified 
from human kidney using the primers: 5'-AGTGCCATGGCCTTCTCGGAGATCCTGG-
3' and 5'-GTTGTCCTCAGCTGGAGCCCAGGCCTGG-3'. MRP5 cDNA was amplified 
in two parts from skeletal muscle with the following primers: 5'-
CTCCACTCAGAGAAGATGAAGGATATCGAC-3' and 5'-
CCACATAAGCGAAGGTTCCACTGATTGCAA-3'; 5’-
AAACCTCTCTCATTTCAGCCATTTTAGGCC-3' and 5'-
GGGTGTAGATCTAACAGGGAGGAGTCAGCCCTT-3'. Full-length MRP5 was 
assembled from the two parts by ligation at the Xba I site. The PCR products for MRP1, 
MRP5 and OAT3 were cloned into pcDNA3.1/V5-His-TOPO vector (Invitrogen). 
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3.2.3 Adenoviral vectors 
Adenoviral vectors containing LacZ, OATP2B1, or MRP1 were generated in 
pAD/CMV/V5-DEST using the ViraPower Adenoviral Expression System (Invitrogen, 
Carlsbad, CA). The titer of the virus preparations were measured by infection of HEK293 
cells on 24-well plates with limiting dilutions of the viral stock using Adeno-X Rapid 
Titer Procedure (Clontech, Mountian View, CA). 
 
3.2.4 Gene Expression Analysis  
The mRNA expression of OATP2B1, MRP1, MRP2, MRP4, MRP5, and breast cancer 
resistance protein (BCRP) were measured by SYBR green quantitative real-time PCR 
with an ABI Prism 7700 sequence detection system (Applied Biosystems). Human 
skeletal muscle total RNA was sourced from BioChain (Hayward, CA). Total RNA was 
extracted from cultured cells using Trizol reagent (Invitrogen) and RNA quality and 
quantity was determined using Agilent Bioanalyzer 2100 (Agilent, Santa Clara, CA).  
cDNA was synthesized using Multiscribe reverse transcriptase (Applied Biosystems) 
according to manufacturer’s instruction and 30 ng of cDNA was used in each PCR 
reaction. The sequences of primers used for quantitative PCR are listed in Supplemental 
Table C1 (Appendix C). The amount of the transporter was normalized to 18S-rRNA and 
relative expression was determined using the ΔΔCT method. 
 
3.2.5 Immunoblot Analysis. 
Primary human skeletal muscle myoblast (HSMM) cells were harvested in 5 mmol/L 
Tris-HCl (pH 7.4) flash frozen in liquid nitrogen and homogenized to obtain total cellular 
protein. Normal human skeletal protein lysate was purchased from BioChain 
(Hayward,CA). Protein samples were separated by SDS-PAGE and transferred to 
NuPAGE nitrocellulose membrane Western blotting system (Invitrogen, Carlsbad, CA). 
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HeLa cells overexpressing OATP2B1, MRP1, MRP4 or MRP5 using a vtf7 vaccinia 
virus method, described below, was used as positive control. Membranes were probed 
with custom-made rabbit polyclonal OATP2B1 antibody based on a C-terminus epitope 
(CSPAVEQQLLVSGPGKKPEDSRV), MRPr1 (Alexis Biochemicals), MRP4 M4I-80 
(Kamiya), or MRP5 H-100 (Santa Cruz). Anti-rat and rabbit horseradish peroxidase–
labeled antibodies (Bio-Rad, Hercules, CA) were used as the secondary. The immobilized 
secondary antibody was detected using the ECL Plus Western Blotting Detection System 
(GE Healthcare) and KODAK ImageStation 4000 MM (Mandel). 
 
3.2.6 Immunohistochemistry 
Paraffin-embedded sections from normal human skeletal muscle tissue (5 µm) were 
obtained from BioChain. The tissue sections were deparaffinized in xylol and rehydrated 
with graded solutions of ethanol/water. For heat-induced epitope retrieval, the tissue 
sections were boiled in citrate buffer (10 mmol/L, pH 6.0). After washing twice in ice-
cold PBS, the slides were blocked with 2% fetal bovine serum (FBS) – phosphate 
buffered saline (PBS).  Thereafter, the slides were incubated with diluted anti–OATP2B1, 
MRPr1, MRP4 M4I-80 or MRP5 H-100 in a humidified atmosphere for 2h at room 
temperature. After several washing steps with PBS, the sections were incubated with the 
fluorescent-labeled secondary antibody (Invitrogen). After washing the slides with PBS, 
the tissue was mounted in antifading mounting medium containing 4',6-diamidino-2-
phenylindole (DAPI; Vector Laboratories). Images were obtained by confocal 
fluorescence microscopy. As negative control, the primary antibody was omitted. 
 
3.2.7 Cell Culture 
Primary human skeletal muscle myoblast (HSMM) cells were obtained from Lonza 
(Walkersville, MD). HSMM cells were cultured in SkBM-2 medium (Lonza) according 
to the manufacturer’s instructions at 37°C in a humidified atmosphere of 5% CO2/95% 
air. The cells were plated onto 12-well plates for transport studies and 96-well plates for 
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toxicity assays at a density of ~1 × 106 cells/mL. When the HSMM cells achieved ~70% 
confluence in SkBM-2 growth medium, cells were cultured in differentiation medium, 
DMEM-F12 (Lonza) supplemented with 2% horse serum (Invitrogen) for one week. The 
resulting differentiated cells were then cultured in SkBM-2 growth medium for two 
weeks before experiments. 
 
3.2.8 Identification of Statin Transporters 
HeLa cells (human cervical cancer cell line) were grown in 12-well plates (approximately 
0.8 × 106 cells/well) and infected with vaccinia (vtf-7) at a multiplicity of infection of 10 
plaque-forming units/cell in serum-free Opti-MEM I medium (Invitrogen) and allowed to 
absorb for 30 minutes. Cells were transfected with 1 µg of transporter cDNA or parental 
plasmid lacking insert as control using Lipofectin (Invitrogen) and incubated at 37°C for 
16h. Double transfection experiments of both uptake and efflux transporters used 1 µg 
total transporter cDNA in a 1:4 ratio of uptake to efflux. The parental plasmid lacking 
insert was used in place of uptake or efflux transporter cDNA in the single transfections.  
Transport was evaluated using labeled substrate as previously reported (Cvetkovic et al., 
1999). Drug accumulation was determined at selected time intervals by washing cells 
three times with ice-cold PBS followed by lysis with 1% sodium dodecylsulfate. 
Retained cellular radioactivity was quantified by liquid scintillation spectrometry. 
 
3.2.9 Statin Accumulation and Toxicity in Skeletal Muscle Cells 
HSMM cells were transduced with the adenoviruses containing the transporter coding 
region in SkBM-2 medium containing a total of 1 × 107 infectious units per mL 
(IFU/mL). For single transporter overexpression, cells were transduced with 5 × 106 
IFU/mL of Ad-MRP1 or Ad-OATP2B1 as well as 5 × 106 IFU/mL of Ad-LacZ, whereas 
for overexpression of two transporters, 5 × 106 IFU/mL of each adenovirus was used.   
After 24h, cells were treated with various concentrations of atorvastatin or rosuvastatin 
for 48-72h. Cellular viability was evaluated by methylthiazolyldiphenyl-tetrazolium 
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bromide (MTT) assay (see below), measurement of ATP content using CellTiter-Glo 
Luminescent Cell Viability Assay (Promega Biosciences, San Luis Obispo, CA) and 
assessment of caspase 3 and 7 activation using Caspase-Glo 3/7 Assay (Promega). 
 
3.2.9.1 MTT Assay 
The MTT assay was performed on HSMM cells in 96-well plates with approximately 
1×105 cells per well. The cells were treated with rosuvastatin and atorvastatin 24h after 
transduction with adenovirus. After the cells were incubated for 72h, 25 μL of 5 mg/mL 
MTT in PBS was added to each well. The plates were incubated for 4 h at 37°C and the 
formazan formed was dissolved in 50 μL DMSO. The background absorbance at 670 nm 
was subtracted from the absorbance at 560 nm to obtain the raw absorbance data. 
 
3.2.10 Statistical Analysis 
Statistical differences between group parameters were determined by 1-way ANOVA or 
2-way ANOVA, using Bonferroni’s multiple comparison test, as appropriate (GraphPad 
Software Inc, San Diego, CA). A P value of <0.05 was considered statistically 
significant. 
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3.3 Results 
3.3.1 Identification Of Statin Transporters In Skeletal Muscle 
Little is known about the expression of drug transporters in human skeletal muscle.  
Therefore, we screened a cDNA library of human skeletal muscle for expression of a 
wide variety of drug transporters including OATPs, organic anion transporters (OATs), 
organic cation transporters (OCTs), MRPs, breast cancer resistance protein (BCRP) and 
P-glycoprotein (P-gp). The known statin uptake transporters such as OATP1B1, 
OATP1B3, OAT1, and OAT3 (Burckhardt and Burckhardt, 2003; Hirano et al., 2004; Ho 
et al., 2006; Lau et al., 2007; Sasaki et al., 2002; Takeda et al., 2004) as well as efflux 
transporters such as MRP2, P-gp and BCRP (Hirano et al., 2005; Huang et al., 2006; 
Kivisto et al., 2005; Matsushima et al., 2005; Sasaki et al., 2002) were not detected in 
skeletal muscle (not shown). However, we detected mRNA expression of the known 
statin uptake transporter OATP2B1 (Grube et al., 2006; Ho et al., 2006) (Fig. 3.1A). The 
mRNA level of OATP2B1 was highly detectable in skeletal muscle, although it is 
significantly lower than tissues with very high expression (liver, kidney and small 
intestine). Given that MRP2 transports statins, the expression of other members of this 
efflux transporter family was examined revealing high expression of MRP1, MRP4 and 
MRP5 in skeletal muscle. Quantitative mRNA analysis and Western blot confirmed the 
expression of these drug transporters in human skeletal muscle (Fig. 3.1A and B).  
Immunolocalization of OATP2B1, MRP1, MRP4 and MRP5 in normal human skeletal 
muscle by confocal microscopy demonstrated that each was expressed on the 
sarcolemmal membrane (Fig. 3.1C). 
We then determined whether the transporters identified in skeletal muscle were capable 
of statin transport using a recombinant (vtf-7) vaccinia virus overexpression system in a 
human cervical cancer cell line (HeLa) (Cvetkovic et al., 1999). As we previously 
described, OATP2B1 is capable of rosuvastatin transport (Ho et al., 2006) and here we 
confirm that atorvastatin is also a transport substrate (Fig. 3.2) (Grube et al., 2006; 
Niessen et al., 2009). Indeed, in this model, OATP2B1 increases the cellular 
accumulation of rosuvastatin and atorvastatin by 2-fold. While OATP2B1 is the relevant 
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Figure 3.1 Expression of uptake and efflux transporters in various human tissues and 
HSMM cells. 
(A) Relative gene expression of MRP1, MRP2, MRP4, MRP5, BCRP, and OATP2B1 in 
a range of human tissues and cultured HSMM cells. Expression was normalized to 
expression in human skeletal muscle. (B) Protein expression of MRP1, MRP4, MRP5, 
and OATP2B1 in human skeletal muscle and cultured HSMM cells by Western blot. 
Lysates from HeLa cells transfected with blank vector or transporter cDNA served as 
negative and positive controls, respectively.  (C) Cellular localization of MRP1, MRP4, 
MRP5, and OATP2B1 in normal human skeletal muscle was determined by 
immunofluorescence confocal microscopy. Transporters are shown in green while nuclei 
are shown in blue. Scale bar = 50µm. 
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Figure 3.2 Intracellular accumulation of statins in HeLa cells transiently transfected with 
various uptake drug transporters. 
Intracellular accumulation of [3H]rosuvastatin and [3H]atorvastatin in cells expressing 
OATP2B1, OATP1B1, OATP1B3, OATP1A2, OAT3 and rOatp1b2. Results are 
presented as percent of vector control ± SEM (n=3). *p<0.05, **p<0.01, ***p<0.001 
compared to vector control. The presence (+) or absence (-) of transporter expression in 
various tissues is shown below. 
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transporter for uptake of statins into skeletal muscle, we present new and confirming data 
that other OATPs (1B1, 1B3 and 1A2) transport both atorvastatin and rosuvastatin (Fig. 
3.2). It should be noted that the differences in statin transport between OATP2B1 and 
other transporters as shown in this model (Fig. 3.2) likely do not reflect the relative statin 
uptake efficiencies in vivo, since transporter expression was not normalized and the 
absolute expression of these transporters in different tissues is undetermined. 
Drug interactions involving inhibition of the major liver OATPs (1B1 and 1B3) are 
associated with elevated plasma statin levels. Similarly, OATP2B1 is susceptible to 
inhibition by co-administered medications (Sai et al., 2006). Here, we show that 
stimulated intracellular accumulation of atorvastatin and rosuvastatin by OATP2B1 is 
attenuated after co-incubation with cerivastatin, gemfibrozil, gemfibrozil-glucuronide, 
fenofibrate, rifampin and glyburide (Fig. 3.3). Interestingly incubation with cyclosporine 
A caused a significant reduction in rosuvastatin accumulation but increased atorvastatin 
levels (Fig. 3.3). 
The transport efficiency of human OATPs compared to rodent OATPs, is lower in this 
experimental system (Ho et al., 2006). For instance, the rat ortholog of the human 
transporters OATP1B1 and OATP1B3, rOatp1b2, appeared capable of mediating a 
significantly greater accumulation of rosuvastatin and atorvastatin into cells using this 
technique, in relation to human OATP2B1 (Fig. 3.2). For this reason, we used rOatp1b2 
as the model transporter to maintain statin uptake into cells thereby allowing for the 
identification of pertinent transporters capable of statin efflux (see below). 
Although highly expressed in skeletal muscle, it was not known whether MRP1, MRP4 
or MRP5 transported statins.  Hence, HeLa cells were double transfected with the uptake 
transporter, rOatp1b2, and various efflux transporters. In this system, modulation of 
cellular retention of atorvastatin or rosuvastatin served as an indicator for efflux transport 
activity. Indeed, we confirm that rosuvastatin and atorvastatin are transported by MRP2, 
P-gp, and BCRP using this double transporter (uptake/efflux) transfection system (Fig 
3.4). Rosuvastatin retention in cells expressing rOatp1b2 together with MRP1, MRP4 or 
MRP5 was lower (77, 80 and 27% lower, respectively) than cells expressing rOatp1b2, 
  
86 
alone (Fig. 3.4). This was also true for atorvastatin when MRP1 and MRP4 (63 and 47% 
lower, respectively) but not MRP5 were double transfected with rOatp1b2. These 
findings demonstrate that MRP1, MRP4, and MRP5 are novel statin transporters. 
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Figure 3.3 Chemical inhibition of statin uptake by OATP2B1 in transiently transfected 
HeLa cells. 
Intracellular accumulation of [3H]rosuvastatin and [3H]atorvastatin in cells expressing 
OATP2B1 (grey bars) co-treated with cerivastatin, gemfibrozil, gemfibrozil-glucuronide, 
fenofibrate, rifampin, glyburide or cyclosporine A at 100 µM. Results are presented as 
fmol per µg of protein ± SEM (n=3).  *p<0.05, **p<0.01, and ***p<0.001 compared to 
OATP2B1 DMSO treatment. 
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Figure 3.4 Intracellular accumulation of statins in HeLa cells transiently transfected with 
rOatp1b2 and various efflux drug transporters. Intracellular accumulation of 
[3H]rosuvastatin and [3H]atorvastatin in HeLa cells expressing rOatp1b2 and/or MRP1, 
MRP2, MRP4, MRP5, P-gp, or BCRP. Results are presented as percent of rOatp1b2 
mediated uptake ± SEM (n=3 to 8). ***p<0.001 compared to vector control and efflux 
transporter alone. †††p<0.001 compared with rOatp1b2 mediated uptake. The presence 
(+) or absence (-) of transporter expression in various tissues is shown below. 
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Figure 3.4 Intracellular accumulation of statins in HeLa cells transiently transfected with 
rOatp1b2 and various efflux drug transporters. 
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3.3.2 Statin Disposition In An In Vitro Model Of Human Skeletal 
Muscle  
To evaluate the role of statin transport in toxicity, we employed differentiated, primary 
human skeletal muscle myoblasts (HSMM) as an in vitro model. First, we assessed 
whether HSMM cells expressed statin efflux transporters and found that MRP1, MRP4, 
and MRP5 are constitutively expressed (Fig. 3.1A and B) while MRP2, BCRP and P-gp 
are absent. Cellular localization studies revealed that some MRP1 is expressed on the cell 
surface of HSMM cells, although significant levels of the transporter are found in 
intracellular spaces. By contrast, MRP4 and MRP5 are not found on the plasma 
membrane, but localize within the golgi in HSMM cells (Fig. 3.5A). To test whether 
functional MRP activity is present in HSMM cells, statin accumulation was examined 
after chemical inhibition of efflux transport.  When HSMM cells were co-incubated with 
known MRP inhibitors MK-571 (Gekeler et al., 1995), dipyridamole (Curtin and Turner, 
1999), quercetin (Walgren et al., 2000), or verapamil (Goh et al., 2002) there was a 
significant increase in cellular retention for both atorvastatin and rosuvastatin when 
compared to cells treated with vehicle (Fig. 3.5B). Together with membrane localization 
studies, the results indicate that HSMM cells natively express functional MRP1 
transporter whose activity determines the intracellular accumulation of statins. Co-
incubation with cerivastatin also significantly increased the cellular retention of 
atorvastatin and rosuvastatin in HSMM cells (Fig. 3.5B), suggesting that this statin 
interacts with and is a possible substrate of MRPs. With respect to statin uptake, none of 
the known statin uptake transporters were expressed in HSMM cells and importantly, 
OATP2B1 is not expressed despite that it is present in vivo (Fig. 3.1).  
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Figure 3.5 Statin accumulation in HSMM cells after co-treated with MRP inhibitors. 
(A) Immunofluorescence localization of MRP1, MRP4 and MRP5 (green), golgi (red) 
and nuclei (blue) in differentiated HSMM cells using confocal microscopy. Scale bar = 
20µm. (B) Intracellular accumulation of [3H]rosuvastatin and [3H]atorvastatin after 30 
mins in HSMM cells co-treated with or without 100 µM cerivastatin or the non-specific 
MRP inhibitors dipyridamole, MK-571, quercetin, and verapamil at 100 µM. Results are 
presented as percent of DMSO control ± SEM (n=3-4), **p<0.01, ***p<0.001. 
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3.3.3 Role Of Transporters In Statin Toxicity In An In Vitro Model 
Of Human Skeletal Muscle  
We next examined the effect of transporters on skeletal muscle exposure and toxicity of 
statins. In this experiment, we overexpressed OATP2B1 and MRP1 in HSMM cells using 
adenoviral vectors (Ad-OATP2B1 and Ad-MRP1, respectively). Examination by 
confocal microscopy demonstrated robust overexpression of these transporters in HSMM 
cells (Fig. 3.6). There was significant plasma membrane expression of MRP1, whereas 
for OATP2B1 there was some transporter on the cell membrane, but the majority was 
confined intracellularly.   
Adenoviral over-expression of OATP2B1 in HSMM cells caused a significant increase in 
the cellular retention of both atorvastatin and rosuvastatin over 60 min (Fig. 3.6B). Upon 
transduction with Ad-OATP2B1 and Ad-MRP1, the cellular retention of both 
rosuvastatin and atorvastatin were significantly attenuated compared to Ad-OATP2B1 
alone. Transduction with Ad-MRP1 alone did not significantly reduce the levels of 
rosuvastatin in HSMM cells; however, there was a trend towards reduced atorvastatin 
accumulation. Consequently, the effect of statin efflux transporters on intracellular statin 
levels is not pronounced in the absence of influx transporters. These results indicate that 
overexpression of OATP2B1 and MRP1 leads to changes in intracellular statin levels in 
an HSMM cell model. 
Preliminary studies were performed to define the time- and concentration-dependency for 
atorvastatin and rosuvastatin cytotoxicity in HSMM cells. Cell viability, as evaluated by 
intracellular ATP levels, declined after 5 days of statin treatment. At comparable 
concentrations (e.g. 100 µM), atorvastatin was more toxic than rosuvastatin (Fig. 3.7A). 
The cytotoxicity of atorvastatin and rosuvastatin in HSMM cells after adenoviral-
mediated transporter gene delivery was assessed by two measures of mitochondrial 
function, ATP content and MTT reduction to formazan (Fig. 3.7B-D), as well as 
activation of Caspases 3/7, a marker of apoptosis induction (Fig. 3.7D). Transduction of 
HSMM cells with Ad-OATP2B1 sensitized HSMM cells to atorvastatin toxicity as 
demonstrated by signals from all three toxicity end-points (Fig. 3.7B-D). There was a 
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similar trend for rosuvastatin toxicity but only the increased activity of caspases 3/7 
reached statistical significance (Fig. 3.7D). This result is likely because overexpressed 
OATP2B1 was not well localized on the plasma membrane, leading to modest elevation 
of intracellular statin concentrations. Similarly, when HSMM cells were transduced with 
Ad-MRP1 alone, there was a lack of effects on statin cytotoxicity, consistent with the 
absence of significant changes in intracellular statin accumulation. However, when cells 
were transduced with both Ad-OATP2B1 and Ad-MRP1, there was protection against 
toxicity by both statins when compared to HSMM cells transduced with Ad-OATP2B1 
alone to viabilities similar to those cells transduced with Ad-MRP1 alone (Fig. 3.7B-7D).   
Taken together, these results indicate that OATP2B1 expression promotes statin toxicity 
while MRP1 is cytoprotective in human skeletal muscle cells. 
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Figure 3.6 Statin accumulation in HSMM cells after adenoviral transduction of MRP1 
and OATP2B1. 
(A) Immunofluorescence localization of MRP1 or OATP2B1 (green) and nuclei (blue) in 
HSMM cells after adenoviral infection with Ad-LacZ, Ad-MRP1, Ad-OATP2B1, or Ad-
OATP2B1 and Ad-MRP1 in differentiated HSMM cells using confocal microscopy. 
Scale bar = 50µm. (B) Intracellular accumulation of [3H]rosuvastatin and [3H]atorvastatin 
in HSMM cells after  adenoviral over-expression of OATP2B1 and MRP1. Results are 
presented as fmol per µg of protein ± SEM (n=4). ***p<0.001 compared with no virus, 
Ad-LacZ or Ad-MRP1. ††p<0.01, †††p<0.001 compared with Ad-OATP2B1. ‡p<0.05, 
‡‡‡p<0.001 compared with Ad-MRP1. 
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Figure 3.7 Statin cytotoxicity in HSMM cells after adenoviral transduction of MRP1 and 
OATP2B1. (A) Dose-dependent, cellular viability of HSMM cells after treatment with 
atorvastatin and rosuvastatin for 5 days measured by intracellular ATP concentration. 
Results are presented as percent of DMSO control ± SEM (two independent experiments 
with 3 determinations per experiment). (B) Cellular viability of HSMM cells after 
treatment with atorvastatin and rosuvastatin for 72h measured by intracellular ATP 
concentration. Results are presented as percent of DMSO control ± SEM (n=5). (C) 
Cellular viability of HSMM cells after treatment with atorvastatin and rosuvastatin for 
72h measured by formazan formation using a MTT assay. Results are presented as 
percent of DMSO control ± SEM (n=4). (D) Induction of apoptosis in HSMM cells after 
treatment with atorvastatin and rosuvastatin for 48h measured by activation of caspase 3 
and 7. Results are presented as percent of DMSO control ± SEM (n=4),   *p<0.05, 
**p<0.01, and ***p<0.001. 
  
96 
 
Figure 3.7 Statin cytotoxicity in HSMM cells after adenoviral transduction of MRP1 and 
OATP2B1.  
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3.4 Discussion 
Drug transporters have recently been implicated in statin-induced myopathy. However, 
those that have been previously considered have been the transporters located in the liver 
and small intestine, which are largely responsible for controlling plasma statin 
concentrations. Indeed, genetic polymorphisms in the hepatic statin uptake transporter, 
OATP1B1, leading to reduced transport function are associated with a dramatic increase 
in risk for simvastatin-related myopathy (Link et al., 2008).  Moreover, inhibition of both 
OATP1B1 and liver glucuronidation activity by concomitant treatment with the 
antilipidemic drug, gemfibrozil, causes elevation of cerivastatin plasma concentrations 
conferring greater predisposition to rhabdomyolysis (Prueksaritanont et al., 2002; Shitara 
et al., 2004). Although high plasma statin level is thought to be a risk factor, it does not 
entirely predict myopathy. In fact, there are individuals who exhibit high statin plasma 
levels but do not develop myopathy, suggesting that other factors including skeletal 
muscle fiber statin concentration may have an impact on side-effect risk (Jacobson, 
2006). Despite the recognition that drug transporters control intracellular statin 
concentrations, the relevant transporters in human skeletal muscle have long been over-
looked.   
In this report we identified drug transporters in human skeletal muscle capable of 
transporting statins.  Previous reports have shown that OATP2B1 is a high affinity uptake 
transporter for both atorvastatin and rosuvastatin (Grube et al., 2006; Ho et al., 2006).  
OATP2B1 is expressed on the apical and basolateral membranes of enterocytes and 
hepatocytes, respectively, and contributes to the oral absorption and hepatic distribution 
of statins. In addition, OATP2B1 is localized on the plasma membrane of cardiac 
endothelial cells (Grube et al., 2006), as well as in platelets (Niessen et al., 2009), where 
it is thought to be involved in the pleiotropic cardiovascular effects of statins. Here, we 
show for the first time, OATP2B1 is similarly expressed on human skeletal muscle 
sarcolemmal membrane. These findings are consistent with a report that suggested the 
presence of Oatp1a4 and Oatp2b1 in rat skeletal myofibers at the mRNA level (Sakamoto 
et al., 2008). However, demonstration of rat Oatp1a4 and Oatp2b1 protein expression in 
muscle was not confirmed, nor were data presented to show that these transporters 
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mediate statin uptake (Sakamoto et al., 2008). Despite that direct measurement of statin 
accumulation was not monitored, co-treatment of rat skeletal myofibers with the OATP 
inhibitor, estrone sulfate, afforded protection against the toxicity of the hydrophilic and 
lipophilic statins, pravastatin and fluvastatin, respectively (Sakamoto et al., 2008).   
The known statin efflux transporters, namely P-gp, MRP2 and BCRP are not expressed in 
human skeletal muscle (Fig. 3.1A). However, isoforms of the MRP transporter family 
such as MRP1, MRP4 and MRP5 are highly expressed in skeletal muscle, though 
previous to this report, their capacity for statin efflux was unknown. Here, we 
demonstrate that the three human skeletal muscle MRPs (MRP1, MRP4, and MRP5) 
transport rosuvastatin and/or atorvastatin. These transporters are expressed on the 
sarcolemmal membrane of muscle fibers, indicating a protective role against intracellular 
statin accumulation. There is wide substrate overlap among MRPs (Leslie et al., 2005) 
and this is certainly also the case for statins which are transported by the skeletal muscle 
MRPs, albeit at differing efficiencies. Recently, a role for rat Mrp1 in statin-induced 
myopathy has been suggested in studies that demonstrate precipitation of rosuvastatin-
mediated skeletal muscle toxicity in rats co-treated with the MRP inhibitor, probenecid 
(Dorajoo et al., 2008). Interpretation of these findings remains difficult for a number of 
reasons including a lack of demonstration that rat Mrp1 transports rosuvastatin, absence 
of Mrp1 expression data in tissues such as skeletal muscle, and a deficiency of 
information regarding differences in plasma and tissue concentrations of rosuvastatin 
after probenecid cotreatment (Dorajoo et al., 2008).  
The dynamic interplay between uptake and efflux transporter activities likely controls 
muscle fibre statin concentrations, which determines susceptibility to toxicity. We have 
shown that the toxicity of rosuvastatin and atorvastatin in primary human skeletal muscle 
cells is dependent on the achieved intracellular drug concentrations. This is highlighted 
by the findings that reduction of cellular statin accumulation by MRP1 overexpression in 
cultured skeletal muscle cells heterologously expressing OATP2B1 (Fig. 3.6B), afforded 
cytoprotection against statin exposure (Fig. 3.7C and D). In the guinea pig, skeletal 
muscle concentrations of rosuvastatin and atorvastatin are less than 10% of that found in 
plasma, suggesting that the balance is tipped towards higher efflux than uptake activity 
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(Madsen et al., 2008).  In our evaluation of the literature, the plasma-to-skeletal muscle 
concentration ratio of statins in humans is not known, but this value will undoubtedly be 
dependent on the relative expression and intrinsic activities of the attendant uptake 
(OATP2B1) and efflux (MRP1, MRP4, MRP5) transporters. The current results would 
also suggest that drug-statin interactions occurring not only at the level of the hepatocyte 
cell membrane, but also in skeletal muscle fibers could contribute to myopathy.  
Certainly, a number of clinically used drugs are substrates/inhibitors of the here identified 
skeletal muscle statin transporters (Fig. 3 and 5B) (Bakos and Homolya, 2007; Borst et 
al., 2007). Our data suggest that skeletal muscle statin uptake by OATP2B1 can be 
inhibited by concomitantly administered drugs such as gemfibrozil, fenofibrate and 
glyburide (Fig. 3.3). This finding could be considered contradictory to the increased risk 
of statin myopathy in patients co-treated with gemfibrozil. However, it should be 
mentioned that the gemfibrozil inhibits hepatic statin clearance to increase systemic statin 
exposure and there remains the possibility that inhibition of skeletal muscle efflux 
transport could offset the protection provided by OATP2B1 inhibition. Indeed, we 
demonstrate that statin efflux can be blocked by concurrent treatment of HSMM cells 
with known inhibitors of MRPs (Fig. 3.5B). Moreover, one must consider not only 
pharmacokinetic but also pharmacodynamic interactions in extrapolating the current 
transport inhibition findings to myopathy risk.    
There are limitations with the differentiated HSMM cell model for the study of statin 
toxicity. Firstly, although MRP1, MRP4 and MRP5 are constitutively expressed in 
HSMM cells, only MRP1 localized to the plasma membrane (Fig. 3.5A). This is in 
contrast to immunofluorescence data that show these MRPs are expressed on the 
sarcolemmal membrane of intact skeletal muscle fibers (Fig. 3.1C). It is for this reason 
we are only able to assess the effect of MRP1 but not MRP4 or MRP5 on cytoprotection 
against statins in this model of skeletal muscle. Furthermore, HSMM cells do not natively 
express OATP2B1 as is found in vivo, hence we required viral gene delivery to assess the 
role of uptake transport on statin toxicity. That OATP2B1 is not expressed in HSMM 
cells compares well with other skeletal muscle genes that we have found at very low 
levels in relation to intact skeletal muscle including CK-M isoform (Supplemental Figure 
C1, Appendix C). Therefore, in interpreting the current toxicity findings it should be 
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considered that this in vitro model of skeletal muscle differs phenotypically to muscle 
fibres in vivo.    
In conclusion, statin transporters are present in human skeletal muscle, which control 
intracellular drug exposure. We propose a role for OATP2B1 in sensitizing skeletal 
muscle cells to statin toxicity and that the novel statin efflux transporters, MRP1, MRP4 
and MRP5 protect muscle from toxicity.  The dynamic functional interplay between these 
uptake and efflux transporters in vivo likely determines risk for statin-induced myopathy. 
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4 TRANSPORT FUNCTION AND TRANSCRIPTIONAL 
REGULATION OF A LIVER-ENRICHED HUMAN 
ORGANIC ANION TRANSPORTING POLYPEPTIDE 
2B1 TRANSCRIPTIONAL START SITE VARIANT2 
                                                
2 The material in this chapter is based on a manuscript in preparation: Knauer MJ, 
Girdwood AJ, Leake BF, Ho RH, Kim RB, Tirona RG. Transport Function and 
Transcriptional Regulation of a Liver-Enriched Human Organic Anion Transporting 
Polypeptide 2B1 Transcriptional Start Site Variant (2012). 
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4.1 Introduction 
The Organic Anion Transporting Polypeptides (OATPs, gene symbol solute carrier 
family SLCO) are a superfamily of transmembrane proteins. The SLCO genes encode 12-
transmembrane domain proteins capable of transporting a wide variety of amphipathic 
substrates in a sodium independent manner. Different OATPs have partially overlapping 
substrates and differing tissue expression patterns. For example, OATP1B1 and 
OATP1B3 and are primarily expressed on the basolateral membrane of hepatocytes, 
whereas others, like OATP2B1, have a much broader expression pattern (Hagenbuch and 
Meier, 2004). OATP2B1 is expressed in liver, placenta, small intestine, kidney, brain, 
skin, heart, platelets, and skeletal muscle (Hagenbuch and Meier, 2004; Knauer et al., 
2010; Kullak-Ublick et al., 2001; Niessen et al., 2009; Tamai et al., 2000). A wide variety 
of drugs are transport substrates of OATP2B1 including: benzylpenicillin (Tamai et al., 
2000), bosentan (Treiber et al., 2007), ezetimibe-glucuronide (Oswald et al., 2008), 
fexofenadine (Nozawa et al., 2004a), glibenclamide (Satoh et al., 2005), troglitazone 
(Nozawa et al., 2004b), atorvastatin (Grube et al., 2006), fluvastatin (Kopplow et al., 
2005), pitavastatin (Shirasaka et al., 2011), pravastatin (Shirasaka et al., 2010), and 
rosuvastatin (Ho et al., 2006) as well as steroid sulfate conjugates like estrone sulfate 
(E1S) (Tamai et al., 2001). OATP2B1 has also been implicated in the pH dependent 
absorption of multiple drugs across the human intestine epithelial cells (Kobayashi et al., 
2003; Nozawa et al., 2004a).  OATP2B1, like OATP1B1 and OATP1B3, is thought to 
mediate the sodium independent uptake of amphiphilic organic anions into the liver 
(Aoki et al., 2009). Given expression in placenta and mammary gland, OATP2B1 has 
been connected to the uptake and supply of precursor molecules for steroid synthesis 
(Ugele et al., 2003). Previously, we have described a potential role for OATP2B1 in the 
skeletal muscle uptake and sensitization to statin toxicity (Knauer et al., 2010). 
Originally cloned from human brain, OATP2B1 is predicted to be a 709 amino acid 
protein (Kullak-Ublick et al., 2001; Tamai et al., 2000). Gene regulation analysis using 
promoter reporters in intestinal and liver cells revealed that the constitutive expression of 
the originally cloned OATP2B1 protein variant was regulated by the Sp1 transcription 
factor (Maeda et al., 2006). Recently, Pomari and colleagues have shown that differential 
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promoter usage in tissues results in the expression of several OATP2B1 transcription start 
site (TSS) variants (Fig. 4.1) (Pomari et al., 2009). These OATP2B1 variants utilize 5 
distinct first exons and associated promoters but share common subsequent exons (exons 
2 to 14).  One TSS variant represents the original full length (709 amino acids) protein 
with translation start site within this first exon (termed exon 1b). The other variants 
arising from transcription initiation at exons 1a, 1c, 1d and 1e are expected to produce a 
shorter protein (687 amino acids) than the 1b variant, as translation is predicted to start in 
exon 2.  Hence, the short OATP2B1 protein variants lack 22 amino acids from the N-
terminus in comparison to the original full length form. To date, there is an absence of 
information regarding the relative expression of the OATP2B1 transporter variants in key 
tissues responsible for drug absorption and elimination. Moreover, the transport 
competency of the short OATP2B1 protein has not previously been demonstrated.  In this 
report, we find that the short OATP2B1 transporter variant is the predominant form 
expressed in human liver while the major form in small intestine is the full length 
version. The liver enrichment of the short OATP2B1 variant was partly due to 
transcriptional regulation by hepatocyte nuclear factor 4α (HNF4α). Importantly, we 
demonstrate the short OATP2B1 protein variant has comparable transport activity to the 
full length form.  
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Figure 4.1 OATP2B1 Transcription start site variants. 
(A) Exon/intron structure of the beginning of the SLCO2B1 gene. Exons are shown as 
boxes and introns as lines. The grey shading indicated the translated regions of the exons. 
(B) The N-terminal amino acid sequence of the OATP2B1 protein encoded using 
different translation start sites encoded in exon 1b or exon 2. (C) Topology of OATP2B1, 
with the black shows the 22 amino acids that are missing in the truncated variant. 
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4.2 Materials and Methods 
4.2.1 Reagents 
[3H] esterone 3-sulfate (54.26 Ci/mmol, >97% radiochemical purity) was purchased from 
PerkinElmer (Woodbridge, ON, Canada) and [3H] rosuvastatin (5 Ci/mmol, 99% 
radiochemical purity) was purchased from American Radiolabeled Chemicals (St. Louis, 
MO). Unlabeled rosuvastatin was obtained from Toronto Research Chemicals (North 
York, ON). All other chemicals and reagents were obtained from Sigma-Aldrich (St. 
Louis, MO) unless otherwise stated. 
 
4.2.2 Cell Culture 
Human cervical adenocarcinoma HeLa (American Type Culture Collection, ATCC, 
Manassas, VA), human hepatocellular carcinoma HepG2 (ATCC), human colorectal 
adenocarcinoma Caco-2 (ATCC) and human hepatocellular carcinoma Huh-7 (Japanese 
Collection of Research Bioresources; http://cellbank.nihs.go.jp) cells were cultured in 
DMEM supplemented with 10% FBS, 50 U/mL penicillin, 50 µg/mL streptomycin and 2 
mM L-glutamine (Invitrogen, Carlsbad, CA). Cells were maintained at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air. The cells were plated onto 12-well plates 
for transport studies and 24-well plates for dual luciferase reporter assays at a density of 
~1 × 106 cells/mL. 
 
4.2.3 Transporter Expression Plasmids 
The expression plasmid for the full length (1b) OATP2B1 (OATP2B1-FL) is described 
elsewhere (Tirona et al., 2003a). The cDNA of the short variant of OATP2B1 1e 
(OATP2B1-Short) was obtained by PCR, using Expand Long Template PCR System 
(Roche Applied Science, Indianapolis, IN), from a human liver cDNA library using 
oligonucleotide primers (Table 4.1) and ligated into pEF6/V5-His-TOPO vector 
(Invitrogen). 
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4.2.4 Adenoviral vectors 
An adenoviral vector containing OATP2B1-Short was generated using the ViraPower 
Adenoviral Expression System (Invitrogen) as previously described for OATP2B1-FL 
(Knauer et al., 2010). 
4.2.5 SLCO2B1 luciferase reporter plasmids 
The 5' region of the SLCO2B1 full length promoter (1b exon) and truncated promoter (1e 
exon) were PCR amplified with Expand Long Template PCR System (Roche Applied 
Science, Indianapolis, IN) from human genomic DNA using primers listed in Table 4.1. 
The resulting SLCO2B1 1b promoter PCR product (-2000 to +1 bp) was digested with 
Kpn I and Xho I then ligated into pGL3-Basic (Promega, Madison, WI). The SLCO2B1 
1e promoter amplicon was cloned into pCR2.1, digested with Hind III and Xho I then 
ligated into pGL3-Basic.  Disruption of the DR1-1 site in the SLCO2B1 1e promoter was 
done by site-directed mutagenesis (QuickChange, Stratagene, La Jolla, CA) using 
primers listed in Table 4.1. 
4.2.6 Gene Expression Analysis 
The absolute mRNA expression of each OATP2B1 TSS variant, was determined by 
SYBR green quantitative real-time PCR (RT-PCR), with an ABI Prism 7700 sequence 
detection system (Applied Biosystems, Carlsbad, CA). Total RNA from a cohort of 23 
healthy human livers and 17 intestinal samples were obtained from healthy individuals 
undergoing diagnostic esophagogastroduodenoscopy was described elsewhere (Ho et al., 
2006; Urquhart et al., 2010). Human skeletal muscle, kidney, placenta and brain total 
RNA was sourced from BioChain (Hayward, CA). cDNA was synthesized using 
Multiscribe reverse transcriptase (Applied Biosystems, Carlsbad, CA) according to 
manufacturer’s instruction and 40 ng of cDNA was used in each PCR reaction.  Primer 
sequences for quantitative PCR were obtained from Pomari et al., (2009) and are listed in 
Table 4.1. Standard curves of the OATP2B1 TSS variant amplicons cloned into pCR2.1 
TOPO vector (Invitrogen) were generated for absolute determination of copy number. 
Expression was normalized to the copy number of 18S-rRNA. 
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Table 4.1 Primer Sequences 
Primer Sequence Type 
SLCO2B1 1e 
Fw 5ʹ′-­‐GAGGCTGGGATTGAAGCTTCAGGGAGAGCC-­‐3ʹ′	  
Cloning 
SLCO2B1 1e 
Rv 
5ʹ′-­‐CAAGACAGCTCACACTCGGGAATCCTCTGG-­‐3ʹ′ Cloning 
SLCO2B1 1b 
2kb pro Fw 
5ʹ′-­‐ATCAATCAGATAAACTTAGCCAGACAAGC-­‐3ʹ′ Cloning 
SLCO2B1 1b 
2kb pro Rv 5ʹ′-­‐CATGACTGCTGGAGTGCAGTGAGCTCC-­‐3ʹ′	  
Cloning 
SLCO2B1 1e 
84 5ʹ′-­‐TCCCTGAAGCTTCAATCCCAGCCTTTTCTG-­‐3ʹ′ 
Cloning 
SLCO2B1 1e -
200XhoI 
5ʹ′-­‐ATTTCTCGAGAAGGTTTGCTGTCAGCGCGTCAGCAG-­‐3ʹ′ Cloning 
SLCO2B1 1e -
500XhoI 
5ʹ′-­‐ATTTCTCGAGGCCCCTGGAGCCACCTGGCCTACCTGG-­‐3ʹ′ Cloning 
SLCO2B1 1e -
1000XhoI 5ʹ′-­‐ATTTCTCGAGACCCAGGTCTGAGGCCTTAAAGCC-­‐3ʹ′ 
Cloning 
SLCO2B1 1e -
2250XhoI 5ʹ′-­‐ATTTCTCGAGTGGAGGGGTTTACCTGGAGGAAGACC-­‐3ʹ′ 
Cloning 
OATP2B1 - R 5ʹ′-­‐CACTGTGGAGATGGAGCTC-­‐3ʹ′	   qPCR 
OATP2B1 - 1a 5ʹ′-­‐CCTGATAAACTTCATGATGGAG-­‐3ʹ′ qPCR 
OATP2B1 - 1b 5ʹ′-­‐GGCTGGAGCTCACTGCAC-­‐3ʹ′	   qPCR 
OATP2B1 - 1c 5ʹ′-­‐GCACACAGGAGGTCGGAG-­‐3ʹ′	   qPCR 
OATP2B1 - 1d 5ʹ′-­‐ACTGCAGTACGGCAGGAAG-­‐3ʹ′	   qPCR 
OATP2B1 - 1e 5ʹ′-­‐TGGGATTGAAGCTTCAGGGAG-­‐3ʹ′	   qPCR 
OATP2B1 1e 
DR1-1 Del 
5ʹ′-­‐CCAGAGGCACAGGCTGTGGACTCCCTCCACAAACAG 
CCATATCTC-­‐3ʹ′ 
Mutagenesis 
OATP2B1 1e 
DR1-1 Mut 
5ʹ′-­‐CCAGAGGCACAGGCTGTGGAGTTTACCATCCACAAA 
CAGCCATATCTC-­‐3ʹ′ 
Mutagenesis 
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4.2.7 Immunoblot and Immunohistochemistry 
HeLa cells were transduced with adenovirus encoding LacZ (control), OATP2B1-FL or 
OATP2B1-Short. Protein samples were separated by SDS-PAGE and transferred to 
NuPAGE nitrocellulose membrane using the XCell SureLock Western blotting system 
(Invitrogen, Carlsbad, CA). Membranes were probed with custom-made rabbit polyclonal 
OATP2B1 antibody based on a C-terminus epitope 
(CSPAVEQQLLVSGPGKKPEDSRV) (Invitrogen). Anti-rabbit horseradish peroxidase–
labeled antibody (Bio-Rad, Hercules, CA) was used as the secondary. The immobilized 
secondary antibody was detected using the ECL Plus Western Blotting Detection System 
(GE Healthcare) and KODAK ImageStation 4000 MM (Mandel). HeLa cells were 
transduced with adenovirus encoding LacZ (control), OATP2B1-FL or OATP2B1-Short 
on culture slides and were stained as previously described (Knauer et al., 2010). The 
custom-made rabbit polyclonal OATP2B1 antibody was used to localize transporter 
expression and anti-rabbit Alexa Fluor® 488 (Invitrogen) was used as the secondary 
antibody. Images were obtained by confocal fluorescence microscopy. For the negative 
control, the primary antibody was omitted. 
 
4.2.8 Transport Studies 
For transport kinetic experiments, HeLa cells (human cervical cancer cell line) were 
grown in 12-well plates (approximately 0.8 × 106 cells/well) and infected with vaccinia 
(vtf-7) at a multiplicity of infection of 10 plaque-forming units/cell in serum-free Opti-
MEM I medium (Invitrogen) and allowed to absorb for 30 minutes. Cells were 
transfected with 1 µg of transporter cDNA or parental plasmid lacking insert as control 
using Lipofectin (Invitrogen) and incubated at 37°C for 16h. To examine pH dependent 
transport of OATP2B1, HeLa cells were transduced with the adenoviruses containing the 
full length or short OATP2B1 variant transporter coding region in DMEM medium at a 
multiplicity of infection (MOI) of 100 and incubated at 37°C for 48h. Transport was 
evaluated in Opti-MEM using labeled substrate as previously reported (Cvetkovic et al., 
1999). Drug accumulation was determined after 5 min for rosuvastatin and 10 min for 
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estrone 3-sulfate by washing cells three times with ice-cold PBS followed by lysis with 
1% sodium dodecylsulfate. Retained cellular radioactivity was quantified by liquid 
scintillation spectrometry. Transport studies with varying pH environments were 
preformed in Krebs-Heinseleit bicarbonate Buffer (KHB) using rosuvastatin (100 nM) 
and estrone 3-sulfate (100 nM) as previously reported (Urquhart et al., 2010). 
 
4.2.9 Luciferase Reporter Assays 
Reporter gene constructs were transfected into HeLa, HepG2, Huh-7 or Caco-2 cells 
using Lipofectamine 2000 (Invitrogen) according to the manufacture’s protocol. Cells 
were plated into 24 wells plates at approximately 0.6 × 106 cells per well for 24h before 
transfection. Each well was transfected with 250 ng of reporter construct and 2.5 ng of 
pRL-CMV vector (Promega) as an internal control in 400 µL Opti-MEM. After 24h the 
media was changed to DMEM with 10% FBS, then cells were incubated for 24h at 37°C.  
Cells were then rinsed with PBS and harvested using passive lysis buffer (Promega). 
Luciferase activity was measured in cell extracts using Dual-Luciferase reporter assay 
(Promega) and detected using a Flouroskan Ascent FL luminometer (Thermo Scientific, 
Hudson, NH). Relative luciferase activity is reported as the ratio of firefly/Renilla 
luciferase activities. Nuclear receptor expression vectors were prepared as previously 
described (Tirona et al., 2003b) and in certain instances, 250 or 500 ng/well of each 
nuclear receptor expression plasmid or blank vector control plasmid were used for 
reporter assays. 
 
4.2.10 Chromatin Immunoprecipitation (ChIP) 
For DNA cross-linking and chromatin immunoprecipitation, the EZ ChIP Assay 
(Millipore, Billerica, MA) was used according to the manufacturer’s instructions. Briefly, 
HepG2, Huh-7, HeLa and Caco-2 cells were cultured in 10-cm dishes.  DNA was cross-
linked, sheared by sonication (Virsonic 100, Virtis, Gardiner, NY), and then chromatin 
was incubated with 2 µg anti-HNF4α C-19 (sc-6556; Santa Cruz Biotechnology, Santa 
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Cruz, CA) antibody overnight at 4°C. Binding of HNF4α was determined by qPCR 
(Table 4.2 for primer sequences). Western Blot of total cell lysates was preformed using 
anti-HNF4α C-19 (sc-6556; Santa Cruz Biotechnology) (1:1000) and anti-actin C-11 (sc-
1615; Santa Cruz Biotechnology) (1:200). 
 
4.2.11 Statistical Analysis 
Statistical differences between group parameters was determined by unpaired Student’s 
T-test, 1-way ANOVA, or 2-way ANOVA, using Bonferroni’s multiple comparison test, 
as appropriate (GraphPad Software Inc, San Diego, CA). A p value of <0.05 was 
considered statistically significant. 
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Table 4.2 Primer Sequences used for qPCR after ChIP 
Primer Sequence 
Distance 
to exon 
1e TSS 
(bp) 
Amplicon 
Size (bp) 
ChIP 2B1 1e F1 5ʹ′-AGAGAGCAAGGGCCACCTAT-3ʹ′ 2152 125 
ChIP 2B1 1e R1 5ʹ′-TATAGGGACCTCAGCCACCA-3ʹ′   
ChIP 2B1 1e F2 5ʹ′-TCTGACTCCCAGGCTCAAGT-3ʹ′ 1622 125 
ChIP 2B1 1e R2 5ʹ′-GCAACATGGTGAAACCTCAT-3ʹ′   
ChIP 2B1 1e F3 5ʹ′-GCCTTTCCCACAGAGAACAG-3ʹ′ 903 123 
ChIP 2B1 1e R3 5ʹ′-GCCCTTCATGGGTAGAGTCA-3ʹ′   
ChIP 2B1 1e F4 5ʹ′-CTCTCAGAACCCGGAGGAAT-3ʹ′ 77 124 
ChIP 2B1 1e R4 5ʹ′-TCAAAGCCTTCCTGGGAGTA-3ʹ′   
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4.3 Results 
4.3.1 Tissue Expression of OATP2B1 TSS Variants  
We preformed variant-specific quantitative RT-PCR to determine the absolute expression 
of the OATP2B1 variants in tissues important in drug disposition, namely the duodenum 
and liver. While transcripts for the OATP2B1 1b, 1d and 1e variants were readily 
observed; we were not able to detect OATP2B1 1a and 1c transcripts in these tissues (not 
shown). In duodenum, the OATP2B1 variant 1b, encoding the full length protein variant 
was the most abundant transcript found (Fig. 4.2).  On average, OATP2B1 1d and 1e 
transcripts were 10-fold lower than 1b transcripts in the intestine.  In liver, OATP2B1 1e 
transcript (short variant) was the predominant form followed by 1b and 1d transcripts.   It 
is notable that for each transcript, the absolute expressions of OATP2B1 1b and 1d were 
similar when comparing duodenum versus liver levels.  The clear exception was for the 
OATP2B1 1e transcript, whose expression was 100-fold greater in liver than in 
duodenum.  We confirmed that the OATP2B1 1e transcript detected by qPCR arose from 
an mRNA encoding the short protein variant by long range PCR using liver cDNA 
template, cloning of the amplicon and sequencing.  
Variant-specific quantitative RT-PCR of OATP2B1 variants was also preformed in 
samples of kidney, brain, placenta, and skeletal muscle. Like liver and intestine, 
transcripts for OATP2B1 1b, 1d, and 1e were observed, but OATP2B1 1a and 1c 
transcripts were not detected in these tissues (Table 4.3). Similar to duodenum, the 
OATP2B1 1b variant was the most abundant transcript found in kidney, brain, placenta 
and skeletal muscle. Again we noted, the absolute expressions of OATP2B1 1b 
transcripts (full length form) in kidney, placenta and skeletal muscle were similar when 
compared to duodenum and liver levels. Of the tissues analyzed, brain shows highest 
expression of the OATP2B1 1b transcript, encoding the full length protein. On average, 
OATP2B1 1d and 1e transcripts were over 10 to 100-fold lower than 1b transcripts in the 
brain, placenta and skeletal muscle, exhibiting a comparable expression pattern to that of 
intestine. However, in kidney the expression of the OATP2B1 1e transcript was 10-fold 
higher than duodenum, brain, placenta, and skeletal muscle and only 2 fold lower then 
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the OATP2B1 1b transcript. These findings demonstrate 3 different expression patterns 
of OATP2B1 protein variants. Liver primarily expresses the shorter OATP2B1 protein, 
kidney expresses similar levels of full length and short OATP2B1, while the other tissues 
analyzed predominantly express full length OATP2B1. 
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Figure 4.2 Tissue specific expression and quantitation of the alternative OATP2B1 first 
exons in 23 liver and 17 intestinal samples. 
Absolute quantification was done by qPCR using sense primers for the specific first exon 
and an antisense primer located within exon 3. ***p<0.001 
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Table 4.3 Absolute mRNA Expression of OATP2B1 TSS Variants. 
  Absolute mRNA Expression 
  (Copies OATP2B1/Copies of 18S) 
Tissue 1b (FL) 1d (short) 1e (short) 
Kidney 2.06 × 10-5 7.42 × 10-8 8.59 × 10-6 
Brain 1.59 × 10-4 1.21 × 10-7 1.45 × 10-7 
Placenta 1.45 × 10-5 ND 2.24 × 10-7 
Sk. Muscle 2.84 × 10-5 3.43 × 10-7 1.32 × 10-6 
ND - not detected 
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4.3.2 Transport Function of OATP2B1-Short 
Many groups have studied the transport function of OATP2B1-FL but to our knowledge 
the transport function of the short variant has not been previously assessed. Here, we 
examined the transport function of the OATP2B1-Short variant in comparison to 
OATP2B1-FL using two substrates: estrone 3-sulfate and rosuvastatin. Both OATP2B1-
FL and OATP2B1-Short show time- and concentration-dependent uptake kinetics for 
estrone 3-sulfate and rosuvastatin (Fig. 4.3C-F). The apparent affinities (Km) for both 
substrates were not significantly different between OATP2B1-FL and OATP2B1-Short 
(Table 4.4). The maximal velocity (Vmax) of the OATP2B1-Short was slightly higher for 
both rosuvastatin and estrone 3-sulfate; however, the differences did not reach statistical 
significance (Table 4.4). Transport clearance (CL) of the OATP2B1-Short was also 
slightly higher for both rosuvastatin and estrone 3-sulfate but it also did not reach 
statistical significance. Heterologous expression of OATP2B1-FL and OATP2B1-Short 
in HeLa cells, using recombinant adenoviruses and protein detection with an OATP2B1 
antibody directed towards a common C-terminus epitope, showed that both variants 
products are expressed at comparable levels and traffic to the cell surface (Fig 4.3A and 
B). HeLa cells show some protein expression of OATP2B1 by immunoblot (Fig. 4.3A) 
and RT-PCR analysis suggests that HeLa cells natively express low levels of the full 
length OATP2B1 (data not shown). These findings indicate that the SLCO2B1 1e 
promoter transcript produces a short transporter variant with similar transport activity as 
the previously characterized full length OATP2B1 protein. 
We further examined the pH dependent transport of the OATP2B1-Short variant since 
previous studies have demonstrated OATP2B1-FL transports certain substrates in a pH 
dependent manner (Kobayashi et al., 2003; Nozawa et al., 2004a). For both the full length 
and the short OATP2B1 variants, we observed that rosuvastatin transport was stimulated 
with decreasing pH (Fig 4.3G). Rosuvastatin transport by OATP2B1-Short is 
significantly greater than OATP2B1-FL at low pH (5.5 and 6.0) (Fig. 4.3G).  In contrast, 
estrone 3-sulfate transport activities for both OATP2B1-FL and OATP2B1-Short do not 
appear to be pH-dependent (Fig. 4.3H). These results suggest that amino acids in the 
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predicted intracellular N-terminus of OATP2B1 modulate substrate-specific, pH-
dependent membrane transport. 
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Figure 4.3 Function of OATP2B1 transcription start site variants. (A) Western blot 
showing expression of OATP2B1 variants in HeLa cells after adenoviral overexpression. 
(B) Cellular localization of full length or truncated variant OATP2B1 in HeLa cells after 
adenoviral overexpression. OATP2B1 shown in green and the nucleus in blue. 
Intracellular accumulation of [3H]rosuvastatin (C,E) or [3H]estrone 3-sulfate (D,F) in 
HeLa cells transiently transfected with OATP2B1-FL (full-length) or OATP2B1-Short 
(truncated). Concentration-dependent transport of [3H]rosuvastatin (E) and [3H]estrone 3-
sulfate (F) by OATP2B1-FL (full-length) or OATP2B1-Short (truncated). pH dependent 
transport of [3H]rosuvastatin (G) or [3H]estrone 3-sulfate (H) in HeLa cells transduced 
with OATP2B1-FL (full length) or OATP2B1-Short (truncated) adenovirus.  Results are 
presented fmol per µg protein per min ± SEM (n=3). * p<0.05 
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Figure 4.3 Function of OATP2B1 transcription start site variants. 
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Table 4.4 Transport kinetics of OATP2B1 transcription start site variants. 
    Vmax ± SD Km  ± SD CL  ± SD 
        Vmax/Km 
    
(fmol/µg 
protein/min) (µM) 
(µL/µg 
protein/min) 
Rosuvastatin 
         
 
OATP2B1-FL 3.4 ±  1.6 7.1 ±  3.1 530.0 ±  349.9 
 
OATP2B1-Short 4.9 ±  3.4 8.4 ±  5.5 653.9 ±  216.7 
           Estrone 3-sulfate 
         
 
OATP2B1-FL 31.1 ±  13.4 47.2 ±  9.4 660.3 ±  296.1 
 OATP2B1-Short 43.2 ±  19.0 57.7 ±  14.9 722.7 ±  160.1 
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4.3.3 Transactivator Screen of the SLCO2B1 1e Promoter 
The full length form of OATP2B1 appears to be ubiquitously expressed in many tissues 
and the constitutive expression of OATP2B1-FL is under regulatory control by the Sp1 
transcription factor (Maeda et al., 2006). However, regulatory control mechanisms of the 
other OATP2B1 TSS variants have not been previously assessed. We have focused on the 
OATP2B1 1e TSS variant because it shows liver specific expression unlike the 
OATP2B1 1b variant found ubiquitously (Pomari et al., 2009) (Fig. 4.2 and Table 4.3). 
The SLCO2B1 1e promoter was cloned from genomic DNA (-2250 to +78) and ligated 
into pGL3-basic. The +1 position was considered to be the transcription start site of exon 
1e described by Pomari and colleagues (GeneBank no. FM209054) (Pomari et al., 2009).  
We screened the ability of a variety of nuclear receptors (HNF4α, constitutive androstane 
receptor, liver X receptor, pregnane X receptor, small heterodimer partner 1, peroxisome 
proliferator activated receptors α and γ, liver receptor homolog 1 and vitamin D receptor) 
to activate the SLCO2B1 1e promoter using co-transfection and luciferase reporter assays 
in HeLa cells (Fig. 4.4A). Of the nuclear receptors analyzed, we found that HNF4α 
strongly transactivated the SLCO2B1 1e (-2250/+78) promoter. Interestingly, we found 
that HNF4α did not transactivate the SLCO2B1 1b promoter (Fig. 4.4B).  
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Figure 4.4 Nuclear receptor screen for transactivation of the SLCO2B1 1e promoter 
responsible for producing the truncated protein variant. 
(A) Dual luciferase reporter assay in HeLa cells transfected with nuclear receptor 
expression plasmids and SLCO2B1 1e promoter (-2250 to +78) or control pGL3-basic 
vector to determine if they were able to transactivate the SLCO2B1 1e promoter. (B) 
Transcription activation of the SLCO2B1 1e promoter and not the 1b promoter in HeLa 
cells transfected with HNF4α and SLCO2B1 1b (-2250/+78) or 1e (-2000/+1) promoter 
constructs. Results are presented as relative luciferase activity fold of pGL3-Basic control 
± SEM. ***p<0.001 
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4.3.4 Deletion-Mutation Analysis of SLCO2B1 1e Promoter Activity  
Reporter assays were preformed in liver (HepG2 and Huh-7), colon (Caco-2) and cervical 
carcinoma (HeLa) cell lines to evaluate the roles of cellular milieu and cis-acting factors 
to SLCO2B1 1e promoter activity. For this purpose, SLCO2B1 1e promoter constructs 
were created by sequentially deleting the 5' upstream segments (-2250 to +78, -1000 to 
+78, -500 to +78 and -200 to +78). We observed reporter activity in three cell lines 
(HepG2, Huh-7 and Caco-2) for all SLCO2B1 1e deletion constructs (Fig. 4.5A). In 
comparison, SLCO2B1 1b reporter activity was significantly lower than of SLCO2b1 1e. 
The pattern of reporter activity was similar for all cell lines except for HeLa cells, which 
displayed no significant activity for all reporter constructs. Reporter activity decreased 
upon the deletion of -2250 to -1000 region, suggesting the presence of positive regulatory 
sequences. While deletion of the -1000 to -500 revealed a large increase in reporter 
activity in three cell lines (HepG2, Huh-7 and Caco-2) suggesting that the deleted 
segment contains negative regulatory sequences. Even the shortest construct (-200/+78) 
retained reporter activity in HepG2, Huh-7 and Caco-2 suggesting the presence of an 
important positive regulatory sequence in this region. 
Given that OATP2B1 le transcripts are prominently expressed in liver and that SLCO2B1 
1e luciferase reporter activities were higher in hepatic and intestinal cell lines in 
comparison to cervical carcinoma cells, we suspected a role for liver enriched 
transcription factors such as HNF4α in regulating gene expression.  Hence, we performed 
in silico analysis of transcription factor binding sites within the 2.5Kb fragment of the 
SLCO2B1 1e gene promoter using the NUBIscan algorithm (Podvinec et al., 2002).  
Several direct repeats with one base pair spacing (DR1), known to be a potential binding 
site for HNF4α (Bolotin et al., 2010), were predicted which we have termed DR1-1 
(AGGGCAaAGTCCA) located at position -17 to -4, a DR1-2 (AGGCCTcAGACCT) 
located at -954 to -941 and DR1-3 (AGAGCAaGGGCCA) located at -2149 to -2136. On 
the basis that the -200/+78 construct had retained significant activity in liver and 
intestinal cells, we hypothesized that the DR1-1 site would represent a functional HNF4α 
binding site. Guided by the position weight matrix for HNF4α-binding sequence motifs 
(Bolotin et al., 2010), the DR1-1 site was mutated at three key base pairs (Fig. 4.5B). 
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Furthermore, we deleted three base pairs in DR1-1 to disrupt the HNF4α motif spacing 
(Fig. 4.5B). Reporter assays were preformed in HeLa cells transfected with HNF4α and 
the DR1-1 mutation constructs (Fig. 4.5C). It is notable that in contrast to HepG2, Huh-7 
and Caco-2 cells, HeLa cells do not express native HNF4α (Fig. 4.5D). Disruption of the 
DR1-1 response element by mutation or deletion significantly decreased the 
transcriptional activation of the SLCO2B1 1e promoter by HNF4α, suggesting that the 
DR1-1 site is a functional HNF4α binding site (Fig. 4.5C). These studies demonstrate that 
the SLCO2B1 1e promoter contains a functional HNF4α-binding sequence near the 1e 
transcription start site. 
 
4.3.5 HNF4α Binding to SLCO2B1 1e Promoter 
To confirm that HNF4α binds to the DR1-1 response element, chromatin 
immunoprecipitation (ChIP) was preformed with a HNF4α antibody in HeLa, HepG2, 
Huh-7 and Caco-2 cells. HNF4α-bound DNA was used as template for real-time PCR 
using primers designed to cover sequences along the SLCO2B1 1e promoter covering 2.2 
kb upstream and the three predicted DR1 response elements (Fig. 4.6A). The analysis 
revealed significant binding of HNF4α to the proximal region of the SLCO2B1 1e 
promoter near the DR1-1 (-4 bp) response element in HepG2, Huh-7 and Caco-2 cells but 
not HeLa cells (Fig. 4.6B). Analysis of the other DR1 response elements does not 
demonstrate significant HNF4α binding in HepG2, Huh-7 and Caco-2 cells. HeLa cells 
do not natively express HNF4α, so predictably we did not detect binding of HNF4α to the 
SLCO2B1 1e promoter. Results from the reporter assays and ChIP taken together, reveal 
that HNF4α binds to the functional DR1-1 site in the proximal region of the SLCO2B1 1e 
promoter to control expression of the truncated OATP2B1 variant. 
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Figure 4.5 A functional HNF4α-binding motif in the proximal region of the SLCO2B1 1e 
promoter. (A) Dual luciferase reporter assay in HepG2, Huh-7, Caco-2, and HeLa cells 
transfected with various constructs of the SLCO2B1 1e promoter (-2250 to +78, -1000 to 
+78, -500 to +78 and -200 to +78) or SLCO2B1 1b promoter (-2000 bp to +1). Results 
are presented as relative luciferase activity fold of pGL3-Basic control ± SEM (n=3-4). 
(B) Sequences of the proximal DR1-1 HNF4α-binding motif with a three base pair 
deletion (Del) or mutation of three key base pairs (Mut) based on the HNF4α position 
weight matrix (Bolotin et al., 2010). (C) Dual luciferase reporter assay in HeLa cells 
transfected with SLCO2B1 1e promoter constructs (WT, DR1-1 Del or DR1-1 Mut) and 
HNF4α or control pEF vector. Predicted HNF4α binding sites are shown in white along 
the 1e promoter constructs, the DR1-1 HNF4α-binding motif is shaded to indicate the 
binding motif disrupted by deletion or mutation. Results are presented as relative 
luciferase activity fold of pGL3-Basic control ± SEM (n=5), *p<0.05 versus wild type 
HNF4α binding site construct. (D) Western blot showing HNF4α expression in in HeLa, 
HepG2, Huh-7 and Caco-2 cells. 
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Figure 4.5 A functional HNF4α-binding motif in the proximal region of the SLCO2B1 1e 
promoter. 
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Figure 4.6 Chromatin Immunoprecipitation. 
(A) Diagram of 2.3Kb of the SLCO2B1 1e promoter with the location of DR1 sites and 
primer pairs used for qPCR. ChIP using an anti-HNF4α antibody in HeLa (B), HepG2 
(C), Huh-7 (D) and Caco-2 (E) cells. Quantification was done by qPCR on HNF4α 
immunoprecipitated DNA (bound fraction), IgG immunoprecipitated DNA (background 
fraction) and input DNA with four sets of primers located along the SLCO2B1 1e 
promoter. Results are presented as the difference between the recoveries in the bound and 
background fractions. *p<0.05 versus all other primer pairs 
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4.4 Discussion 
In the present study, we characterized the transport function and transcriptional regulation 
of OATP2B1 1e variant. The SLCO2B1 1e variant encoding OATP2B1-Short was cloned 
from a human liver cDNA library. Heterologous expression of OATP2B1-Short (1e) in 
HeLa cells resulted in cell surface expression and functional transport activity. We found 
no pronounced differences in transport activity between the OATP2B1-FL and 
OATP2B1-Short protein for two typical OATP substrates: rosuvastatin and estrone 3-
sulfate. However, we did see a significant increase in rosuvastatin uptake by OATP2B1-
Short, but not for OATP2B1-FL at low pH. Reporter assays and chromatin 
immunoprecipitation revealed a functional HNF4α binding motif in the proximal region 
of the SLCO2B1 1e promoter. 
The expression of the alternative OATP2B1 variants in intestine and kidney were 
reported previously (Pomari et al., 2009). We confirm that the OATP2B1 exon 1b 
transcription variant has broad expression pattern consistent with previous reports and 
regulation by a constitutive nuclear receptor Sp1 (Maeda et al., 2006; Pomari et al., 
2009). Quantitative PCR revealed that expression of the OATP2B1 1b full length variant 
was highest in the brain, the tissue of first cloning (Tamai et al., 2000). We confirm the 
liver enriched expression of the OATP2B1 exon 1e variants using absolute quantitative 
PCR, as was previously suggested using semi-quantitative PCR (Pomari et al., 2009). 
Interestingly we report 100-fold variation in the hepatic mRNA expression of the 
OATP2B1 1e variant between individuals. 
We demonstrate that the SLCO2B1 1e variant encodes a shortened protein capable of 
trafficking to the cell surface and has functional transport activity. While there was a non-
significant trend towards higher transport efficiency for OATP2B1-Short in comparison 
to OATP2B1-FL during studies with concentration-dependent uptake, clear differences 
were observed in the transport efficiencies among the variants at low pH. Other studies 
have also documented the pH dependent transport of rosuvastatin, fluvastatin, 
pravastatin, atorvastatin, cerivastatin, and pitavastatin by OATP2B1 (Kobayashi et al., 
2003; Varma et al., 2011). Previous studies have demonstrated pH dependent transport of 
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estrone 3-sulfate by OATP2B1; however, we did not detect a significant difference in the 
pH dependent transport of estrone 3-sulfate (Kis et al., 2010; Kobayashi et al., 2003; 
Nozawa et al., 2004a; Sai et al., 2006). It has been suggested that an inward proton 
gradient acts as the driving force for the OATP2B1 mediated intestinal absorption and 
cellular uptake of substrates (Nozawa et al., 2004a; Sai et al., 2006; Varma et al., 2011). 
The pH sensitivity of OATP2B1 has been linked to a conserved histidine in 
transmembrane domain three (Leuthold et al., 2009). Here, we propose a role for the 
amino acids in the predicted intracellular N-terminus in modulating substrate-specific, 
pH-dependent membrane transport of OATP2B1. 
In this study, the liver specific nuclear receptor, HNF4α, was found to stimulate 
transcription of the SLCO2B1 exon 1e promoter. Moreover, a functional HNF4α binding 
motif was found in the proximal region of the SLCO2B1 1e gene promoter very close to 
the transcription start site. Indeed, others have recently identified this HNF4α binding 
motif in the SLCO2B1 exon 1e promoter using the ChIP-Seq method (Fang et al., 2012).  
HNF4α is expressed highly in metabolic tissues like the liver, kidney and intestine 
(Bookout et al., 2006). HNF4α has been shown to regulate key drug metabolism genes 
including Cytochromes P450 (CYP)3A4, CYP3A5, CYP2D6, CYP2C9, and CYP2C19 as 
well as drug transporter genes such as ABCC2, ABCB1 and SLCO1B1 (Jover et al., 2001; 
Jover et al., 2009; Kamiyama et al., 2007; Kawashima et al., 2006; Tirona et al., 2003b). 
Like other transcriptional targets, we suspect that HNF4α-mediated regulation of 
OATP2B1 1e variant expression can be influenced by a variety of different factors 
including genetics, gender, environmental factors and diet (Hwang-Verslues and Sladek, 
2010). 
We have found 100-fold difference in OATP2B1 1e expression among individuals.  It is 
interesting to speculate that interindividual differences in the tissue expression of 
OATP2B1 1e variant contributes to variable drug response. In principle, conditions that 
alter HNF4α expression and activity, such as diabetes and liver diseases, may impact on 
OATP2B1 1e expression. Factors enhancing HNF4α activity would increase expression 
of the OATP2B1 1e variant and could increase the hepatic and renal exposure OATP2B1 
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substrates. Increased HNF4α activity in the intestine would lead to upregulation of 
OATP2B1 1e and enhanced intestinal absorption of substrate drugs. 
In this report, we assessed the transport function and regulation of the liver-enriched 
OATP2B1 1e transcription start site variant. The encoded OATP2B1-Short protein is a 
functional membrane transporter for estrone 3-sulfate and rosuvastatin. Analysis of the 
SLCO2B1 1e TSS variant promoter revealed a DR1 binding motif capable of binding 
HNF4α to control the liver specific expression of the short OATP2B1 1e variant. These 
findings indicate that differential regulation of OATP2B1 splice variant expression in 
tissues could contribute to variation in drug response. 
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5 TARGETED DISRUPTION OF MURINE ORGANIC 
ANION TRANSPORTING POLYPEPTIDE 2B1 
(Oatp2b1/Slco2b1) AND THE IMPACT ON 
ROSUVASTATIN DISPOSITION3 
 
                                                
3
 The material in this chapter is based on a manuscript in preparation: Knauer MJ, Takada H, Mansell SE, 
Kim RB, Tirona RG. Targeted disruption of murine organic anion transporting polypeptide 2b1 
(Oatp2b1/Slco2b1) and the impact on rosuvastatin disposition. (2012) 
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5.1 Introduction 
The Organic Anion Transporting Polypeptide (OATP) transporters belong to a large 
superfamily of membrane proteins that mediate the sodium-independent uptake of a 
variety of amphipathic compounds including hormones, bile acids, and drugs clinically 
used today. OATP transporters are found in many organs involved in drug disposition or 
response such as liver, intestine, brain and kidney. The superfamily of OATP transporters 
has currently identified 11 human OATPs and 15 mouse Oatps (Hagenbuch and Gui, 
2008). There has been great interest in understanding the role of OATP transporters in 
drug disposition, particularly the members of the OATP1B family found highly expressed 
on the basolateral membrane of hepatocytes. It is now well appreciated that functionally 
relevant single nucleotide polymorphisms (SNPs) in OATP1B1, first identified by our 
group (Tirona et al., 2001), are associated with higher plasma concentrations of statins 
such as atorvastatin, rosuvastatin, simvastatin, pravastatin and pitavastatin (Chung et al., 
2005; Ho et al., 2007; Pasanen et al., 2007; Pasanen et al., 2006). Importantly, a genome 
wide analysis revealed an association between a common reduced function variant 
OATP1B1 (*5, 521T>C, rs4149056) and statin myopathy in patients on high dose 
simvastatin (Link et al., 2008).  
OATP2B1 (SLCO2B1) is another member of the OATP family, found much more widely 
expressed than OATP1B transporters in tissues that include liver, kidney, brain, intestine, 
colon, heart, lung, placenta, ovary, testis and skeletal muscle (Knauer et al., 2010; 
Kullak-Ublick et al., 2001; Tamai et al., 2000). Functionally, OATP2B1 has a much 
narrower substrate specificity compared to members of the OATP1B family (Hagenbuch 
and Gui, 2008). It also displays substrate specific, pH-dependent transport properties in 
human intestine epithelial cells (Kobayashi et al., 2003; Nozawa et al., 2004) indicating 
that OATP2B1 is involved in the intestinal absorption of statins (Varma et al., 2011). 
Moreover, OATP2B1 is thought to determine the extra-hepatic distribution of statins in 
the heart, skeletal muscle and platelets (Grube et al., 2006; Knauer et al., 2010; Niessen et 
al., 2009). While SLCO2B1 genetic polymorphisms are associated with the 
pharmacokinetics of montelukast and fexofenadine, as well as androgen response in 
  
143 
prostate cancer, little is known regarding their effects on statin disposition (Imanaga et 
al., 2011; Mougey et al., 2009; Wright et al., 2011; Yang et al., 2011). 
Knockout mouse models have been proven useful to study the roles of Oatps on drug 
disposition and glucose, cholesterol and bile acid homeostasis (Csanaky et al., 2011; 
Gong et al., 2011; Lu et al., 2008; Meyer zu Schwabedissen et al., 2011; van de Steeg et 
al., 2010; Zaher et al., 2008; Zhang et al., 2012a; Zhang et al., 2012b). The murine 
ortholog of human OATP1B1 and OATP1B3 is Oatp1b2. Oatp1b2 was the first Oatp to 
be studied in a knockout mouse model (Chen et al., 2008; Lu et al., 2008; Zaher et al., 
2008). Oatp1b2-/- mice had significantly lower liver to plasma ratios for lovastatin, 
pravastatin, atorvastatin, and rosuvastatin, but not for simvastatin or cerivastatin (Chen et 
al., 2008; Degorter et al., 2012; Zaher et al., 2008), suggesting a variable impact in the 
hepatic uptake of different statins by Oatp1b2 (Chen et al., 2008). More recently an 
Oatp1a/1b-/- model was generated by targeted chromosomal deletion, eliminating 
expression of Oatp1a1, Oatp1a4, Oatp1a5, Oatp1a6 and Oatp1b2 (van de Steeg et al., 
2010). The systemic exposure of pravastatin was greatly increased in Oatp1a/1b-/- mice, 
but only minor decreases were observed in liver exposure (Iusuf et al., 2012). They 
proposed that other transporters, like Oatp2b1, might compensate for the loss of 
Oatp1a/1b transporters in the hepatic uptake of pravastatin (Iusuf et al., 2012). Oatp2b1 is 
the murine ortholog of human OATP2B1 and it shares a ubiquitous expression pattern, 
but it is also found in the mouse liver at high levels (Cheng et al., 2005). To our 
knowledge, until now there have been no published reports on the generation and 
characterization of an Oatp2b1 knockout mouse. 
Rosuvastatin is a hydrophilic statin with low membrane permeability that is thought to 
undergo very minimal metabolism; therefore, its disposition is highly dependent upon 
transporters (Kitamura et al., 2008; Shitara and Sugiyama, 2006).  The liver selectivity of 
rosuvastatin is due to transport by hepatic uptake transporters, like OATP1B1, 
OATP1B3, OATP2B1 and the sodium-taurocholate co-transporting polypeptide (NTCP). 
In humans OATP1B1 and OATP1B3 are considered important transporters involved in 
the hepatic uptake of rosuvastatin (Ho et al., 2006). OATP2B1 is thought to be important 
for the absorption and extrahepatic distribution of rosuvastatin in humans; however, high 
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expression in the murine liver suggests it may play a significant role in the hepatic uptake 
as well. 
Previously OATP2B1 has been implicated in the muscle uptake and myotoxicity of 
statins in vitro (Knauer et al., 2010; Sakamoto et al., 2008). However, there is a lack of in 
vivo studies examining statin transporters within skeletal muscle and their influence on 
myotoxic side effects of statins. We have proposed that the interplay between statin 
uptake versus efflux transporters modulates skeletal muscle statin exposure and toxicity. 
Inhibition of specific uptake transport mechanisms that control intracellular skeletal 
muscle concentrations of statins could lead to reduced accumulation of drug and 
decreased risk for toxicity. However, the in vivo relevance of OATP2B1 in statin 
intestinal absorption, hepatic clearance and muscle uptake has yet to be determined. In 
the present study, we describe the generation of a novel Oatp2b1 knockout mouse model 
with the aim of elucidating the in vivo role of Oatp2b1 in the pharmacokinetics and tissue 
distribution of rosuvastatin. 
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5.2 Methods 
5.2.1 Materials 
Rosuvastatin and rosuvastatin-d6 were obtained from Toronto Research Chemicals 
(North York, ON). [3H] rosuvastatin (5 mCi/mmol, 99% radiochemical purity) was 
purchased from American Radiolabeled Chemicals (St. Louis, MO). All other chemicals 
and reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. 
 
5.2.2 Targeting of Slco2b1  
The Oatp2b1tm1a/tm1a mouse strain (Slco2b1tm1a(KOMP)Wtsi) used for this research project 
was generated using a Knockout-First promoter driven approach by the trans-NIH 
Knock-Out Mouse Project (KOMP) and obtained from the KOMP Repository 
(www.komp.org) (Fig 5.1) (Skarnes et al., 2011). The ‘knockout-first’ allele contains an 
IRES:lacZ trapping cassette and a floxed promoter driven cassette inserted into the intron 
between exons 3 and 4, disrupting Slco2b1 gene function (Skarnes et al., 2011). NIH 
grants to Velocigene at Regeneron Inc (U01HG004085) and the CSD Consortium 
(U01HG004080) funded the generation of gene-targeted ES cells for 8500 genes in the 
KOMP Program and archived and distributed by the KOMP Repository at UC Davis and 
CHORI (U42RR024244). For more information or to obtain KOMP products go to 
www.komp.org.  
 
5.2.3 Gene Expression Analysis 
Tissues were harvested from male C57BL/6 wild type and Oatp2b1tm1a/tm1a mice and snap 
frozen at -80°C until RNA isolation. Total RNA was extracted from tissues after 
homogenization using Trizol reagent according to the manufacturer’s protocol 
(Invitrogen, Carlsbad, CA). cDNA was synthesized using Multiscribe reverse 
transcriptase (Applied Biosystems, Carlsbad, CA), according to manufacturer’s 
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instruction, from 2.5 μg of RNA per reaction. The resulting cDNA was used for 
quantitative real-time PCR (qPCR).  
Expression of Slco2b1 (Oatp2b1), Slco1a1 (Oatp1a1), Slco1a4 (Oatp1a4), Slco1a5 
(Oatp1a5), Slco1c1 (Oatp1c1) were determined by TaqMan assays Mm00614448_m1, 
Mm01267415_m1, Mm01267407_m1, Mm01267394_m1 and Mm00451845_m1, 
respectively (Applied Biosystems). Expression of other transporters was done using 
SYBR green assays with primers listed in Table 5.1.  All qPCR reactions were preformed 
with an Applied Biosystems 7500 Fast Real-Time PCR system (Applied Biosystems). 
The amount of the transporter was normalized to 18S-rRNA and relative expression was 
determined using the ΔΔCT method. 
 
5.2.4 Transport Experiments 
Human cervical adenocarcinoma (HeLa) (American Type Culture Collection, ATCC, 
Manassas, VA), cells were cultured in DMEM supplemented with 10% FBS, 50 U/mL 
penicillin, 50 µg/mL streptomycin and 2 mM L-glutamine (Invitrogen, Carlsbad, CA). 
Cells were maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air. HeLa 
cells were grown in 12-well plates (approximately 0.8 × 106 cells/well) and infected with 
vaccinia (vtf-7) at a multiplicity of infection of 10 plaque-forming units/cell in serum-free 
Opti-MEM I medium (Invitrogen) and allowed to absorb for 30 minutes. Cells were 
transfected with 1 µg of total transporter cDNA (mOatp2b1 or hOATP2B1) or parental 
plasmid lacking insert as control using Lipofectin (Invitrogen) and incubated at 37°C for 
16h. Transport was evaluated using labeled substrate as previously reported (Cvetkovic et 
al., 1999). [3H] rosuvastatin accumulation, after 10 mins, was determined by washing 
cells three times with ice-cold PBS followed by lysis with 1% sodium dodecylsulfate. 
Retained cellular radioactivity was quantified by liquid scintillation spectrometry. 
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5.2.5 Pharmacokinetic Study Design 
Animals were housed in a temperature-controlled environment with a 12h light/dark 
cycle and received a standard diet and water ad libitum. Male Oatp2b1tm1a/tm1a and wild-
type C57BL/6 (Jackson Laboratory, Bar Harbour, MA) were between 8 and 16 weeks of 
age, weighing 20 – 30 g, were used for experiments. Animals were dosed with 10 mg/kg 
rosuvastatin by oral gavage in 0.5% hydroxypropylmethylcellulose or 1 mg/kg 
rosuvastatin by tail vein injection in saline with <2% DMSO. All blood samples were 
collect by serial sampling at 10, 20, 30 min and 1, 2, 4, and 8 hours after oral dosing and 
5, 15, 30 min and 1, 2, 4, and 6 hours following intravenous dosing (Peng et al., 2009). 25 
uL of blood was collected with a heparinized pipet after saphenous or tail vein puncture. 
Blood was transferred to a tube for centrifugation at 12,000 g for 5 min to obtain plasma 
(10 uL).  At the final time point animals were euthanized by isoflurane overdose; blood 
was collected by cardiac puncture and liver, quadriceps and kidney were excised, rinsed 
in PBS, blotted and weighed. All plasma and tissue samples were stored at -80°C until 
analysis by LC-MS/MS. The study protocol was approved by the Animal Use 
Subcommittee of the University of Western Ontario, London, Canada. 
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Figure 5.1 Schematic of the “knockout-first” conditional Slco2b1 allele in 
Slco2b1tm1a(KOMP)Wtsi mice. The ‘knockout-first allele’ contains an IRES:lacZ trapping 
cassette and a floxed promoter driven cassette inserted into the intron between exons 3 
and 4 disrupting Slco2b1 gene function (Skarnes et al., 2011). 
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Table 5.1 Primer Sequences used for qPCR 
Primer   Sequence 
mOatp1b2 Fw Sense 5ʹ′-­‐TGGGCATTGGGAGTATTCTGA-­‐3ʹ′	  
mOatp1b2 Rv Antisense 5ʹ′-­‐CCAGGTGTATGAGTTGGACCC-­‐3ʹ′	  
mBcrp Fw Sense 5ʹ′-­‐AAATGGAGCACCTCAACCTG-­‐3ʹ′	  
mBcrp Rv Antisense 5ʹ′-­‐CCCATCACAACGTCATCTTG-­‐3ʹ′	  
mMrp2 Fw Sense 5ʹ′-­‐CTGAGTGCTTGGACCAGTGA-­‐3ʹ′	  
mMrp2 Rv Antisense 5ʹ′-­‐CAAAGTCTGGGGGAGTGTGT-­‐3ʹ′	  
mNtcp Fw Sense 5ʹ′-­‐GGCTTCCTGATGGGCTACATT-­‐3ʹ′	  
mNtcp Rv Antisense 5ʹ′-­‐AGAGTTGGACGTTTTGGAATCC-­‐3ʹ′	  
mOat3 Fw Sense 5ʹ′-­‐CTTCAGAAATGCAGCTCTTG-­‐3ʹ′	  
mOat3 Rv Antisense 5ʹ′-­‐ACCTGTTTGCCTGAGGACTG-­‐3ʹ′	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5.2.6 LC-MS/MS Analysis 
The concentration of rosuvastatin in plasma and tissues was determined by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) on an Agilent 1100 liquid 
chromatographic system and a TSQ-Vantage triple-quadrupole mass spectrometer 
(Thermo Scientific, Pittsburgh, PA) as previously reported (Degorter et al., 2012). Briefly 
plasma samples were precipitated with 45 uL of acetonitrile containing rosuvastatin–d6 
as an internal standard and centrifuged for 20 min at 14000 rpm at 4°C. The supernatant 
was diluted 1:2 in 0.05% formic acid and analyzed by LC-MS/MS. Liver samples were 
homogenized 1:1 (w/v) in 0.05% formic acid while quadriceps and kidney samples were 
homogenized 1:2 (w/v) in 0.05% formic acid. Standard curves were prepared using blank 
tissue homogenates. Tissue homogenates were precipitated using 1:3 in acetonitrile 
containing rosuvastatin–d6 as an internal standard and centrifuged for 20 min at 14000 
rpm at 4°C. The supernatant was diluted 1:2 with 0.05% formic acid and analyzed by LC-
MS/MS like plasma. The samples were injected onto a Hypersil GOLD C18 column (50 
× 3 mm, 5 µm particle size; Thermo Scientific) and separated using 0.05% formic acid 
and acetonitrile using a gradient ranging from 70:30 to 10:90 respectively. Detection of 
rosuvastatin was done using transitions m/z 482.1 → 258.2 for rosuvastatin and 488.0 → 
264.3 for rosuvastatin-d6. The accuracy and precision of the assay were 5.8% and 8.9%, 
respectively. 
 
5.2.7 Pharmacokinetic Calculations and Statistical Analysis 
Tissue to plasma ratios were calculated by dividing the tissue level by the plasma 
concentration at the final sampling time point (6h IV and 8h PO). The area under the 
curve (AUC) from 0 to h (AUC0-h) was calculated for each animal by the linear trapezoid 
rule.  The area under the curve from 0 hours to infinity (AUC0-∞)	  was	  obtained	  as	  the	  sum	  of	  AUC0-h	  and	  the	  residual	  area,	  calculated	  by dividing the final concentration by 
the terminal rate constant (ke). Half life (T½) was calculated as Ln2/ke. The mean 
resonance time (MRT) was calculated as AUMC/AUC. CLplasma was calculated using the 
equation CLplasma = dose/AUC0-∞. The volume of distribution at steady state (Vss) was 
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calculated as Vss = AUMC × Dose/AUC0-∞2. Bioavailability (F) was calculated for each 
animal dosed by oral gavage. Results are presented as the mean ± SEM. A two-sided 
unpaired Student’s t-test was used to evaluate the statically difference between 
Oatp2b1tm1a/tm1a and wild type mice in gene expression analysis and in pharmacokinetic 
studies. Statistical analysis was preformed using GraphPad Prism 5 (La Jolla, CA). 
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5.3 Results 
5.3.1 Characterization of Oatp2b1tm1a/tm1a Mice 
We have observed the Oatp2b1tm1a/tm1a mice to an age of 18 months in our laboratory. 
Oatp2b1tm1a/tm1a mice were viable and fertile and appear to have a normal life span. No 
differences were noted in the weight or growth rate of Oatp2b1tm1a/tm1a mice compared to 
wild type animals. Macro and microscopic histological and pathological analysis has not 
revealed any obvious aberrations in tissues of Oatp2b1tm1a/tm1a mice. 
The Oatp2b1tm1a/tm1a mice have a LacZ trapping cassette located between exon 3 and 4 to 
disrupt splicing of Oatp2b1 resulting in gene knockout. For confirmation of the Oatp2b1 
knockout by RT-PCR analysis in liver, kidney, ileum, heart, and quadriceps, TaqMan 
primers and probes were located after the LacZ trapping cassette in exon 9 and 10. We 
demonstrated a significant decrease (>98.2%) in Oatp2b1 mRNA expression in 
Oatp2b1tm1a/tm1a mice compared with wild type animals (Fig. 5.2). Confirmation of 
Oatp2b1 knockout at the protein level is ongoing in the laboratory. 
 
5.3.2 Expression Analysis of Other Transporter Proteins in 
Tissues of The Oatp2b1tm1a/tm1a Mice 
Real time PCR analysis was preformed to determine if compensatory changes occurred in 
the expression levels of various uptake and efflux transporters in liver, kidney, ileum, 
heart, and quadriceps of male wild type and Oatp2b1tm1a/tm1a mice. The expression of 4 
other Oatps, Oatp1a1, Oatp1a4, Oatp1b2 and Oatp1c1 were not significantly different 
between wild type and Oatp2b1tm1a/tm1a mice (Fig. 5.3). Oatp1a5 has been reported to be 
expressed in the intestine (Cheng et al., 2005); however, we were unable to detect 
expression of Oatp1a5 using a TaqMan assay. We found that expression of Oatp1a 
transporters tended to be reduced in Oatp2b1tm1a/tm1a mice, but this did not reach 
significance.  
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Expression of the rosuvastatin uptake and efflux transporters sodium-taurocholate co-
transporting polypeptide (Ntcp), organic anion transporter 3 (Oat3), breast cancer 
resistance protein (Bcrp) and multidrug resistance-associated protein 2 (Mrp2) was 
examined in liver and kidney. Ntcp expression in the liver was not significantly different 
between wild type and Oatp2b1tm1a/tm1a mice (Fig. 5.4A). Expression of Oat3 in the 
kidney was upregulated in Oatp2b1tm1a/tm1a mice but it did not reach significance (Fig. 
5.4C). Bcrp expression in liver and kidney was also not significantly different between 
groups (Fig. 5.4B). However, expression of Mrp2 was significantly upregulated in the 
liver but not the kidney of Oatp2b1tm1a/tm1a when compared to wild type animals (Fig. 
5.4D). 
 
5.3.3 Rosuvastatin is a Substrate of mOatp2b1 
Mouse Oatp2b1 is highly expressed in liver, intestine and skeletal muscle like OATP2B1, 
but it was not known whether mOatp2b1 also transported statins. Unpublished work from 
the laboratory has demonstrated in HeLa cells transfected with mOatp1b2 or hOATP2B1 
that mOatp2b1 is capable of transporting rosuvastatin. Rosuvastatin uptake in cells 
expressing mOatp1b2 or hOATP2B1 was greater (113 and 165% higher, respectively) 
than cells transfected with vector alone (Fig. 5.5). This finding demonstrates that mouse 
Oatp2b1, like human OATP2B1, is capable of transporting rosuvastatin. 
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Figure 5.2 Expression of Slco2b1 mRNA in liver, kidney, ileum, heart and skeletal 
muscle (quadriceps) of wild type and Oatp2b1tm1a/tm1a mice.  
mRNA expression as assessed by real-time RT-PCR. Data are presented as mean ± SEM 
of 3 male mice per group. 
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Figure 5.3 Expression of Slco1a1 (A), Slco1a4 (B), Slco1b2 (C), and Slco1c1 (D), in 
liver, kidney, ileum, heart and skeletal muscle (quadriceps) of wild type and 
Oatp2b1tm1a/tm1a mice.  
mRNA expression was assessed by real-time RT-PCR. Data are presented as mean ± 
SEM of 3 male mice per group. 
  
156 
 
Figure 5.4 Expression of uptake and efflux transporters in liver and kidney of wild type 
and Oatp2b1tm1a/tm1a mice.  
mRNA expression of (A) sodium-taurocholate co-transporting polypeptide (Ntcp), (B) 
organic anion transporter 3 (Oat3),  (C) breast cancer resistance protein (Bcrp) and (D) 
multidrug resistance-associated protein 2 (Mrp2) was assessed by real-time PCR. Data 
are presented as mean ± SEM of 3 male mice per group. * p <0.05 significantly different 
from wild type mice. 
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Figure 5.5 Intracellular accumulation of [3H] rosuvastatin in HeLa cells transiently 
transfected with mOatp2b1 and hOATP2B1. 
Results are presented as percent of vector control ± SEM. **p<0.01 compared to vector 
control. 
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5.3.4 Rosuvastatin Pharmacokinetics In Oatp2b1tm1a/tm1a And Wild 
Type Mice After Oral Administration 
Like all statins, rosuvastatin is orally administered and little is known about transporters 
involved with the in vivo intestinal absorption of rosuvastatin. However, in humans, 
absorption of rosuvastatin is thought to be partially facilitated by OATP1A2 and 
OATP2B1 (Shitara and Sugiyama, 2006). In mice, Oatp2b1 is highly expressed 
throughout the gastrointestinal tract and may facilitate the absorption of rosuvastatin 
(Cheng et al., 2005). Therefore, we investigated the role of Oatp2b1 in the oral absorption 
of rosuvastatin in wild type and Oatp2b1tm1a/tm1a mice. We measured rosuvastatin plasma 
levels after the administration of 10 mg/kg of rosuvastatin by oral gavage. Similar to 
previous reports, we found that the oral absorption of rosuvastatin to be very rapid (Peng 
et al., 2009). The highest plasma concentrations were observed at the first time point, 
assessed at 10 min. The plasma rosuvastatin concentrations were not significantly 
different between wild type and Oatp2b1tm1a/tm1a mice (Fig. 5.6). Analysis of the 
pharmacokinetic parameters revealed no significant difference in the AUC0-∞, Cmax, Tmax 
or half life (T½) between wild type and Oatp2b1tm1a/tm1a mice (Table 5.2). The systemic 
bioavailability of rosuvastatin was also not significantly different between wild type and 
Oatp2b1tm1a/tm1a, 9.2 % vs 10.9% respectively. Theses results indicate that Oatp2b1 is not 
essential for the oral absorption of rosuvastatin and that Oatp2b1 has no significant effect 
on the bioavailability or systemic exposure of rosuvastatin when examined in this mouse 
model. 
 
5.3.5 Rosuvastatin Pharmacokinetics in Oatp2b1tm1a/tm1a and Wild 
Type Mice After Intravenous Administration 
Rosuvastatin pharmacokinetics was also examined after intravenous dosing (1mg/kg). 
The results were similar to oral administration experiment; plasma rosuvastatin 
concentrations were not significantly different between wild type and Oatp2b1tm1a/tm1a 
mice (Fig. 5.7). Pharmacokinetic analysis revealed no differences in the AUC0-∞, C0, 
clearance or half life (T½) between wild type or Oatp2b1tm1a/tm1a mice (Table 5.3). The 
  
159 
volume of distribution was elevated in the wild type vs. Oatp2b1tm1a/tm1a mice, 207 mL vs 
128 mL respectively, but the difference did not reach statistical significance (p value = 
0.42). The volume of distribution of rosuvastatin is greater than the reported total body 
water volume of 21.75 mL for a 30 g mouse (Davies and Morris, 1993). This suggests 
that rosuvastatin has significant accumulation in tissues. Rosuvastatin tissue distribution 
studies conducted in rats demonstrate that the liver is the primary site for rosuvastatin 
accumulation (Nezasa et al., 2002). 
The plasma clearance of rosuvastatin was not significantly different between wild type 
and Oatp2b1tm1a/tm1a mice, 277 mL/h versus 242 mL/h respectively. Rosuvastatin is 
reported to be primarily excreted in the bile unchanged (Nezasa et al., 2002), however the 
values for rosuvastatin clearance are significantly greater than plasma flow to the liver of 
59 mL/h (Davies and Morris, 1993). These results indicate significant non-hepatic 
clearance of rosuvastatin unaffected by Oatp2b1. 
Taken together, the results from both oral and intravenous experiments indicate that 
Oatp2b1 does not significantly affect the systemic exposure of rosuvastatin. 
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Figure 5.6 Plasma Concentration-time curves of rosuvastatin in wild type and 
Oatp2b1tm1a/tm1a mice after administration of rosuvastatin by oral gavage (10mg/kg) (A). 
Rosuvastatin concentrations shown on a semi-log plot (B). Blood samples were taken at 
various time points by serial sampling. Data are presented as the mean ± SEM of 6 male 
mice per group. 
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Table 5.2 Non-compartmental analysis of pharmacokinetic data in wild type and 
Oatp2b1 knockout mice after oral administration of rosuvastatin 10 mg/kg. Data are 
presented as the mean ± SEM of 6 male mice per group. 
 
Parameter Wild Type (n=6) Oatp2b1tm1a/tm1a (n=6) p-value 
Dose (mg/kg) 10 10 
 AUC0-∞ (ng*h/mL) 127.62 ± 23.23 154.33 ± 26.14 0.57 
Cmax (ng/mL) 78.34 ± 31.39 89.42 ± 28.10  
Tmax (h) 0.39 ± 0.33 0.31 ± 0.16  MRT (h) 4.31 ± 0.46 5.38 ± 1.19 0.46 
T ½ (h) 3.76 ± 0.63 4.48 ± 0.91 0.58 
F (%) 9.19% ± 1.67% 10.92% ± 1.85% 0.50 
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Figure 5.7 Plasma Concentration-time curves of rosuvastatin in wild type and 
Oatp2b1tm1a/tm1a mice after a single intravenous dose of rosuvastatin (1mg/kg) (A). 
Rosuvastatin concentrations shown on a semi-log plot (B). Blood samples were taken at 
various time points by serial sampling. Data are presented as the mean ± SEM of 8-9 
male mice per group. 
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Table 5.3 Non-compartmental analysis of pharmacokinetic data in wild type and 
Oatp2b1 knockout mice after intravenous administration of rosuvastatin 1 mg/kg. Data 
are presented as the mean ± SEM of 8-9 male mice per group. 
 
Parameter Wild Type (n=9) Oatp2b1tm1a/tm1a (n=8) p-value 
Dose (mg/kg) 1 1 
 AUC0-∞ (ng*h/mL) 138.91 ± 31.56 141.32 ± 24.38 0.95 
C0 (ng/mL) 577.74 ± 181.66 484.17 ± 59.55 0.65 
MRT (h) 0.59 ± 0.13 0.52 ± 0.05 0.62 
T ½ (h) 1.41 ± 0.31 1.17 ± 0.13 0.50 
CLplasma (mL/h) 277.21 ± 62.90 242.33 ± 44.30 0.66 
Vss (mL) 207.90 ± 87.89 128.01 ± 31.44 0.42 
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5.3.6 Tissue Distribution of Rosuvastatin in Oatp2b1tm1a/tm1a Mice 
Oatp2b1 is thought to facilitate the extrahepatic tissue distribution of rosuvastatin. We 
have reported previously that OATP2B1 contributes to the distribution of rosuvastatin 
into skeletal muscle and sensitization to myotoxicity (Knauer et al., 2010). We 
investigated the tissue distribution of rosuvastatin into liver, kidney and skeletal muscle 
(quadriceps) after both oral and intravenous dosing. Previous studies in rats demonstrate 
that rosuvastatin primarily accumulates in the liver while the muscle to plasma ratio is 
less than unity (Nezasa et al., 2002; Sidaway et al., 2009). The tissue distribution of 
rosuvastatin 8 hours after oral dosing is reported in Figure 5.8 for wild type and 
Oatp2b1tm1a/tm1a mice. The mean rosuvastatin liver to plasma ratio was 143 in wild type 
and 109 in Oatp2b1tm1a/tm1a mice. Unlike studies in rats where the muscle to plasma ratio 
was less than one, the mean rosuvastatin muscle to plasma ratio was 7 in wild type and 2 
in Oatp2b1tm1a/tm1a mice. However, we found no difference between the rosuvastatin 
tissue concentration, tissue to plasma ratio in liver or quadriceps between wild type and 
Oatp2b1tm1a/tm1a mice.  
The rosuvastatin tissue distribution after 6 hours after intravenous dosing is reported in 
Figure 5.9. The mean rosuvastatin kidney to plasma ratio was 2.3 in wild type and 8.6 in 
Oatp2b1tm1a/tm1a mice. The muscle to plasma ratio was 17 in wild type and 15 in 
Oatp2b1tm1a/tm1a mice after intravenous dosing. We found no difference between the 
rosuvastatin tissue concentration, tissue to plasma ratio in kidney or quadriceps between 
wild type and Oatp2b1tm1a/tm1a mice. However, Oatp2b1tm1a/tm1a mice had a higher 
rosuvastatin liver concentration compared with wild type mice. This resulted in a 
significant elevation in the liver to plasma ratio for Oatp2b1tm1a/tm1a mice versus wild type 
animals, 195 versus 79 respectively. These results indicate that Oatp2b1 does not 
contribute significantly to the distribution of rosuvastatin to skeletal muscle or kidney in 
mice.  
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Figure 5.8 Concentrations in plasma, liver, and skeletal muscle (quadriceps), and liver to 
plasma and skeletal muscle (quadriceps) to plasma concentration ratios of rosuvastatin in 
Oatp2b1tm1a/tm1a mice compared to wild-type controls, 8 hours after a 10 mg/kg oral dose. 
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Figure 5.9 Concentration in plasma, liver, skeletal muscle (quadriceps), and kidney, and 
liver to plasma, skeletal muscle (quadriceps) to plasma, and kidney to plasma concentration 
ratios of rosuvastatin in Oatp2b1tm1a/tm1a mice compared to wild-type controls, 6 hours after a 
1 mg/kg intravenous dose. 
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5.4 Discussion 
Here we report for the first time the generation and characterization of a novel mouse 
model lacking Oatp2b1. Oatp2b1tm1a/tm1a mice were viable, fertile and did not display any 
clear pathological abnormalities. The present study demonstrates that Oatp2b1 is not 
significantly involved in the intestinal absorption of rosuvastatin after oral administration. 
We show that Oatp2b1 does not affect the systemic exposure, clearance or volume of 
distribution of rosuvastatin after oral and intravenous dosing. The extrahepatic 
distribution of rosuvastatin in Oatp2b1tm1a/tm1a mice is unchanged compared to wild type 
animals. However, we did see an increase in the rosuvastatin liver to plasma ratio after 
intravenous dosing. 
OATP1A2 and OATP2B1 transporters in the intestine have been proposed to mediate the 
intestinal absorption of statins in humans. We show that Oatp2b1 is not significantly 
involved in the intestinal absorption of rosuvastatin in our knockout mouse model. 
Interestingly, the intestinal absorption of rosuvastatin in pigs has also been shown to be 
unaffected by co-administration of gemfibrozil, an OATP2B1 inhibitor (Bergman et al., 
2009). Rosuvastatin is quite polar, LogD -0.25 to -0.5 (Table 1.1), and drug transporters 
are likely involved in its absorption. The murine Oatp1a family of transporters are highly 
expressed in the intestine, like human OATP1A2, and maybe also be involved in 
rosuvastatin absorption. However, studies using Oatp1a/1b knockout mice demonstrate 
that intestinal absorption of pravastatin, another hydrophilic statin, is not dependent on 
Oatp1a/1b transporters (Iusuf et al., 2012). It is possible that Oatp2b1 and Oatp1a 
transporters compensate for the loss of the other transporter or that another transporter is 
responsible for rosuvastatin absorption in mice. However, we did not observe significant 
changes to the expression of Oatps in the ileum of the Oatp2b1tm1a/tm1a mice. We used 
whole ileum to extract total RNA not just enterocytes, so it is possible that Oatp 
expression is altered in other sections of the small intestine or that the expression is 
altered selectively in enterocytes. Additional studies are required to determine the 
transporter(s) responsible for the intestinal absorption of rosuvastatin. 
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The systemic exposure of rosuvastatin was unchanged after oral or intravenous dosing in 
Oatp2b1tm1a/tm1a mice. This suggests that Oatp2b1 does not have a significant contribution 
to the clearance or volume of distribution of rosuvastatin. This could be expected 
because, at least in humans, rosuvastatin hepatic uptake is probably mediated by multiple 
transporters including OATP1B1, OATP1B3, OATP2B1 and NTCP (Ho et al., 2006). 
Data from Oatp1b2-/- mice suggests that the effect of Oatp1b2 increases plasma levels by 
about 1.5 fold (Degorter et al., 2012). It has been suggested that other hepatic uptake 
processes can compensate for loss of the hepatic Oatp1b2 like Oatp2b1.  
Although the volume of distribution of rosuvastatin is slightly smaller in Oatp2b1tm1a/tm1a 
mice, the extrahepatic distribution of rosuvastatin into muscle and kidney appears 
unchanged compared to wild type animals. However, we did not find any significant 
differences in the rosuvastatin muscle concentration or muscle to plasma ratio in the 
quadriceps of Oatp2b1tm1a/tm1a mice compared to wild type animals. A repeated dosing 
study would allow for the study of rosuvastatin after drug levels have reached steady 
state. Oatp2b1 knockout may lead to changes in the steady state rosuvastatin muscle 
levels, which are not apparent in this single dose study.  As mentioned before the muscle 
to plasma ratio was greater than one in wild type and Oatp2b1tm1a/tm1a mice compared to 
reports of less than one in rats and guinea pigs (Madsen et al., 2008; Sidaway et al., 
2009). Unpublished data from studies we have done in Mrp1-/- mice suggest a muscle to 
plasma ratio less then one for [3H]rosuvastatin (Appendix D). An explanation for this 
difference could be the differences in the rosuvastatin dosage or time of sampling. 
Muscle may be a slowly equilibrating tissue in the distribution of statins and time and 
dose may factor into the muscle to plasma ratio.  
Assuming there is no difference in other transporters relevant to the hepatic disposition of 
a drug between the Oatp2b1tm1a/tm1a and wild type mice, when Oatp2b1-mediated uptake 
does not represent a rate-limiting step, the liver to plasma ratio would be equal between 
Oatp2b1tm1a/tm1a and wild type mice. In contrast, when Oatp2b1 uptake plays a critical 
role in the hepatic disposition of a drug, liver to plasma ratios in wild type mice would be 
significantly higher than that of Oatp2b1tm1a/tm1a mice. Our data showed that Oatp2b1 did 
not play a significant part in the uptake of rosuvastatin in the liver. Interestingly, we saw 
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the opposite to what was expected and there was an increase in the liver to plasma ratio 
for rosuvastatin after intravenous dosing. This result does not appear to be related to 
changes in the expression of other transporters. Although we see that Mrp2 is upregulated 
in the liver, we would expect this change to increase elimination into the bile and 
decrease liver to plasma ratios. Importantly, we demonstrate there does not appear to be 
any major compensatory upregulation of other Oatps in the liver or other tissues. The 
underlying mechanism for the increased liver to plasma ratio in Oatp2b1tm1a/tm1a mice is 
not known and requires further study. Interestingly, a similar increase in the liver to 
plasma ratio was shown for pravastatin in Oatp1b2-/- mice, with no explanation given 
(Chen et al., 2008). The hepatic extraction of rosuvastatin is considered very high, 0.63 in 
humans (Martin et al., 2003) and 0.89 in pigs (Bergman et al., 2009), so the increase in 
the rosuvastatin liver to plasma ratio in Oatp2b1tm1a/tm1a mice could be attributed to a 
decrease in hepatic elimination versus an increase in uptake. However, we do not have 
evidence to support this hypothesis. We see a trend toward reduced volume of 
distribution in Oatp2b1tm1a/tm1a mice, and lower muscle to plasma levels. Skeletal muscle 
has the largest organ volume in the mouse with total volume of muscle almost 8 fold 
higher than the liver (1.3 vs. 10 mL) (Davies and Morris, 1993). Even a small reduction 
in the rosuvastatin distribution into one muscle group would translate into a much larger 
reduction in the total muscle distribution. In turn this would lead to increased plasma 
levels and AUC, which are slightly higher in the Oatp2b1tm1a/tm1a mice.  
The liver accounts for the majority of the volume of distribution of statins. In the 
Oatp2b1tm1a/tm1a mice we see a small reduction in the Vss but a significant increase in liver 
levels. Theoretically this means that rosuvastatin has much less extrahepatic distribution 
in Oatp2b1tm1a/tm1a mice then wild type mice, resulting in a large reduction in the tissue 
distribution of a few tissues or a small reduction in distribution to many tissues. 
Unfortunately, we only examined the tissue distribution in liver, kidney and quadriceps, 
so it is possible that some tissues have large decreases in the rosuvastatin distribution or 
that there is a small reduction in the rosuvastatin tissue distribution in many tissues.  
This study has many limitations, one of which is the lack of data to confirm Oatp2b1 
knockout at the protein expression level. Studies are ongoing in our laboratory to test 
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newly made custom Oatp2b1 antibodies and LC-MS/MS to quantify protein expression 
in mice. There are other transporters involved in rosuvastatin absorption, elimination and 
distribution. We have suggested that Mrp1, Mrp4 and Mrp5 may be involved in the 
muscle exposure of rosuvastatin (Knauer et al., 2010) but we have not examined 
expression of efflux transporters in the muscle of Oatp2b1tm1a/tm1a mice. Bcrp, P-gp and 
Mrp2 may also play a role in the intestinal bioavailability of rosuvastatin; therefore, 
expression of efflux transporters needs to be assessed in the intestinal enterocytes of 
Oatp2b1tm1a/tm1a mice. 
In conclusion, we report the generation of a novel knockout mouse model of Oatp2b1, as 
a tool to study the in vivo role of Oatp2b1 in drug disposition. We show that knockout of 
Oatp2b1 does not have a significant effect on the absorption, systemic exposure, or 
extrahepatic tissue distribution of rosuvastatin. A role for Oatp2b1 in the skeletal muscle 
toxicity of statins remains to be determined.  
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6.1 Summary and Discussion 
6.1.1 Chapter Three 
The aim of this chapter was to determine the spectrum, localization and function of statin 
transporters expressed in human skeletal muscle. We hypothesized that the functional 
expression of statin uptake and efflux transporters control the intracellular statin 
concentration and modulate the response to skeletal muscle exposure. We describe in 
Chapter Three that the uptake transporter OATP2B1 and 3 novel statin efflux 
transporters, MRP1, MRP4 and MRP5, are found in skeletal muscle and are able to 
control the in vitro intracellular accumulation of atorvastatin and rosuvastatin. We 
demonstrate that OATP2B1 sensitizes muscle to toxicity and MRP1 attenuates the 
toxicity of atorvastatin and rosuvastatin using an in vitro skeletal muscle model. This 
chapter confirms the importance of intracellular muscle exposure in the development of 
myotoxicity and describes how novel statin transporters present within skeletal muscle 
can affect the intracellular accumulation of statins and their toxic adverse effects. The 
results of this Chapter support the overall hypothesis of this thesis. 
 
6.1.2 Chapter Four 
The aim of Chapter Four was to examine the regulation and function of OATP2B1 
transcription start site variants. OATP2B1 is ubiquitously expressed in various tissues in 
the body including; small intestine, liver, brain, kidney and skeletal muscle (Knauer et al., 
2010; Kullak-Ublick et al., 2001; Tamai et al., 2000). Many statins are OATP2B1 
substrates and OATP2B1 is believed to be involved in the bioavailability and distribution 
of statins into skeletal muscle as suggested in Chapter Three. Recently, it was shown that 
differential promoter usage in tissues results in the expression of five OATP2B1 
transcriptional start site variants that encode either a full length or shortened protein 
lacking 22 amino acids (Pomari et al., 2009). There was an absence of information 
regarding the relative expression of the OATP2B1 transporter variants in key tissues 
responsible for statin absorption, elimination or muscle distribution. We hypothesized 
that OATP2B1 full length and short variant proteins would have differential expression 
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or function. We found differing expression patterns for the OATP2B1 variants in 
different tissues. The OATP2B1 short variant was highly expressed in liver and its 
hepatic expression was found to be regulated by HNF4α. Functional analysis of the 
OATP2B1 variants with estrone sulfate and rosuvastatin revealed similar results to the 
well-characterized full length variant. However, we observed that the OATP2B1 short 
variant was significantly better at transporting rosuvastatin at low pH compared to the 
full length form. Interestingly, we saw over a 100-fold variation in the hepatic expression 
of the OATP2B1 short variant regulated by HNF4α. HNF4α-mediated gene regulation 
can be influenced by a variety of different factors including genetics, gender, 
environmental factors and diet (Hwang-Verslues and Sladek, 2010). Alterations in the 
expression of OATP2B1 variants, such as the short variant in liver, could lead to changes 
in substrate pharmacokinetics. In the case of statins, changes to OATP2B1 short variant 
expression could affect systemic exposure through alterations in statin absorption or 
hepatic uptake. As discussed above alterations in systemic exposure can lead to changes 
in myopathy risk. These findings indicate that variation in HNF4α-mediated regulation of 
OATP2B1 short variant expression in liver could contribute to variable statin response. 
 
6.1.3 Chapter Five 
The aim of Chapter Five was to investigate the in vivo contribution of Oatp2b1 to the 
pharmacokinetics and tissue distribution of rosuvastatin using a novel Oatp2b1 knockout 
mouse model. We hypothesized that Oatp2b1 is involved in the absorption, hepatic 
uptake and muscle distribution of rosuvastatin. However, we observed that Oatp2b1 does 
not have a significant effect on the systemic exposure, clearance or volume of distribution 
of rosuvastatin. Rosuvastatin absorption and extrahepatic distribution in Oatp2b1 KO 
mice was unchanged compared to wild type animals. These results do not support the 
hypothesis that Oatp2b1 is significantly involved in rosuvastatin pharmacokinetics or risk 
for myopathy. 
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6.2 Therapeutic Implications 
It is envisioned that the knowledge gained from this project may provide the basis for 
new preventative strategies to lower the risks of statin associated muscle injury and 
develop methods to treat those patients affected with this problematic drug side effect. It 
is accepted that statin myotoxicity is dose dependent and systemic exposure affects the 
risk for myopathy. However, we have shown that muscle exposure can also affect the risk 
of myopathy. Drug interactions at the level of metabolism have long been thought of as 
mechanisms for increasing the systemic exposure of drugs. The cerivastatin experience 
highlighted that drug interactions are also possible at the level of transporters to alter 
systemic exposure. We have demonstrated that drug interactions can also occur at the 
level of the muscle involving transporters and could prove important for therapeutics. 
Pharmacogenetics and genetics-based dosing for statins is becoming more important 
given the evidence that polymorphisms in BCRP and OATP1B1 alter statin efficacy 
(Bailey et al., 2010; Chasman et al., 2012). The SEARCH study was the first to 
demonstrate a genetic predictor of simvastatin-induced myopathy (Link et al., 2008). 
Dosing algorithms have already been proposed based on the SLCO1B1*5 polymorphism 
to lower the risk of statin induced myopathy (Niemi, 2010). This work demonstrates a 
role for transporters in skeletal muscle as potential determinates of toxicity. This may 
lead to discoveries relating genetic polymorphisms in muscle transporters and myopathy. 
 
6.3 Future Directions 
One of the most important questions that needs to be addressed is whether muscle 
concentrations are different between individuals with and without statin myopathies. This 
will not be an easy question to answer in humans but it may prove important for 
understanding the mechanism of statin induced myopathy. Recently, a non-invasive PET 
imaging approach has been used to study the hepatic distribution of pravastatin in rats 
(Ijuin et al., 2012). In the future, this approach could be applied to humans to non-
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invasively measure the statin concentrations in skeletal muscle in patients with and 
without statin myopathy. 
Interindividual differences in intestinal and hepatic drug transporters have been shown to 
be important for efficacy and toxicity. Assuming that muscle statin levels are different 
between affected and non-affected individuals we propose that variation in muscle 
transporters and the balance of uptake and efflux processes will be important for muscle 
exposure and risk. However, there is an absence of information on the expression of 
muscle transporters in patients. More studies investigating the genetic variation, 
transporter expression and function of muscle transporters from muscle biopsies are 
required. 
We reported in Chapter Three that OATP2B1 is responsible for the uptake of statins into 
muscle and can potentiate the myotoxic effects of theses drugs. However, It is not known 
if there are interindividual differences in OATP2B1 expression within skeletal muscle or 
if expression can be regulated in muscle. Alterations in HNF4α activity due to genetics or 
environmental factors could lead to changes in expression and activity of drug 
metabolizing enzymes and transporters, including OATP2B1, responsible for statin 
disposition. OATP2B1 has a role in determining the systemic exposure and muscle 
exposure of statins; however, it is not known if changes in HNF4α regulation translate 
into differences in risk for myopathy. 
As mentioned before, generation of a novel Oatp2b1 KO mouse could be potentially used 
for many different research areas. We must confirm Oatp2b1 knockout at the protein 
level using mass spectrometry or Western blotting with custom antibodies.  
Our preliminary work in the Oatp2b1tm1a/tm1a mouse demonstrates the need for more 
experiments on the involvement of Oatps in the intestinal absorption of statins measuring 
the portal vein statin concentrations (Matsuda et al., 2012) or using everted gut sac 
experiments (Alam et al., 2012). Future studies will also include long term multiple 
dosing pharmacokinetic experiments to elucidate the role of Oatp2b1 in steady state statin 
levels. Although, most statins are substrates of OATP2B1 we cannot rule out 
pharmacokinetic differences between substrates or other statins. Other substrates and 
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statins need to be assessed with pharmacokinetic studies in the Oatp2b1 KO mouse to 
understand potential substrate specific differences in pharmacokinetics. 
Research suggests that multiple transporters are involved in the hepatobilillary transport 
of statins and that redundancies exist in uptake and efflux transport processes. We have 
demonstrated that single transporter knockout mice of mOatp2b1 and mMrp1 (Chapter 5 
and Appendix D) do not have significant alterations in the rosuvastatin muscle to plasma 
ratio. We have suggested that compensation by other transporters may occur in knockout 
animals. Future experiments preformed in mouse models with multiple transporter 
knockouts or tissue specific transporter knockouts may prove valuable to assess the role 
of transporters in specific tissues. One unique feature about the Oatp2b1tm1a/tm1a mouse 
strain is that the “knockout mouse first” targeting strategy used can be used to generate 
tissue specific knockout animals.  
6.4 Conclusions 
The role of drug transport proteins in drug absorption and distribution is becoming 
increasingly evident. We now recognize that interindividual variability in drug transport 
activity can lead to variation in pharmacokinetics, drug response and toxicity. The focus 
of this thesis was the involvement of drug transporters in statin induced myopathy, with 
focus on those expressed in skeletal muscle. Statins are substrates of numerous drug 
transporters and variation in these transporters has been shown to alter statin efficacy and 
system exposure. We proposed that drug transporters also control skeletal muscle 
exposure and modulate the response to statin myopathy. 
The first section of the thesis focused on the identification of novel statin transporters in 
skeletal muscle and their involvement in controlling muscle exposure and toxicity. The 
second part of this thesis examined the regulation of OATP2B1 variants and the 
interindividual differences in expression of OATP2B1 variant proteins. Finally, we 
employed an in vivo mouse model of Oatp2b1 KO to assess rosuvastatin 
pharmacokinetics and tissue distribution. Taken together these studies provide insight 
into the in vitro and in vivo role of drug transporters in statin skeletal muscle exposure 
and myotoxic response. 
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necessary approvals. Please consult directly with your institutional safety 
officers. 
Submitted by: Copeman, Laura  on behalf of the Animal Use 
Subcommittee University Council on Animal Care 
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Appendix C: Supplementary Information I  
 
Supplementary Figure C1.  Characterization of primary cultured human skeletal 
myoblasts (HSMM).  Morphology of HSMM cells pre-differentiation (A) and post-
differentiation (B).  HSMM cells were stained with phalloidin Alexa 488 (Invitrogen) to 
visualize actin and DAPI for nuclei.   Expression of the skeletal muscle-selective genes 
MyoD (C) and creatine kinase isoform M (CK-M) (D) in pre-differentiated and post-
differentiated cultured HSMM cells, as well as, intact human skeletal muscle was 
determined by quantitative PCR. 
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Supplementary Table C1. Real-time PCR primers used for gene expression 
quantitation. 
 
Gene Forward Primer Reverse Primer
18S 5'-GTAACCCGTTGAACCCATT-3' 5'-CCATCCAATCGGTAGTAGCG-3'
OATP2B1 5'-CTTCATCTCGGAGCCATACC-3' 5'-AGATGCTGGGTTTCTGTGTAG-3'
MRP1 5'-CGGAAACCATCCACGACCCTAATC-3' 5'-ACCTCCTCATTCGCATCCACCTTG-3'
MRP2 5'-ATGCTTCCTGGGGATAAT-3' 5'-TCAAAGGCACGGATAACT-3'
MRP4 5'-AAGTGAACAACCTCCAGTTCCAG-3' 5'-GGCTCTCCAGAGCACCATCT-3'
MRP5 5'-CCCAGGCAACAGAGTCTAACC-3' 5'-CGGTAATTCAATGCCCAAGTC-3'
BCRP 5'-TGGCTGTCATGGCTTCAGTA-3' 5'- GCCACGTGATTCTTCCACAA -3'
CK-M 5'-CTAACTACGTGCTCAGCAGC-3' 5'-GGGTAGTACTTCCCTTTGAAC-3'
MyoD 5'-AGTAAATGAGGCCTTTGAGACACTC-3' 5'-TCGATATAGCGGATGGCGTT-3'
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Appendix D: Supplementary Information II - Impact of Drug 
Transport on the Tissue Distribution of Rosuvastatin: Studies in 
Multidrug Resistance Associated Protein 1 Knockout Mice4 
                                                
4
 This section is based on unpublished work: Knauer MJ, Mansell SE and Tirona RG. Impact of Drug 
Transport on the Tissue Distribution of Rosuvastatin: Studies in Multidrug Resistance Associated Protein 1 
Knockout Mice. 2012. 
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Introduction 
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
are highly effective drugs for the treatment of hypercholesterolemia. Statins lower blood 
cholesterol by inhibiting the hepatic synthesis of mevalonate, the rate-limiting step in 
cholesterol biosynthesis, leading to increased low-density lipoprotein receptor expression, 
and reductions in LDL-C (Endo, 1992; Jacobson, 2008). Statins have a favourable risk-
benefit ratio and are generally well tolerated (Pasternak, 2002). However, statins are 
known to cause skeletal muscle side-effects, ranging from mild myalgia to fatal 
rhabdomyolysis (Thompson et al., 2006). Observational reports suggest that myalgia, 
defined as muscle aches or weakness in the absence of blood creatine kinase (CK) 
elevation, occurs in 5-15% of statin-treated patients (Bruckert et al., 2005; Buettner et al., 
2008; Evans and Rees, 2002; Jacobson, 2008; Thompson et al., 2003). It is well 
documented that myotoxicity is statin dose-dependent, but little is known regarding the 
precise mechanism of toxicity (Ballantyne et al., 2003; Huerta-Alardin et al., 2005). 
Recently, we demonstrated a role for human Organic Anion Transporting Polypeptide 
(OATP) 2B1 and Multidrug Resistance Associated Proteins (MRP) 1, MRP4 and MRP5 
in the uptake and efflux transport as well as toxicity of statins in skeletal muscle cells in 
vitro (Knauer et al., 2010). However, there is a lack of in vivo studies examining statin 
transporters within skeletal muscle and their influence on myotoxic side effects of statins. 
We have proposed that the interplay between statin uptake versus efflux transporters 
modulates skeletal muscle statin exposure and toxicity. Inhibition of specific efflux 
transport mechanisms controlling intracellular skeletal muscle concentrations of statins 
could lead to local accumulation of drug and increased risk for toxicity. Studies in the 
guinea pig and rat suggest that statins do not accumulate considerably into skeletal 
muscle as evidenced by a low ratio of muscle to plasma drug levels of  < 1 (Madsen et 
al., 2008; Nezasa et al., 2002; Sidaway et al., 2009). This indicates that efflux 
mechanisms present in skeletal muscle may be acting to prevent drug accumulation. 
Another study in rats showed that co-administration of an Mrp1 inhibitor, probenecid, 
promoted rosuvastatin myotoxicity (Dorajoo et al., 2008). However, this study did not 
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measure plasma or skeletal muscle rosuvastatin concentrations and failed to demonstrate 
rosuvastatin transport by rMrp1. Hence, it is unclear if the rosuvastatin skeletal muscle 
toxicity was due to changes in the systemic exposure or myofibre levels of rosuvastatin. 
In this report, we have investigated the in vivo role the efflux transporters in regulating 
the tissue distribution of rosuvastatin in a mouse model of Mrp1 deficiency. Rosuvastatin 
was chosen for this study because it is among the most prescribed statins in Canada, it is 
said to undergo minimal metabolism, which could complicate pharmacokinetic analysis, 
and it is highly dependent on transporters for systemic clearance (Kitamura et al., 2008). 
In this study, we demonstrate that rosuvastatin is indeed a transport substrate for mouse 
Mrp1.  The distribution of rosuvastatin in Mrp1-/- mice was similar to wild-type animals. 
However, Mrp1-/- animals had a significantly higher liver to plasma ratio of rosuvastatin 
compared to wild-type animals. Importantly, we observed a lack of difference in skeletal 
muscle rosuvastatin distribution between Mrp1-/- and wild-type mice. Gene expression 
analysis demonstrated elevated levels of Mrp2, Mrp4 and Mrp5 in KO mouse tissues, 
which normally express high levels of Mrp1.  Tissue distribution of rosuvastatin was not 
different in tissues of Mrp1-/- animals despite that rosuvastatin is an Mrp1 substrate. 
These findings highlight the interplay between multiple redundant transporters in the 
tissue pharmacokinetics of rosuvastatin. 
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Methods 
Reagents 
[3H] rosuvastatin (5 mCi/mmol, 99% radiochemical purity) was purchased from 
American Radiolabeled Chemicals (St. Louis, MO). [3H] rosuvastatin (79 Ci/mmol, 
97.1% radiochemical purity) and unlabeled rosuvastatin were also kindly provided by Dr. 
Yi Wang (AstraZeneca, Wilmington, DE).  Unlabeled rosuvastatin was obtained from 
Toronto Research Chemicals (North York, ON). All other chemicals and reagents were 
obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. 
 
Cloning of Mouse Mrp1 
Expression plasmids for rOatp1b2 and MRP1 are described elsewhere (Knauer et al., 
2010; Tirona et al., 2003). Mouse Mrp1 (mMrp1) cDNA was obtained by PCR, using 
Expand Long Template PCR System (Roche Applied Science, Indianapolis, IN), from a 
cDNA library of mouse skeletal muscle. mMrp1 cDNA was amplified in two parts from 
skeletal muscle with the following primers: 5'-
AGCATGGCGCTGCGCAGCTTCTGCAGCG-3' and 5'-
GGTTCACACCCTTCTCACCGATCTCTGTGCGGTC -3'; 5’-
GCTCCGTGGCCTACGTGCCCCAGCAGG-3' and 5'-
CATTGGATATGCCAGAGACCAGCTCACACCAAGCC -3'. Full-length mMrp1 was 
assembled from the two parts by ligation at the Spf I site. mMrp1 was sequence verified 
and cloned into pcDNA3.1/V5-His-TOPO vector (Invitrogen). 
 
Transport Experiments 
HeLa cells (human cervical cancer cell line) were grown in 12-well plates (approximately 
0.8 × 106 cells/well) and infected with vaccinia (vtf-7) at a multiplicity of infection of 10 
plaque-forming units/cell in serum-free Opti-MEM I medium (Invitrogen) and allowed to 
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absorb for 30 minutes. Cells were transfected with 1 µg of total transporter cDNA, in a 
1:4 ratio of uptake to efflux, or parental plasmid lacking insert as control using Lipofectin 
(Invitrogen) and incubated at 37°C for 16h. Transport was evaluated using labeled 
substrate as previously reported (Cvetkovic et al., 1999). Drug accumulation was 
determined at selected time intervals by washing cells three times with ice-cold PBS 
followed by lysis with 1% sodium dodecylsulfate. Retained cellular radioactivity was 
quantified by liquid scintillation spectrometry. 
 
Animals 
Animals were housed in a temperature-controlled environment with a 12h light/dark 
cycle and received a standard diet and water ad libitum. Male Mrp1-/- (FVB.129P2-
Abcc1atm1Bor N12) (Taconic, Hudson, NY) and wild-type FVB mice were between 10 and 
16 weeks of age were used for experiments. Genotype was confirmed PCR using the 
following primers: 5'-TGCTGGCTGAGATGGACAAG-3' and 5'-
CGGTCTAGCAGCTCCTGATA-3' (Schuetz et al., 2001) and protein expression by 
Western blot using MRPr1 antibody (Alexis Biochemicals) (Knauer et al., 2010). The 
study protocol was approved by the Animal Use Subcommittee of the University of 
Western Ontario, London, Canada. 
 
Rosuvastatin Tissue Distribution 
Male wild type FVB and Mrp1-/- mice were dosed with 1 mg/kg rosuvastatin with 2 µCi 
[3H] rosuvastatin by tail vein injection in in saline with <2% DMSO. After 6 hrs animals 
were euthanized with isoflurane; blood was collected by cardiac puncture and various 
tissues were excised, rinsed in PBS, blotted and weighed. Blood was transferred to a tube 
for centrifugation at 12,000 g for 5 min to obtain plasma. Tissues were homogenized in 
water with 4% BSA in a ratio of 1:10 (w:v). Rosuvastatin concentration in plasma and 
tissue was quantified by liquid scintillation spectrometry. All plasma and tissue samples 
were stored at -20°C until analysis. 
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Gene Expression Analysis 
The mRNA expression of Oatp2b1, Mrp2, Mrp4, and Mrp5 were measured by SYBR 
green quantitative real-time PCR with an ABI Prism 7700 sequence detection system 
(Applied Biosystems). Total RNA was extracted from various tissues using Trizol reagent 
(Invitrogen) and RNA quality and quantity was determined using Agilent Bioanalyzer 
2100 (Agilent, Santa Clara, CA).  cDNA was synthesized using Multiscribe reverse 
transcriptase (Applied Biosystems) according to manufacturer’s instruction and 30 ng of 
cDNA was used in each qPCR reaction. The sequences of primers used for quantitative 
PCR are listed in Table D1. The amount of the transporter was normalized to 18S-rRNA 
and relative expression was determined using the ΔΔCT method. 
 
Statistical Analysis 
Statistical differences between groups were determined by unpaired Student’s T-test or 1-
way ANOVA or 2-way ANOVA using Bonferroni’s multiple comparison test, as 
appropriate (GraphPad Software Inc, San Diego, CA). A P value of <0.05 was considered 
statistically significant. 
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Table D1. Primer Sequences for qPCR 
Primer   Sequence 
mOatp2b1 Fw Sense 5ʹ′-­‐CTTCATCTCAGAACCATACC-­‐3ʹ′	  
mOatp2b1 Rv Antisense 5ʹ′-­‐ACTGGAACAGCTGCCATTG-­‐3ʹ′	  
mMrp2 Fw Sense 5ʹ′-­‐GTCATCACTATCGCACACAG-­‐3ʹ′	  
mMrp2 Rv Antisense 5ʹ′-­‐TTCTACAGGGTGGTTGAGAC-­‐3ʹ′	  
mMrp4 Fw Sense 5ʹ′-­‐GGTTGGAATTGTGGGCAGAA-­‐3ʹ′	  
mMrp4 Rv Antisense 5ʹ′-­‐TCGTCCGTGTGCTCATTGAA	  -­‐3ʹ′	  
mMrp5 Fw Sense 5ʹ′-­‐GTCAAACTCCACCACCTGTC-­‐3ʹ′	  
mMrp5 Rv Antisense 5ʹ′-­‐AGAGAGAACGCACATGAAGG-­‐3ʹ′	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Results 
Rosuvastatin is a Substrate of mMrp1 
Mouse Mrp1 is highly expressed in skeletal muscle like human MRP1, but it was not 
known whether mMRP1 transported statins.  Hence, HeLa cells were double transfected 
with the uptake transporter, rOatp1b2, and human MRP1 or mouse Mrp1. In this system, 
modulation of cellular retention of rosuvastatin served as an indicator for efflux transport 
activity. Rosuvastatin retention in cells expressing rOatp1b2 together with MRP1, Mrp1 
was lower (78 and 73% lower, respectively) than cells expressing rOatp1b2, alone (Fig. 
D1). This finding demonstrates that mouse Mrp1, like human MRP1, is capable of 
transporting rosuvastatin. 
Rosuvastatin Tissue Distribution in Mrp1-/- Mice 
MRP1 is thought to facilitate the in vivo export of rosuvastatin from human skeletal 
muscle. We have reported previously that MRP1 in vitro is responsible for the efflux of 
rosuvastatin from skeletal muscle and sensitization to myotoxicity (Knauer et al., 2010). 
Here, we investigated the tissue distribution of rosuvastatin into liver, kidney, small 
intestine, spleen, heart, brain, lung, testis, and skeletal muscle (quadriceps and 
gastrocnemius) after intravenous dosing in wild type and Mrp1-/- mice. Deletion of Mrp1 
was confirmed by western blot and PCR analysis of genomic DNA (Fig. D2). The 
rosuvastatin tissue concentration and tissue to plasma ratio is reported in Table D2 for 
wild type and Mrp1-/- mice. Mrp1-/- mice had significantly elevated plasma levels of 
rosuvastatin compared to wild type mice. Also the rosuvastatin tissue concentration in 
Mrp1-/- mice was significantly higher in liver, testis and lungs. The tissue to plasma ratio 
of rosuvastatin in kidney, spleen, brain, heart, lung, testis and small intestine was similar 
in Mrp1-/- mice in comparison to wild-type animals. However, Mrp1-/- animals had a 
significantly higher liver to plasma ratio of rosuvastatin compared to wild-type animals. 
Importantly, we observed no difference in skeletal muscle concentration or tissue to 
plasma ratio for rosuvastatin between Mrp1-/- and wild-type mice. Interestingly, like 
skeletal muscle, tissues with high expression of Mrp1 such as brain, testis, and lung 
  
199 
(Leslie et al., 2005), also do not show a difference in the tissue to plasma drug 
concentration ratio between wild type and Mrp1-/- animals. These results indicate that 
Mrp1 does not appear to be significantly involved in the efflux of rosuvastatin from 
skeletal muscle or other tissues with high Mrp1 expression. However, the increase in 
rosuvastatin plasma levels in Mrp1-/- mice suggests that Mrp1 contributes to plasma 
clearance or volume of distribution of rosuvastatin. 
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Figure D1. Intracellular accumulation of rosuvastatin in HeLa cells transiently 
transfected with rOatp1b2 and human MRP1 (hMRP1) or mouse (mMrp1). Results are 
presented as percent of rOatp1b2 mediated uptake ± SEM (n=3). ***p<0.001 compared 
to vector control and efflux transporter alone. †††p<0.001 compared with rOatp1b2 
mediated uptake. 
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Figure D2. Confirmation of mMrp1 Knockout (KO) in mice by (A) PCR based 
genotyping and (B) Western blot analysis. 
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Table D2. Tissue Distribution of Rosuvastatin in Mrp1-/- Mice 
 
*p < 0.05 compared to wild type mice. 
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Expression of Other Transporters in Mrp1-/- Mice 
With the exception of liver, we did not find differences in the tissue to plasma 
concentration ratio for rosuvastatin. Hence, we examined the expression of other 
transporters in tissues that may compensate for deletion of Mrp1. We chose to examine 
the relative expression of uptake transporter Oatp2b1 and three other efflux transporters 
Mrp2, Mrp4 and Mrp5. Expression of Oatp2b1 and Mrp2 were lower in the liver and 
small intestine of Mrp1-/- mice compared to wild type mice (Fig. D3). No significant 
changes were seen in the expression of Oatp2b1 or Mrp2 in other tissues. Expression of 
Mrp4 and Mrp5 was higher in the skeletal muscle (Mrp4 – quadriceps; Mrp5 – 
gastrocnemius) and lung of Mrp1-/- mice compared to wild type mice (Fig. D3). 
Expression of Mrp4 and Mrp5 were slightly higher in brain and testis of Mrp1-/- mice, but 
this difference did not reach significance. No significant changes were seen in the 
expression of Mrp4 or Mrp5 in the other tissues examined. 
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Figure D3. Relative expression of statin uptake and efflux transporters in Wild-type 
(white bars) and mMrp1 KO (black bars) mice. Results are normalized to WT Quadriceps 
expression (set to 1). *p<0.05, **p<0.01, ***p<0.001 
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Discussion 
Here we report that rosuvastatin is a substrate of mouse Mrp1 similar to our previous 
findings with human MRP1. The tissue distribution of rosuvastatin in kidney, spleen, 
brain, heart, and small intestine was similar in Mrp1-/- mice in comparison to wild-type 
animals. The tissue rosuvastatin levels were elevated in the liver, testis and lungs of 
Mrp1-/- mice. However, Mrp1-/- animals had a significantly higher rosuvastatin plasma 
concentration and only liver to plasma concentration ratio of rosuvastatin was 
significantly higher. Importantly, we observed a lack of difference in skeletal muscle 
rosuvastatin distribution between Mrp1-/- and wild-type mice. Gene expression analysis 
demonstrated elevated levels of Mrp2, Mrp4 or Mrp5 in KO mouse tissues that normally 
express high levels of Mrp1.   
Despite being a Mrp1 substrate, the tissue distribution of rosuvastatin was not different in 
tissues of Mrp1-/- animals. However, we did see an increase in the rosuvastatin plasma 
levels in Mrp1-/- animals. This suggests that Mrp1 may have an effect on the clearance of 
rosuvastatin. Our result suggests that deletion of Mrp1 would increase the systemic 
exposure of rosuvastatin and potentially the toxic side effect. Dorajoo and colleagues 
showed that inhibition of Mrp1 by probenecid in rats lead to muscle toxicity (Dorajoo et 
al., 2008). Unfortunately they did not report measuring the plasma or muscle 
concentrations of rosuvastatin. So it remains unclear if Mrp1 inhibition results in an 
increase in systemic or local muscle exposure. More studies are needed to examine the 
potential effect of Mrp1 has on rosuvastatin clearance. 
The Mrp1 is expressed at low levels in the liver; however, the rosuvastatin liver to plasma 
ratio is elevated in the Mrp1-/- mice. This could be attributed to reduced biliary excretion 
by Mrp2, whose expression is lower in Mrp1-/- mice, or other bile canalicular efflux 
transporters like breast cancer resistance protein (Bcrp) and P-glycoprotein (P-gp) 
(Kitamura et al., 2008). Another explanation for increased liver to plasma ratio would be 
an increased hepatic uptake of rosuvastatin by Oatp1a1, Oatp1a5, Oatp1b2, Oatp2b1 or 
sodium-taurocholate co-transporting polypeptide (Ntcp). We did not examine the 
expression of Oatp1a/1b or Ntcp, but we observed a downregulation in Oatp2b1 
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expression in Mrp1-/- liver. This downregulation of Oatp2b1 is not consistent with 
increased hepatic uptake. Clearly, more analysis is required to better understand the 
mechanisms involved in the increased hepatic accumulation of rosuvastatin in Mrp1-/- 
mice. 
Mrp1 is highly expressed in brain, testis, lung, and skeletal muscle, but the rosuvastatin 
tissue distribution as monitored by tissue/plasma concentration ratio, was not affected by 
Mrp1 gene deletion. Gene expression analysis of other Mrps revealed that Mrp2, Mrp4 
and/or Mrp5 are upregulated in these tissues. This suggests that there is functional 
compensation from other statin transporters in regulating statin accumulation in these 
tissues. 
There are a number of limitations to this study that impact on the interpretation of the 
results.  First, we used scintillation spectroscopy to measure statin levels in plasma and 
tissues under the assumption that rosuvastatin is largely unmetabolized.  Recent studies in 
our laboratory and elsewhere have demonstrated a significant proportion of radiolabel 
cannot be attributed to rosuvastatin itself and that metabolism is an unappreciated 
mechanism of elimination in mouse and perhaps humans (Kitamura et al., 2008; Nezasa 
et al., 2002).  Specific analytical methods as that described in Chapter 5 are required to 
better understand the role of drug transporters in the tissue distribution of rosuvastatin.  
Second, we measured plasma and tissue rosuvastatin levels at a single time point (6 
hours). This sparse sampling experimental design precludes the ability to formally 
estimate key pharmacokinetic parameters such as volume of distribution and clearance.  
Lastly, the expression of the entire complement of statin transporters was not examined in 
mouse tissues further preventing a broader understanding of the influence of other statin 
transporters in the tissue distribution and pharmacokinetics of rosuvastatin in the Mrp1-/- 
knockout model. 
In conclusion, knockout of Mrp1 in mice does not appear to affect the tissue distribution 
of rosuvastatin into skeletal muscle. Upregulation of Mrp4 and Mrp5 in muscle may 
compensate for the loss of Mrp1 in regulating rosuvastatin tissue distribution.  A role for 
Mrp1 in the skeletal muscle toxicity of statins remains to be determined. 
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